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1. INTRODUCTION AND BACKGROUND FOR THE PROPOSED RESEARCH 
1.1. Protein Glycosylation 
Glycans are oligosaccharides attached to proteins or lipids 
1
. A typical glycan is a complex 
non-linear branched oligosaccharide composed of 10 to 15 monosaccharide residues. Glycan 
structure is defined by the order of monomeric units, exact position of the glycosidic bond, its 
anomeric configuration (α or β), the number of branches and the position of branching 2. The 
process of oligosaccharides attachement to a protein is called glycosylation and those proteins 
are referred to as glycoproteins. The complete set of glycans  produced by a  given cell type or 
organism is called glycome and comprehensive study of structures and functions of glycans is 
referred to as glycomics. Mammalian glycome consist of nine monosaccharides which 
theoretically could make 10
12
 combination of hexasaccharides 
3
. Moreover, a broad range of 
different glycans can be made by altering the number, order and type of monosaccharides 
units and the attachment of many different glycans to the same protein result in different 
glycoforms of the same protein molecule 
4
. It is estimated that mammalian glycoproteins 
consist of up to 2000 different glycan determinants 
5
 and changes in glycans have an essential 
impact in modifying the structure and function of polypeptides parts of glycoprotein 
6
, making 
the glycoproteome much more complex than the proteome itself 
7
. 
Glycosylation of proteins is an important post-translational modification and glycans play an 
important role in normal physiological processes such as protein folding, degradation and 
secretion as well as in cell signalling, cell-cell interactions and immune functions 
8
. 
Dysregulation of glycosylation caused by a combination of several individual mutations leads 
to various forms of congenital disorders of glycosylation 
9
. In addition mutations that cause 
formation of new glycosylation site can also be deleterious. There are several classes of 
glycans, including Asn (N)-linked and Ser/Thr (O)-linked glycans 
1
. N-glycosylation is the 
oldest pathway that take place when a block of 14 sugars attached to dolichol phosphate (the 
dolichol phosphate precursor) is transferred to asparagine (Asn) residue in newly synthesized 
polypeptides in the endoplasmatic reticulum 
10
. During passage through the Golgi 
compartments to their intra and extra-cellular destinations, these N-glycans will be subject to 
a large-scale alteration 
11
. Common mammalian monosccharides comprise glucose (Glc), 
mannose (Man),galactose (Gal), N-Acetylglucosamine (GlcNAc), fucose (Fuc) and sialic 
acid. Additionally, multiple residues can be attached to a single monosccharide which can 
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lead to complex branched structure. Therefore, oligosaccharides are amongst the most 
structurally diverse biopolymers in the nature. 
Almost all membrane and secreted proteins are modified by covalent addition of glycans 
12
 
and the complete absence of glycans is embryologically lethal 
13
. Contrary to polypeptide 
parts of proteins, which are defined by the sequence of nucleotides in the corresponding genes 
(made by a direct DNA template), glycans are formed by complex network of interactions by 
hundreds of glycogenes 
14
 that code for various glycosyltransferases, glycosidases, enzymes 
for sugar nucleotide biosynthesis, transporters, transcription factors, ion channels and other 
proteins 
15
. Therefore, the final structure of the glycan will be ultimately affected by changes 
in the abundance and/or localization of any of the enzymes, glycoprotein substrates and 
activated sugar donors involved in glycan biosynthesis 
16
. Thus, it is well established that 
glycans are a product of a complex biosynthetic pathway affected by hundreds of genetic and 
environmental factors 
14, 17,
 
18
.  
Despite their different and complex biosynthetic origin, both polypeptide and glycan parts of 
glycoproteins participate as a single molecular entity in the function of a glycoprotein 
6
. Even 
though the glycans are not directly encoded in genes, a high heritability of mammalian 
glycome composition was reported 
19, 20
 and various large population studies of human plasma 
glycome revealed a high inter-individual variability in glycan composition 
20, 21
. This 
heterogenity of glycome composition triggered by alteration in glycosylation has resulted in 
the tremendous complexity in glycan structures and even a minor changes in the glycan 
structures can have important functional effects. It is evident that this structural variety of 
glycans is responsible for adapting to changing environment and also in evading from many 
pathogens 
22
. ABO blood groups are the best conspicuous example of variability in 
monosaccharides at the end of glycan antennas as a result of modification caused by mutation 
in genes leading to a large part of individual phenotypic variations. The majority of human 
variability derives from single nucleotide polymorphisms (SNPs) which individually do not 
indicate any obvious phenotypes, but if present in specific combinations,  they can have 
significant phenotypic effects
 23
. In addition, there is a growing evidence that changes in 
protein glycosylation have been reported to be of importance in the development and 
progression of different cancers, thus raising the possibility for early detection, imaging and 
therapy 
24
. 
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1.2. Glycans relevance as biomarkers 
Glycans appear to play a key role in a wide range of diseases. The complexities of 
oligosaccharide structures and the lack of analytical methods for elucidating them have 
hampered the overall process  and only recently glycans have been tested as potential disease 
biomarkers due to the recent advances in the development of novel analytical tools. It is now 
well established that structure of glycan expressed by diseased cells are different as compared 
to those of normal cells 
25
 and these aberrant glycans are widely known to occur as a response 
to the disease 
26, 27, 28
. Since , glycans are not a result of direct genetic template, it appears that 
changes in protein glycosylation have the potential to be more notable than protein expression 
during transformation to the diseased condition 
26
. Even small changes in the associated 
protein (glycosyltransferases) expression have a direct effect on glycans and there are various 
examples that emphasize the role of glycosyltransferase overexpression in tumorigenesis 
29, 30
. 
As a result, the effect of the disease is significantly amplified and easier to detect 
1
.  
On the other side, it is widely reported that abnormality in protein glycosylation is associated 
with a complex diseases such as cancer, diabetes, cardiovascular, congenital, immunological 
and infectious disorders 
3, 8, 31
. Furtheremore, changes in protein glycosylation in either the 
level of or type of glycosylation have been shown to be of importance in the development and 
progression of different cancers. Hence, glycans are engaged in all major physiological events 
during various stages of tumor progression, from tumor cell proliferation, metastasis and 
angiogenesis 
26, 32, 33
, and a  number of different studies have made preliminary reports of 
potentially important glycan biomarkers for cancer and other diseases 
1, 33, 34, 35, 36
. Therefore, 
due to the importance of alteration in glycosylation in health and disease, there has been 
extensive research effort on the discovery of glyco-biomarkers that could have potential 
diagnostic or prognostic monitoring capabilities. 
Many known biomarkers for cancer are in fact glycoproteins, and specifically those for 
colorectal cancer are carcinoembryonic antigen (CEA) and CA19-9. However, diagnostic 
tests typically only measure the protein fraction, despite the fact that in many cases it has been 
convincingly demonstrated that glycosylation changes significantly improve the diagnostic 
value of these biomarkers 
37, 38
. Increased branching of oligosaccharides has been reported to 
be associated with cancer metastasis and tumor progression in melanoma, breast and 
colorectal cancer 
39, 40, 41
. The enzyme N-Acetylglucosaminyltransferase V (GnT-V, Mgat 5), 
which promotes increased branching of glycans has been reported to be associated with 
cancer 
42
. Its expression was subsequently reported to correlate with poor prognosis in 
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colorectal 
43
, endometrial 
44
 and bladder cancer. In mouse models, knockdown of GnT-V was 
found to inhibit breast cancer cell growth with activation of CD4+ T cells and macrophages 
45
. Functional proteomics studies indicated that GnT-V reinforces the invasive/metastatic 
potential of colon cancer through aberrant glycosylation on tissue inhibitor of 
metalloproteinase 1 
46
. More recently 1,3 fucosyltransferases were reported to be master 
regulators of prostate cancer cell trafficking 
47
, while the ST6GalNAc gene (one of many 
sialyl-transferases) was found to be associated with brain metastasis in breast cancer 
48
. A 
recent study reported that polymorphisms in several glyco-genes are also associated with 
increased or decreased risk for epithelial ovarian cancer 
49
. 
Glycosylation found on cell surfaces and in extracellular matrices is very important in 
multicellular organisms because it makes the first point of contact in cellular interactions 
50
. 
This has significant impact in cancer progression and metastasis because cancer progression 
and metastasis is a complex process requiring adhesive interactions, many of which are 
mediated by cell surface glycans and lectins. N-glycosylated cell adhesion molecules such as 
E-cadherin and integrins play key roles in cell-cell and cell-extracellular matrix interactions, 
thereby affecting cancer metastasis
 51
. A key element of protein glycosylation is the addition 
of fucose to the non-reducing ends of N-glycans and this has already been linked to cancer 
and inflammation 
52
. Indeed, fucosylated haptoglobin and sialyl-Lewis-x (SLex) have 
previously been proposed as cancer biomarkers for pancreatic, ovarian, breast and thyroid 
cancer 
39, 40, 41, 53, 54
. Fucosylated alpha-fetoprotein is highly specific tumor marker for 
hepatocellular carcinoma 
55
. Although, changes in fucosylation are associated with 
progression of prostate cancer 
56
. More recently mutation in hepatocyte nuclear factor 
(HNF1A) gene which finally cause a decrease in plasma protein antennary fucosylation is a 
promising biomarker for both, HNF1A-MODY(maturity onset diabetes of the young)  
diagnosis and HNF1A  impaired function 
57
. 
Breast cancer patients with lymph node metastasis have been shown to have significantly 
higher levels of glycans containing the SLex structure than patients without a metastasis, 
suggesting a basis for a new biomarker for cancer prognosis 
40
. In particular, malignant 
properties of cancer cells including invasivness and metastatic potential is thought to be a 
characteristic feature associated with aberrant sialylations in these cells. An increase in 
sialylation is commonly observed in various tumors, which may be due to either an increased 
activity of sialyltransferases or increased numbers of possible sialylation sites on N-linked 
carbohydrates 
58
. Sialylation of transferrin and total serum proteins coud be used as a new 
prognostic marker of acute pancreatitis 
59
. Moreover, decreases in triantennary 
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trigalactosylated glycans and/or bisected core fucosylated  biantennary monosialylated 
glycans and increases in tetraantennary tetrasialylated glycans were found to be correlated 
with perineural invasion in prostate cancer 
60
. Triantenary N-glycans are associated with 
tumor stage in hepatocarcinoma patients 
61
. Modulators of protein glycosylation and glycan 
branches have been considered to be important candidates for novel anticancer drugs 
26, 62
. 
Even though it appears that the reported markers are cancer associated rather than cancer 
specific, they nevertheless could provide an insight into the molecular mechanisms of 
carcinogenesis and disease pathogenesis 
63
.   
Finally, Immunoglobulin G (IgG) molecule is a prominent example of changes in protein 
glycosylation as a response to the disease. Human serum IgG glycosylation is known to 
change with various physiological and pathological conditions, especially, it is evident a 
significant change of IgG glycosylation between control and cancer patients 
64
.  
Taking all of these studies in consideration it is predicted that, in the future, it will be possible 
to not only diagnose diseases, but perhaps even determine disease progression and specific 
strain based solely on glycan profiling 
1
. 
1.3. Immunoglobulin G 
Immunoglobulins (Ig) are glycoprotein molecules made by plasma cells in response to 
challenge from microbiological agents or cancer cells. Compared to other classes of 
immunoglobulins (IgM, IgA, IgD, IgE), IgG molecules represent the predominant class of Igs 
in the serum with typical concentration of almost 10 mg/ml 
65
, reflecting its role as a major 
effector molecule of the humoral immune system in defending organisms against many 
pathogens. IgG molecules are multifunctional glycoproteins which are one of the best studied 
class of glycoproteins present in serum in four different subclasses (IgG1, IgG2, IgG3, IgG4) 
based on their decreasing abundance (65), which also differ from each other on the basis of 
the length of hinge region and the number of interchain disulphide bonds 
66, 67
. 
IgG antibodies consist of two heavy (H) and two light (L) chains linked together by disulphid 
bonds which form two fragment antigen binding Fab moieties divided into two homologus 
domains (VL and CL) and one fragment crystallizable Fc moiety composed of four 
homologous domains (VH, CH1, CH2 and CH3) which are both together linked through a 
flexible hinge region 
68, 69
. While the Fab portion of IgG are responsible for binding antigens 
and provides the structural basis for the tremendous immunological diversity of antibodies, 
the Fc portion promotes a variety of effector functions through interactions with specific 
ligands, e.g. cellular receptors (FcRs), (FcRn) and the C1 component of complement 
 70, 71, 72
. 
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Each heavy chain of IgG carries a single covalently attached bi-antennary N-glycan at the 
highly conserved asparagine 297 residue in each of the CH2 domains of the Fc region of the 
molecule (Figure 1). In contrast to other Ig isotypes, the IgG-Fc glycan moiety is not exposed 
on the IgG surface but rather buried within the hydrophobic core between the two heavy 
chains of the CH2-domain forming multiple non-covalent bonds with polypeptide chains and 
impacting Fc structure 
73, 74
. 
 
Figure 1. The structure of an IgG1 molecule. (A) Fab and Fc portion (B). Complex biantennary glycan structure 
attached to Asn 297 in Fc portion of IgG molecule. Structural schemes are given in terms of blue square (N-
acetylglucosamine), red triangle (fucose), green circle (mannose), yellow circle (galactose), and purple diamond 
( N-acetylneuraminic acid) 64. 
The Fc glycans of human IgG are biantennary complex-type structures which are 
predominantly core-fucosylated and are in part altered by a bisecting N-acetylglucosamine 
(GlcNAc) 
75, 76
, antennae are partially trimmed varying in their degree of galactosylated and 
may carry a sialic acid residue 
77
. 
More than 95% of the final IgG glycans carry a N-acetylglucosamine on both arms and 85% 
are fucosylated
 78
. The percentage of glycans carrying one galactose (G1 glycan) is 40% and 
the frequency of non-galactosylated (G0) or bi-galactosylated glycans (G2) ranges between 
20-40% 
79
.  
In addition, it appears that there are small amounts of human IgG containing nonfucosylated 
glycans with or without bisecting GlcNAc residue
 80
. In general, it is widely known that the 
attached oligosaccharide chains are highly heterogenous and over 36 different glycans can be 
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attached to the conserved Asn 297 of the IgG heavy chains 
81
. Since IgG glycoprotein 
contains two heavy chains, it can lead to hundreds of different IgG isomers that can be 
generated from this single glycosylation site. Immunoglobulin G (IgG) molecule is one of the 
most studied glycoprotein in details in sense of structural and functional aspects of 
glycosylation. 
Interestingly it was found that the variability of glycan composition attached to IgG was 
approximately three times larger than the variability of the total plasma glycome 
20
, providing 
IgG with new physiological functions that could not be possible without this complex post-
translational process. 
Thus, glycosylation is a very complex metabolic process and heterogenity in IgG glycome 
composition argues the fact that these final products, glycans, are not solely genetically 
predefined (Figure 2), hence glycosylation is known to be affected by factors such as type of 
glyco-enzymes and their expression levels 
82
.
    
 
 
 
Figure 2. Structural variations in IgG glycans. Initial GlcNAc2Man3GlcNAc2 structure (red square) can be 
modified by the addition of bisecting GlcNAc (GnTIII), fucose (FUT8) or galactose (GalT). These resulting 
structures can further be modified by the activity of the same enzymes or by the addition of the sialic acid (SiaT) 
83
. 
These attached oligosaccharides are structurally important for the stability of the antibody and 
its effector functions 
84
. In addition, 15–20% of normal IgG molecules also carry complex bi-
antennary oligosaccharides attached to the variable regions of the light chain, heavy chain or 
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both 
85, 86
. There are glycosylation site specific differences between the Fab and the Fc. In 
contrast to Fc portion of IgG, Fab regions are characterised by a high incidence of di- and 
monosialylated structures and of cores with the bisecting GlcNAc residue  
87
. 
In general, these studies indicate that glycosylation of IgG is essential for the expression of 
proper effector functions of IgG, and specific physiological and pathological conditions can 
essentially alter the conformation of Fc region with enormous consequences for IgG effector 
functions. Therefore, variation of the glycosylation of recombinant monoclonal antibodies in 
order to derive improved therapeutic effector functions, represents an important research area 
88
. Despite the importance of protein glycosylation in all physiological and pathological 
processes and their potential as diagnostic markers, understanding of the role of IgG N-
glycans in various pathological conditions is also a good foundation for the development of 
novel therapeutics. 
1.4. The role of the Fc glycans in IgG activity 
Glycosylation appears to be particularly important in the immune system 
89
 and IgG is the 
most conspicuous example in terms of how novel IgG functions triggered by alternative 
glucosylation can provide new adaptive mechanism that allows fight against pathogens or 
cancer cells. Immunoglobulins and their binding receptors (Fc receptors) are key glycoprotein 
components of the immune system that link the innate and adaptive arms of immunity. IgG-
Fc glycans modulate the biological activities of IgG in completely two opposite directions, 
thereby acting as a switch from innate anti-inflammatory activity to an adaptive pro-
inflammatory response on antigenic challenge 
1
. 
Antibodies communicate with effector cells of the immune system through interactions with 
membrane bound Fc receptors, which are complex glycoproteins widely expressed throughout 
haematopoietic system 
90
 such as natural killer cells, macrophages, eosinophils, neutrophils, 
limphocytes and dentric cells. Stimulation of cells through FcγRs results in a wide variety of 
effector functions, including antibody dependent cell mediated cytotoxicity (ADCC) 
91
 
phagocytosis 
92
, oxidative burst 
93
 and release of inflammatory mediators 
94
. Consequently, 
alteration of IgG glycosylation patterns changes their respective effector functions 
95, 96
. There 
are two major types of FcγRs: immune reaction activating (FcγRIa, FcγRIIa and FcγRIIIa) 
and inhibiting receptors (FcγRIIb) 74, also there is an additional Fc receptor known as the 
neonatal Fc receptor, (FcRn). FcRn is involved in IgG, maintaining the serum concentrations 
of the antibody due to the enhanced half life of circulating IgG of up to 21 days and regulating 
IgG homeostasis where high concentrations are required to fight infection 
97
. This receptor is 
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also involved in transcellular transportation of IgG from mother to fetus across the placenta 
and is critically important for the transfer of humoral immunity to the fetus 
98
. 
Some of the immune cells express both activating and inhibitory FcγR and eventual 
interaction betwen IgG and these receptors relies on the affinity of the IgG subclasses to 
distinct FcγRs and the combination of expression level an pattern of FcγRs 99. 
IgG glycosylation has important regulatory functions and immune system has possibility to 
descriminate between different antibody glycoforms, which can also initiate a different impact 
on the efficacy of IgG effector function 
100
. The IgG-Fc glycans maintain the heavy chains in 
an open conformation required for FcγRs interactions and even a small changes in their 
composition have enormous consequences for IgG effector functions 
85, 101
. However, it is 
also evident that deglycosylated IgG molecules are unable to elicit in vivo an inflammatory 
response 
102
 because of their  little ability in activating complement and in binding to FcγR 103, 
104
 as the two heavy chains form a closed conformation, impeding so formation of FcγR 
binding pocket 
105
. 
Antibody mediated tumor eradication depends on two key mechanisms targeted for activation, 
ADCC and complement-dependent cytotoxicity (CDC). In order for IgG to induce these two 
key mechanisms it must rely on proper glycosylation of its Fc region since changes in glycan 
composition will initiate dramatic consequences for effector functions of IgG (Figure 3). 
Fc glycans contain a core Fuc residue in a1,6-position linked to the core GlcNAc residue 
78
. 
Bio-synthesis of core-fucosylated glycans is the result of a transfer of a Fuc residue from 
GDP-Fuc-mediated by a1,6-fucosyltransferase in the trans-Golgi 
106
. Core-fucosylation of N-
glycans attached to the Fc part of IgG appears to be specifically and separately regulated from 
the core-fucosylation of glycans attached to Fab fragments of the same protein
 107
. While the 
majority of plasma proteins are not core-fucosylated 
19
, over 95% of IgG is core-fucosylated 
in what appears to be a mechanism which modulates binding of IgG to Fc gamma RIIIa 
20
 and 
therefore contains “safety switch” which prevents them from eliciting potentially destructive 
ADCC 
108
. FcγRIIIa (CD16) is an activating Fc receptor expressed primarily on natural killer 
(NK) cells and antibodies initiate ADCC via binding to FcγRIIIa which results in eradication 
of target cells. Core-fucosylation of IgG plays an important role in mediating ADCC 
following treatment with therapeutic antibodies because the presence of core-fucose interferes 
with FcγRIIIa binding and this is closely related to the clinical efficacy of anticancer drugs 
109
. Hence, IgG fucosylation is a strong modulator of antigen dependant cell cytoxicity 
(ADCC) 
110, 111
 and specific aspects of FcγRIIIa glycosylation have also been reported to be 
important in this process. Glycans attached to Asn45 and Asn162 of FcγRIIIa are essential for 
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the regulation of preferential binding of IgG without core-fucose to FcγRIIIa 109. Despite the 
role of core fucose in increasing or decreasing ADCC via binding to FcγRIIIa, it was reported 
that interaction with other activating receptors such as FcγRIIA is uneffected by the presence 
of the core fucose 
112
. Nevertheless, proper regulation of the addition of core-fucose to IgG 
could play an important role in determining  cancer prognosis as the addition of core-fucose 
decreases the potential of IgG to elicit ADCC by nearly hundred fold 
95
. Because of improved 
binding to activating Fcγ receptor and enhanced ADCC by afucosylated IgG, core-
fucosylation of IgG has been the subject of intensive research 
95
.  
Hence, a number of  strategies have been developed to reduce fucosylation of IgGs 
107
 such 
as: generation of cell lines with genetic modifications that directly influence core fucosylation 
in a way that either completely lack or have reduced levels of expression of a 1,6-
fucosyltransferase 
113, 114
. For instance, genetic elimination of fucosyltransferase 8 (FUT8) in 
Chinese hamster ovary cells has been a successful approach for the prevention of core 
fucosylated IgG 
115
. Besides, as an alternative method is used overexpression of b (1,4)-N-
acetylglucosaminyltransferase III (GnTIII) an enzyme that adds bisecting GlcNAc residues to 
IgG 
116
 which has been shown to result in reduction of the core fucose content 
117
. However, it 
seems that the lack of core fucose, not the presence of bisecting GlcNAc, has the most critical 
role in enhanced ADCC 
111
 as the presence of bisecting GlcNAc is always associated with 
low fucose content. Biopharmaceutical industry has been focused on generation of 
afucosylated monoclonal antibody therapeutics (mAb) as well, and the majority of approved 
(mAb) therapeutics that target ADCC have been engineered for use in anti-cancer therapies. 
Afucosylated monoclonal antibodies display strong therapeutic potential in anti-cancer 
therapy 
118
. Due to their ability to initiate an enhanced ADCC as a result of their improved 
FcγRIIIa binding, afucosylated IgG even low doses of afucosylated IgG are enough to 
overcome the competition with high concentrations of heavily fucosylated serum IgG 
110
. 
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Figure 3. Modulation of IgG function by alternative glycosylation.Structure of the glycan on IgG Fc part can 
significantly affect effector function of IgG 119.  
 12 
  
Another structural modification of IgG-Fc glycan is the presence of terminal sialic acid 
residues and this has received increased attention since sialylation has also been implicated in 
regulating IgG activity. Increasing sialylation of the Fc glycans results in the decreased 
ADCC activity of IgGs, as terminal sialylation exhibits low affinity for the Fc gamma RIIIa 
receptor 
120
. It has been reported that increased sialylation makes IgGs an anti-inflamatory 
agents
 81, 121
 and this was found to be essential for the function of therapeutic intravenous 
gamma globulins (IVIG) which together with their Fc fragment are anti-inflammatory 
81, 122
. It 
is reported that one class of IgG Fc glycans through binding to FcγRs perform pro-
inflammatory effects of immune complexes and cytotoxic antibodies 
81
, which are so the key 
mediators of many autoimmune diseases such as immune thrombocytopenia (ITP), 
autoimmune hemolitic anemia (AHA), systemic lupus erythematosus (SLE), reumatoid 
arthritis (RA), type I diabetes and multiple sclerosis 
123, 124
. In contrast, therapeutic 
intravenous gamma globulins and its Fc fragments are anti-inflammatory 
81
.  Intravenous 
immunoglobulin (IVIG) is a therapeutic preparation of normal human polyclonal IgG 
obtained from plasma pooled from a large number of healthy blood donors. Due to its anti-
inflammatory effect, IVIG is now widely used as a replacement therapy of patients suffering 
from autoimmune diseases such as: immune thrombocytopenia (ITP), chronic inflammatory 
demyelinating polyneuropathy (CIDP), and rheumatoid arthritis (RA) 
125, 126
.  Because anti-
inflammatory activity of IVIG is maintained through enormous quantity of IVIg (1-2 g per 
kg), it was speculated that it could be possible that only a small sub-fraction of IVIg will 
mediate advantageus effect. Therefore, Kaneko et al 
81
 suggested that anti-inflammatory 
activity of IVIG is derived from sialylation of Fc region. Because a reduction in IVIG activity 
was seen only by desialylated IVIG, it was suggested that sialic acid could be the key sugar 
performing anti-inflammatory activity 
81
. Consistently, in vitro sialylation or acid specific 
lectin enrichment generated sialylated IgG Fcs which in turn suppressed inflammation at a 30-
fold lower dose than IVIG 
127
. Also, sialylated IVIG suppressed induced arthritis and 
nephrotoxic nephritis at a 10 –fold lower dose than whole IVIG 81. These studies confirmed 
that anti-inflammatory activity is a property of IgG Fc portion and that Fc portion alone is 
sufficient to suppress inflammation 
128
. Further support for this concept was provided by data 
showing that only α2,6 linked sialic acid residues have been found to be responsible for the 
anti-inflammatory activity observed for human IVIG 
120
. Moreover Ravetch and colleagues 
129 
pointed out the effect of sialylated Fc fragments as the anti-inflammatory  mediator of IVIG 
in the K/N experimental arthritis mouse model. Contrary to other studies, it was found that 
induction of inhibitory IgG cell surface receptor FcγRIIB on effector macrophages by 
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sialylated IgG has profound effect on anti-inflammmatory activity of these antibodies 
121
. 
Furtheremore, after administration of IVIG in a number of mouse models an increased 
expression of this inhibitory receptor FcγRIIB was observed and mice lacking this receptor 
were unresponsive to IVIG 
122, 125, 130
. Since, human and mouse IgG glycoforms bearing 
terminal sialic acid residues show a reduced affinity for activating FcγRs, it seems clear that 
other receptors might be involved in recognizing sialic acid rich IgG 
81
. Indeed,  Anthony and 
colleagues 
127
 demonstrated that the mechanism that mediate such anti-inflammatory effect 
does not involve FcγRs and FcRn, but sialylated IgG mediate its anti-inflammatory activity 
through binding a C-type lectin receptor on mouse splenic macrophages SIGN-R1 or its 
human orethologue, DC-SIGN. Although, subsequent studies have supported this by 
suggesting a protective mechanism involving the inhibitory Fc receptor (FcγRIIb) and C-type 
lectin SIGNR1 or its human ortholog DC-SIGN 
121, 131
. Because IVIG lost its therapeutic 
activity in FcγRIIB knock-out animals in models of ITP, nephrotoxic nephritis, and serum 
transfer arthritis 
130, 132
 it is obvious that the inhibitory FcγRIIB is also essential for IVIG 
activity. 
The presence or absence of anntenary galactose residues has also been demonstrated to alter 
the activity of antibodies. IgG Fc-glycans carrying galactose residues in their teminal 
antennae bind to the complement component C1q giving rise to classical pathway of 
complement activation but not ADCC activity because they do not influence binding to the 
FcγRIIIa receptor 133. The role of IgG galactosylation was analysed in different inflammatory 
diseases 
77
 and also similar observation were made in  infectous diseases and cancer 
134, 135
. 
Increased levels of IgG-G0 promots proinflammatory response against HIV virus and this 
argues for a functional significance of antibody galactosylation in humans 
136
. Incomplete 
galactosylation of IgG exhibits a low affinity to bind to complement component C1q and 
FcγRs resulting in impaired effector functions 137 and in contrast to galactosylated IgG (G1-
IgG and G2-IgG), agalactosylated IgG can activate in vitro complement system via  the 
interaction of mannose-binding lectin (MBL) with Fc terminal GlcNAc residues 
138
 and thus 
be part of the underlying pathological mechanisms. Furthermore, an increase in terminal 
GlcNAc content results in decreased binding of antibody to C1q and reduced CDC activity 
133
. The MBL is a C-type protein that is involved in clearance of immune complexes and in 
the lectin pathway of complement activation 
139
. It forms a complex with structural 
homologues of C1 complement components and triggers CDC 
138
. Based on the increased 
binding of MBL to agalactosylated glycans  in vitro, it has been suggested that the MBL may 
contribute to an additional inflammation by activating complement 
139
.  In contrast, recent 
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studies performed in MBL knock-out mice showed that despite the capacity to bind MBL and 
activate the complement cascade in vitro, there was no significant contribution of MBL to the 
activity of IgG G0 antibodies  in vivo, suggesting rather that IgG G0 antibodies work 
normally via the classical FcγR pathway 140. Even though this study argues no functional role 
of interaction between MBL and  G0, because of the different role of individual glycans and 
glycoforms in mouse and human, further studies must be performed in humans to elucidate 
the exact functional role of agalactosylation IgG antibodies in terms of interaction with MBL. 
  The pro-inflammatory and anti-inflammatory properties of IgG due to  alternative 
glycosylation is presented in (Figure 4). 
 
 
Figure 4. The schematic representation of the human IgG structure and functional implication of alternative 
glycosylation 141.  
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1.5. IgG glycosylation under physiologic and pathophysiologic conditions 
Despite the biosynthetic complexity, glycosylation under controlled physiological conditions 
or during bioprocessing is highly reproducible. Therefore, it has been  known for a long time 
that aberrant changes of IgG glycosylation are associated with specific physiological and 
pathophysiological conditions 
64
. Recently, there has been an increasing interest in the 
analysis of the N-glycosylation profile of human IgG in health and in a number of diseases 
such as infections, inflammation and autoimmunity 
36, 137, 142, 143, 144, 145, 146
. Although, 
variations in the glycome in cancerous state have been reported long time ago 
29
, less is 
known about the potential role of the Fc glycans in malignancy. Understanding the role of 
changes in glycosylation in autoimmune diseases and cancer is important for defining both 
molecular pathology of such conditions and also for the identification of possible targets for 
subsequent drug development 
147, 148
. The mechanisms that cause disease-related 
glycosylation changes have not yet been clarified, but in order to better understand these 
mechanisms it is very inportant to define glycosylation changes as they relate to normal 
physiologic processses. Therefore, a number of studies have reported age and sex dependence 
of certain IgG glycosylation features in healthy population 
149, 150, 79
. Parekh et al. 
149
; Yamada 
et al. 
150
; Shikata et al. 
79; Knežević et al. 17; Ruhaak et al. 151; Pučić  et al. 20 in their studies 
have found a significant decrease of galactosylation and sialylation of IgG with age and an 
increase of glycan structures with the bisecting GlcNAc, while the core fucosylation of IgG 
oligosaccharides stayed rather stable over time. Yamada et al. 
150
, found different IgG 
glycosylation patterns related to gender, with agalactosylated levels of IgG antibodies being 
higher in both males and females but with males showing higher level of agalactosylated 
glycans than females in their twenties. Even though bisecting GlcNAc shows higher levels 
with age, however, differences between males and females were found. 
The studies mentioned above provided valuable information regarding changes in 
glycosylation with respect to chronological age but the question whether IgG Fc glycans 
would reflect biological age was unknown for a long time,  until  Krištić et al. 152 performed a 
large-scale popullation study of 5,117 individuals from four European populations. This study 
revealed very extensive and complex changes in IgG glycosylation with age, and with a 
combination of several IgG glycans managed to explaine up to 58% of variance in 
chronological age, much more than other markers of biological age like telomere lengths. 
This was the first study confirming the close association of IgG glycans with both 
chronological and biological ages. High galactosylation and sialylation levels of IgG and  
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decrease of bisecting GlcNAc was reported in pregnacy 
153
. In addition, glycosylation of IgG 
from both fetal and maternal circulation was also analyzed and compared. Interestingly, the 
incidence of IgG-G0 was found to be approximately 25% higher in maternal serum as 
compared to fetal umbilical vein serum, which might indicate a glycosylation sensitive 
transport of maternal IgG via the placenta to the fetal circulation with a selection for highly 
galactosylated glycoforms 
154
. 
It seems that glycosylation varies considerably between individuals of the same sex and age, 
but the influence of life time on glycosylation is stroger than differences between sexes. 
Among the most notable features of IgG glycosylation in pathologic conditions, 
galactosylation is the most studied. Increased levels of agalactosylated IgG have been 
reported in many autoimmune diseases suggesting that the absence of galactose may have a 
role in the pathogenity of the autoantibodies. In addiion, until now more than 50 different 
studies have analyzed the role of IgG galactosylation in different inflammatory diseases. 
Despite this, the molecular significance of these changes is still mostly unknown 
64
. In sera of 
patients with rheumathoid arthritis (RA) a significant change in IgG glycosylation with 
increase levels of IgG-G0 was reported 
143
. However, increased levels of agalactosylated IgG 
have been also found in sera of patients with juvenile arthritis, Crohn’s diseas and 
tuberculosis 
144, 155
. Young et al 
156
 have found that G0 values can be used clinically as an 
indicator of disease severity and also in the early diagnosis of rheumatoid arthritis. It was 
suggested that IgG molecules containing less terminal galactose bind better to certain 
rheumatoid factors (RA) 
157
. Also, It was reported  that IgG-G0 have pathogenic role in 
mouse model of arthritis 
158
 and interesingly, increased content of galactose in IgG 
carbohydrate chains was significantly increased during pregnancy, when re-mission of RA 
symptoms occurs 
159
. In addition to RA, alteration in IgG glycosylation has been reported in 
studies of small vessel vasculitis, Wegener’s granulomatosis, microscopic polyangitis and 
Churg-Strauss syndrome 
142
. More recent studies described lower levels of IgG Fc 
galactosylation in well-defined antibody-mediated autoimmune diseases, i.e., Lambert-Eaton 
myasthenic syndrome (LEMS) and myasthenia gravis (MG) 
135
. Changes of IgG glycosylation 
have been also reported in many other non-autoimmune diseases such as malignant states. 
Gercel-Taylor et al. 
160
 and Alley et al. 
161
 have found an elevated expression of 
agalactosylated IgG in the serum of patients with ovarian cancer. Increase in agalactosylation 
levels was also reported in patients with gastric cancer 
148, 162
, lung cance 
163
 and prostate 
cancer 
164
. Recently, it was demonstrated that IgG  glycosylation  signature  might be  useful  
as  a  predictive  marker  for  gastric  cancer 
165
. In contrast, Chen et al. 
166
 have reported a 
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higher levels of galactosylated IgG in female thyroid cancer patients than in female controls. 
Aberrant IgG Fc glycosylation was also reported in multiple mieloma with decreased 
galactosylation in comparison to age and sex matched controls 
167
. 
These described changes of the overall IgG-Fc N-glycosylation, could provide insight into 
potential association of a certain glycosylation feature and antibody pathogenicity 
135
. 
However less is known about the potential role of IgG glycosylation in malignancy and tumor 
immunity. Therefore, further analysis of IgG-Fc glycans may provide clearer understading of 
the possible impact of glycosylation on tumor progession and evaluation of the Fc glycans  as 
a potentially predictive biomarker for monitoring of cancer patients. The functions of certain 
sugar residues for the pro and anti-inflammatory functions of IgG have shed light in sense of 
the functional importance of these sugar moieties attached to immunoglobulin molecule. The 
presence or absence of distinct sugar residues such as galactose,  sialic acid and core fucose 
can dramatically alter IgG activity and changes in serum IgG glycosylation during age, 
pregnacy, autoimmune disease and cancer suggests existance of active regulatory mechanisms 
that could trigger a molecular switch keeping the humoral immune system in an active pro-
inflammatory or a more anti-inflammatory state. 
1.6. The prognostic importance of colorectal cancer 
Colorectal cancer (CRC) is a malignant neoplasm of the colon and the rectum. It is the third 
most common malignancy in the world 
168
. Unfortunately, nearly 800,000 new colorectal 
cancer cases are thought to globally occur each year, which account for 10% of all incident 
cancers, and the mortality from colorectal cancer is estimated at nearly 450,000 per year 
46
. 
This places a major economic burden on the global health care system 
169
. CRC develops 
through a progressive accumulation of genetic, both inherited and somatic,and epigenetic 
changes, leading to the conversion of normal colonic mucosa into invasive cancer. Almost 70 
to 90 % of CRC-s derive from adenomatous polyps (adenomas) 
170
. The risk of CRC increases 
with age especially after the age of 50 years, and the risk is also increased by certain inherited 
genetic mutations (familial adenomatouspolyposis and hereditary non-polyposis colorectal 
cancer), a personal or family history of colorectal neoplasia, or a personal history of 
inflammatory bowel diseases (IBD) 
171
. Several modifiable factors are also associated with 
increased risk of CRC, including obesity, physical inactivity, smoking, heavy alcohol 
consumption, type II diabetes, and a diet high in red or processed meat. 
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CRC is still associated with poor prognosis, low survival rate and usually relatively late 
diagnosis. CRC develops slowly and the risk of recurrence and death from CRC is related to 
tumor stage at diagnosis. It continues to be such a serious health problem because it is largely 
asymptomatic until the latter stages oftentimes when the cancer has already metastasized. The 
growing repertoire of treatments available for CRC, including new chemotherapy approaches, 
combined with challenging benefit:toxicity ratios and cost, means that it is crucial to target 
interventions to patients most likely to benefit. Current cancer screening methods for CRC 
include fecal occult blood test followed by imaging procedures such as sigmoidoscopy, colo-
noscopy, or potentially computed tomography (CT). Although current screening methods are 
helpful, they are not optimal and present major concerns regarding sensitivity, specificity, 
complexity, cost, and compliance. Until now there are no reliable serologic markers available 
which would allow early diagnosis, monitoring and prognosis of patients. Because CRC 
develops slowly from removable precancerous lesions, detection of the disease at an early 
stage during regular health examination can reduce both the incidence and mortality of the 
disease 
168
. Early diagnosis, including detection of adenomas, is considered to be a key aspect 
for improving patient survival and prognostic or predictive biomarkers are essential for 
guiding patient therapy or monitoring treatment efficacy. In addition, the importance of 
detecting colorectal cancer at an early stage is also appreciated by the fact that patients 
diagnosed with TNM Stage I disease have a 5-year survival rate of 90% following surgical 
resection 
172
, whereas when diagnosed at the later stag-es (i.e., Stage IV), the 5-year survival 
rate is only 5%. Nevertheles, advances in cancer treatment have increased survival for some 
cancers, yet the main CRC prognostic marker at present is stage at diagnosis as reflected by 
the AJCC/UICC TNM-classification which describes tumor spread through the bowel wall, 
number of affected lymph nodes and spread of tumor to distant organs (metastasis) 
173
. In 
spite of this, even with the use of the TNM-classification method, there are some patients of 
lower TNM-stages that have a worse clinical outcome than patients of higher TNM-stages 
174
. 
This is clinically important, since patients with AJCC stage 2 CRC may be offered adjuvant 
chemotherapy if their cancer is classified as high risk 
175
. Hence, whilst pathological staging 
(TNM/Dukes') stratifies prognostic groups, it is limited in its ability to categorise poor/good 
prognosis tumours accurately and direct treatment decisions at the individual level. Also, 
current biomarkers which are at least partly released into the circulation from the tumor, 
perform poorly in terms of sensitivity and this greatly limits their value in cancer prognosis 
168.
. In line with this, currently, unfortunately scientists have failed to develop simple and non-
invasive screening test for the early detection of cancers based only on genomic and 
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proteomic studies 
176
. Therefore, the need for early detection and accurate diagnosis, 
prognosis and efficient therapeutic approach has led scientists to search further into the 
molecular level in order to identify novel biomarkers that could further refine pathology-
based prognostic information and offer much potential for clinical and public health benefit, 
thus aiding the existing tumor classification systems in determining CRC prognostication. 
 A recent extensive report endorsed by the US National Academies concluded that “glycans 
are directly involved in the pathophysiology of every major disease” and that “additional 
knowledge from glycoscience will be needed to realize the goals of personalized medicine 
and to take advantage of the substantial investments in human genome and proteome research 
and its impact on human health” 177. It is well known since a half century the relevance of 
alteration in glycosylation in disease states, particularly in the study of cancer 
34
 but glycans 
have only recently been  introduced  as potential disease biomarkers due to the development 
of a large-scale studies of the glycome. In general, immune response occurs in the early stage 
of tumor development and it may not only protect organisms against tumor development, but 
can also promote tumor development and progression by selecting variants with low 
immunogenicity. Inter-individual differences in immune repertoire and the capacity to process 
and present antigens is a key element in cancer immunosurveilance 
178, 179
. Glycans have an 
enormous impact in the immune system and inter-individual variation in glycosylation may 
effect function in immune system in multiple levels 
180
, leading to inter-individual variability 
in cancer immunosurveilance and/or response to therapeutic antibodies, as therapeutic 
antibodies have been set up as ‘standard of care’ therapy for several highly prevalent human 
cancers 
181
. Even though many serum glycoproteins display changes in glycosylation pattern, 
little is known  about changes in IgG glycosylation in patients with cancer. Therefore 
understanding the role of altered IgG glycosylation in colorectal cancer offers the potential for 
the discovery of a new category of glycan based biomarkers which would have high 
discriminative power to predict cancer survival outcome and would help tailor the most 
appropriate surgical and chemotherapy regimens to individual patients thereby improving 
patient outcomes. 
Measurement of plasma N-glycan biomarkers thus shows potential as a novel non-invasive 
approach to determine cancer prognosis. However, published studies have been limited to 
small scale pilot studies due to technical challenges in identifying and quantifying N-glycan 
structures. The N-glycome wide approach which was applied in this thesis has only recently 
been made possible due to recent developments in high-throughput glycan analysis 
182
. This 
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study will be the first to investigate the IgG N-glycome and will employ a sample size which 
is substantially larger than current published studies. 
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2. HYPOTHESIS 
N-glycomic analysis could reveal significant inter-individual differences and identify several 
specific glycan biomarkers which are associated with CRC prognosis.  
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3. AIMS AND PURPOSE OF THE RESEARCH 
3.1. General aim:  
This research aims to identify IgG N-glycans biomarkers with discriminative power to predict 
survival in patients with CRC. 
3.2. Specific aims: 
1. To analyse IgG N-glycans in 1229 patients with CRC and 538 matching controls. 
2. To investigate the association between plasma IgG N-glycans and CRC survival and 
evaluate their potential role as clinical biomarkers for CRC prognosis. 
3. To investigate the relationship between plasma levels of IgG N-glycans and CRC mortality. 
4. To investigate the discriminative power of specific plasma IgG N-glycans as clinical 
biomarkers of CRC prognosis.   
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4. MATERIALS AND METHODOLOGY 
4.1. Study population 
The SOCCS (Study Of Colorectal Cancer in Scotland) study (1999-2006) is a case-control 
study designed to identify genetic and environmental factors associated with non-hereditary 
colorectal cancer risk and survival outcome. This study includes prospective CRC cases from 
almost all hospitals in Scotland therefore is broadly representative of the colorectal cancer 
population. The study has been described in details elsewhere 
183
. 
Samples for the analyses were assembled from a large population-based resource including a 
subset of 1229 patients with pathologically confirmed colorectal adenocarcinoma and 538 
matching controls from the University of Edinburg (age/gender/residence area matched) with 
extensive data about cases and controls including: lifestyle/ behavioural/ diet risk factors, 
tumor related parameters, ancestry, clinical data, and biological samples (DNA, lymphocytes, 
plasma). In addition to demographic data, detailed clinical data for each patient’s CRC 
episode were collected and validated, which include: clinical and imaging data, date of 
diagnosis; presence/date of recurrence; new cancer occurrence data; date of death; cause of 
death; cancer staging assigned according to the American Joint Committee on Cancer (AJCC) 
system (all available clinical, imaging and pathology data were incorporated in final AJCC 
staging). 
Cases were recruited as soon as possible after diagnosis to limit survival bias among those 
recruited and maximize the person-years of follow up IgG glycan composition was analysed 
in the time period after CRC diagnosis or recruitment. Participants completed one 
questionnaire with lifestyle and cancer information, reporting their status 1 year prior to 
diagnosis or recruitment. A semi-quantitative food frequency (http://www.foodfrequency.org) 
and supplements questionnaire was completed by participants. Participants were asked about 
their general medical history, physical activity, and smoking status. Additionally, subjects 
were asked to report any regular intake of aspirin and nonsteroidal anti-inflammatory drugs. 
Reported height, weight, and waist circumference were recorded. Participants were also asked 
to report some demographic, socioeconomic, and race/ethnicity data. Finally, women were 
asked about their menstrual and reproductive history and type of hormone replacement 
therapy and hormonal contraception, if used. 
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Blood was collected and transferred to the research centre within 72 h of sampling. Plasma 
was prepared from whole blood by gentle centrifugation of sodium EDTA tubes through a 
ficoll-hypaque gradient and 1.5 mL of each participant’s plasma was stored at  -80°C. 
 
Effects of surgery on the IgG glycome were evaluated in 28 patients sampled before surgery, 
24h, 48h and 7 days after surgery. Samples were collected at the Clinical Department for 
Laboratory Diagnostics at University Hospital Dubrava, Zagreb, Croatia.  
 
Patients who were sampled before the initial diagnosis of CRC, as well as matching controls 
that did not develop CRC during the same follow-up time were selected from the FINNRISK 
cohort 
184
. 
4.2. Ethics statement 
Approval for the study of 1229 patients with CRC and 538 matching controls was obtained 
from the MultiCentre Research Ethics Committee for Scotland and Local Research Ethics 
committee. 
 
The study of 28 patients with CRC samples before surgery was registrated at 
ClinicalTrials.gov, number NCT01244022 and was approved by the Ethics Committee of 
University Hospital Dubrava. 
 
All participants gave written informed consent. 
 
4.3. IgG N-glycans sample preparation and analyses 
4.3.1 Purification of IgG 
The IgG was isolated using protein G monolithic plates (BIA Separations, Ajdovščina, 
Slovenia) as described previously 
185
. Before use, the monolithic plate was washed with 10 
column volumes (CV) of ultra pure water and then equilibrated with 10 CV of binding buffer 
(1X PBS, pH 7.4). Plasma samples (70-100μl) were diluted 10 X with the binding buffer and 
applied to the Protein G plate. The filtration of the samples was completed in 5 min. The plate 
was then washed five times with 5 CV of binding buffer to remove unbound proteins. IgG 
was released from the protein G monoliths using 5 CV of elution solvent (0.1 M formic acid, 
pH 2.5). Eluates were collected in a 96-deep-well plate and immediately neutralized to pH 7.0 
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with neutralization buffer (1 M ammonium bicarbonate) to maintain the IgG stability. After 
each sample application, the monoliths were regenerated with the following buffers: 10 CV of 
10 X PBS, followed by 10 CV of 0.1 M formic acid and afterward 10 CV of 1 X PBS to re-
equilibrate the monoliths. Each step of the chromatographic procedure was done under 
vacuum (cca. 60 mmHg pressure reduction while applying the samples, 500 mmHg during 
elution and washing steps) using a manual set-up consisting of a multichannel pipet, a 
vacuum manifold (Beckman Coulter, Brea, CA) and a vacuum pump (Pall Life Sciences, Ann 
Arbor, MI). If the plate was not used for a short period, it was stored in 20% ethanol (v/v) at 4 
°C. After repeated use of the plate contaminants present in the sample sometimes did not 
completely elute from the monolithic stationary phase. A specific cleaning protocol was 
developed that included washing with 0.1 M NaOH to remove precipitated proteins and with 
30% propan-2-ol to remove strongly bound hydrophobic proteins or lipids. This procedure 
effectively removed all precipitates and did not significantly diminish IgG binding capacity of 
the immobilized protein G. The purity of the isolated IgG was verified by SDS-PAGE with 
NuPAGE Novex 4–12% Bis-Tris gels in an Xcell SureLock Mini-Cell (Invitrogen) according 
to the manufacturer. Precision Plus Protein All Blue Standards (BioRad, Hercules, CA) was 
used as the molecular weight marker. The gels were run at 180 V for 45 min, stained with 
GelCode Blue (Pierce) and visualized by a VersaDoc Imaging System (BioRad).  
 4.3.2 Release and labelling of IgG glycans  
IgG samples were dried in a vacum concentrator, denatured with addition of 30 μL 1.33% 
SDS (w/v) (Invitrogen, Carlsbad, CA, USA) and by incubation at 65 °C for 10 min. After 
incubation samples were left to cool down to room temperature for 30 minutes. Subsequently, 
10 μL of 4% Igepal-CA630 (Sigma-Aldrich) and 1.25 mU of PNGase F (ProZyme, Hayward, 
CA, USA) in 10 μL 5× PBS were added to the samples. The samples were incubated 
overnight at 37 °C for N-glycan release. The released N-glycans were labelled with 2-
aminobenzamide (2-AB). The labelling mixture was freshly prepared by dissolving 2-AB 
(Sigma-Aldrich) in DMSO (Sigma-Aldrich) and glacial acetic acid (Merck) mixture (85:15, 
v/v) to a final concentration of 48 mg/mL. A volume of 25 μL of labelling mixture was added 
to each N-glycan sample in the 96-well plate. Also, 25 μL of freshly prepared reducing agent 
solution (106.96 mg/ml 2-picoline borane (Sigma-Aldrich) in DMSO) was added and the 
plate was sealed using adhesive tape. Mixing was achieved by shaking for 10 min, followed 
by 2 hour incubation at 65 °C. Samples (in a volume of 100 μL) were brought to 80% ACN 
(v/v) by adding 400 μL of ACN (J.T. Baker, Phillipsburg, NJ, USA).  
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4.3.3 HILIC-SPE 
Free label and reducing agent were removed from the samples using hydrophilic interaction 
liquid chromatography-solid phase extraction (HILIC-SPE). An amount of 200 μL of 0.1 
g/mL suspension of microcrystalline cellulose (Merck) in water was applied to each well of a 
0.45 μm GHP filter plate (Pall Corporation, Ann Arbor, MI, USA ). Solvent was removed by 
application of vacuum using a vacuum manifold (Millipore Corporation, Billerica, MA, 
USA). All wells were prewashed using 5× 200 μL water, followed by equilibration using 3× 
200 μL acetonitrile/water (80:20, v/v). The samples were loaded to the wells. The wells were 
subsequently washed 7× using 200 μL acetonitrile/water (80:20, v/v). Glycans were eluted 2× 
with 100 μL of water and combined eluates were stored at –20 °C until usage. 
4.3.4 HILIC-UPLC 
Fluorescently labelled N-glycans were separated by hydrophilic interaction chromatography 
on a Waters Acquity UPLC instrument (Milford) consisting of a quaternary solvent manager, 
sample manager and a FLR fluorescence detector set with excitation and emission 
wavelengths of 330 and 420 nm, respectively. The instrument was under the control of 
Empower 2 software, build 2145 (Waters, Milford). Labelled N-glycans were separated on a 
Waters BEH Glycan chromatography column, 100 × 2.1 mm i.d., 1.7 μm BEH particles, with 
100 mM ammonium formate, pH 4.4, as solvent A and acetonitrile as solvent B. Separation 
method used linear gradient of 75–62% acetonitrile (v/v) at flow rate of 0.4 ml/min in a 25 
min analytical run. Samples were maintained at 5 °C before injection, and the separation 
temperature was 60 °C. The system was calibrated using an external standard of hydrolyzed 
and 2-AB labelled glucose oligomers from which the retention times for the individual 
glycans were converted to glucose units. Data processing was performed using an automatic 
processing method with a traditional integration algorithm after which each chromatogram 
was manually corrected to maintain the same intervals of integration for all the samples. The 
chromatograms were all separated in the same manner into 24 peaks and the amount of 
glycans in each peak was expressed as percentage (%) of total integrated area. In addition to 
24 directly measured glycan structures, 53 derived traits were calculated. These derived traits 
average particular glycosylation features (galactosylation, fucosylation, sialylation) across 
different individual glycan structures. Consequently, they are more closely related to 
individual enzymatic activities, and underlying genetic polymorphisms. 
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4.4. Survival and risk related parameters 
Data relevant to the survival analysis were obtained from the Scottish registries General 
Register Office and the Scottish Cancer Registry (which are known to have high levels of data 
quality and data completeness) after linkage of our participants with their databases using the 
Community Health Index number. Mortality outcomes were ascertained through linkage with 
the National Records of Scotland. Primary cause of death (“CRC” or “other”) was assigned 
from death certificates separately by two researchers (concordance was >99%). Survival 
follow-up was censored at the date of death or at January, 31 2013, for participants who were 
not known to have died. Clinicopathological staging data was collected where possible (eg. 
TNM is not feasible in patients who did not undergo surgery). Clinical records were reviewed 
and tumor site and multiplicity were determined from clinical and pathological records. Pre-
operative staging imaging was collected through participating centres. Using the collated 
pathology, imaging and clinical data, tumor stage was assigned according TNM staging 
system and mapped onto the American Joint Committee on Cancer (AJCC) tumor-node-
metastasis system (AJCC 1-4). 
 
Blood was collected at various points after the CRC diagnosis and after surgery. Median time 
to sampling was 5.4 months after the diagnosis (interquartile range, IQR: 3.2 to 8.3 months). 
Since illness and treatment may acutely affect IgG glycan levels and confound the analysis, a 
variable describing time from operation to blood collection and a variable determining the 
type of operation were created. 
4.5. Statistical analysis 
Data was analysed using STATA (version 12.0) and R.  
Initially we examined the association between IgG glycan levels (continuous and quartiles) 
and CRC/all-cause mortality using cox proportional hazards models. Three models were 
applied: a crude model (Model I), a model where hazard ratios (HR) were adjusted for age at 
diagnosis, sex and stage of disease (Model II) and a  model where HRs  were adjusted  for age 
at diagnosis, sex, stage of disease, body mass index (BMI), time from operation to blood 
collection, type of operation and CRP (Model III). P-values were adjusted for multiple testing 
using false discovery rate method (Benjamini–Hochberg procedure). 
We estimated the predictive value of a clinical only Cox-regression algorithm for model II 
(which included age, sex, disease stage) and model III (which was adjusted for age, sex, 
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disease stage, BMI and CRP level), by calculating the Harrell’s C concordance coefficient, 
the Area under the ROC curve (AUC) and the Integrated Discrimination Index (IDI defined as 
a difference in discrimination slopes) and compared this to an algorithm that also included 
glycan predictors.This analysis was ran in the whole data set and after AJCC stage 
stratification. The glycan variables included in the final model were selected by applying 
generalised boosted regression, which orders the variables by their relative importance, in 
1000 bootstrap samples 
186, 187
, over the 10 inner training folds, and forward selection of 
ranked glycans by applying log-likelihood ratio test.  
The predictive value of the models was evaluated on independent samples using 10-fold 
cross-validation for all models except for AJCC stage 1 strata, where cross-validation was not 
possible due to the small number of events. P <0.002 was considered statistically significant, 
after applying the Bonferroni correction for 21 independent tests. 
Classification analyses were performed  to a) predict the 5-year risk of CRC death and b) to 
predict the rapid progressors within each stage. A rapid progressor was defined as someone 
who died of CRC and whose follow-up time was in the lower 1/3rd of the patients to die of 
CRC in that stage of cancer, with the cut-off thresholds at 2.9, 2.4, and 1.3 years for stages 2-
4 respectively. We applied several families of classification models (LASSO, nearest 
neighbours, PAM, Support Vector Machines, naive Bayes, Decision Trees, and boosted stump 
classifiers), with and without stratification, with and without initial filtering on the training 
data, with and without log transformations of glycan expressions and clinical factors. The 
choice of the models was influenced by their popularity in biomarker studies, and their ability 
to address high-dimensional (large-p, small-n) problems via regularization or an explicit 
control for model complexity. More information about these estimators is presented in 
Supplementary Box 1, and the motivations for considering multiple classifiers for this 
problem are discussed in Supplementary Section on Model Comparison. 
 
All the results for this analysis were averages over 10 runs using 10-fold cross validation, 
where the validation folds were used neither for filtering nor for estimation of model 
parameters. We also used 10 inner folds to estimate the stopping criteria or optimal value of 
hyperparameters (such as the regularization parameter for LASSO). Then we estimated 
whether adding glycans to clinical covariates would improve the predictive performance of a 
model of the same class on independent test data; that is, we compared LASSO using clinical 
variables with LASSO using clinical variables and glycans, DTs using clinical variables with 
DTs using clinical variables and glycans, etc. This task is different from the association 
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analysis, or from identifying specific glyco-clinical models outperforming a known baseline, 
where corrections for multiple tests are needed to control the probability of false discoveries. 
We applied the paired Wilcoxon sign-rank test comparing models with and without glycans, 
testing whether the difference in the cross-validated AUC of the clinical and glycol-clinical 
models is significantly different from zero.  
Comparison of clinical characteristics among 760 patients and 538 matching controls was 
done by using Wilcoxon and Fischer Exact tests. Data was analyzed and visualized using R 
programming language (version 3.0.1). To make measurements across samples comparable, 
normalization by total area was performed where peak area of each of 24 glycan structures 
was divided by total area  of corresponding chromatogram. Batch correction was performed 
on normalized log-transformed measurements using linear mixed models (R package lme4),  
where technical source of variation was modelled as random effect.  
Association analyses between disease status and glycan traits were performed using a logistic 
regression model with age and sex included as additional covariates. Prior to analyses, glycan 
variables were all transformed to standard Normal distribution (mean=0,sd=1) by inverse 
transformation of ranks to Normality (R package "GenABEL", function rntransform). Using 
rank transformed variables in the analysis makes estimated odds ratios of different glycans 
comparable as transformed glycan variables have the same standardized variance, and in that 
case estimated odds ratios always correspond to one standard deviation change in the 
measured glycan trait. False discovery rate was controlled using Benjamini-Hochberg 
procedure 
188
. For prediction of CRC status, regularized logistic (elastic net) regression model 
was applied (R package "glmnet"). For classification, only 24 initial glycan traits were used as 
predictors. Prior to model training and validation, elastic net regularization parameters (alpha 
and lambda) were tuned on 20% of samples (260 samples), and optimal parameters chosen by 
the tuning procedure (alpha = 0, lambda = 0.1) were used in further analysis. To evaluate 
performance of predictive model 10-cross validation procedure was used on remaining 80% 
of samples. Predictions from each validation round were merged into one validation set on 
which model performance was evaluated based on area under the receiver operating 
characteristic curve (AUC) criteria. The AUCs of different models were compared using a 
bootstrap test. 
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LASSO - sparse logisitic regression. This is a standard logistic regression model with a logit 
link function, and L1 penalties on the weights. To set the penalty parameter, we run 10-fold 
cross-validation over a set of 10 penalties in the range 0.001 to 0.1. We choose the penalty 
resulting in the minimum-deviance model. 
k-nearest neighbours -  k nearest neighbours with k=1. For a new input, this classifier 
predicts the class of the nearest input in the training data, measured by Euclidean distance. 
PAM - Prediction Analysis for Microarrays. This is the "nearest-shrunken-centroid" 
classifier. To set the shrinkage parameter, we run 10-fold cross-validation over 31 equally 
spaced values in the range 0 to 1.5. We choose the parameter that produces the lowest mean 
error rate. 
Support Vector Machines – kernel-based maximum-margin classifiers. We consider linear, 
square, cubic, and squared exponential (Gaussian) kernel functions with fixed 
hyperparameters. 
Naive Bayes – factorized class-conditional classifiers with normal or kernel density 
estimator-based marginal distributions. The KDE bandwidth is selected automatically. 
Decision Trees – non-parametric tree classifiers, with the internal nodes corresponding to 
predictors, and leaves encoding classification labels. Binary trees with the Gini impurity 
splitting criterion were used. 
Boosted stump classifiers – aggregations of multiple boosted one-node decision trees 
(stumps), where each later stump focuses on previously misclassified samples, using a version 
of Adaboost. 
Supplementary Box 1. Information about the estimators used in the classification analysis. 
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4.5.1 Supplementary Section: Model Selection 
One classifier vs multiple classifiers 
In life and clinical sciences, it is common to analyse the predictive performance by using an 
arbitrarily chosen single regression or classification model such as linear regression for 
continuous outcomes or logistic regression for binary outcomes, without motivating the model 
choice. There are multiple models that may in principle be considered for continuous and 
binary outcomes, and deeper insights about the utility of biomarkers may potentially be 
obtained by evaluating many such models. We note that the analysis of the predictive 
performance based on a single model may be misleading, due to the following observations: 
(i) It may happen that by considering a single model, researchers observe that biomarkers do 
not improve the quality of predictions. But this observation may be an artefact of the implied 
modelling constraints (such as the linear decision surface separating cases from controls in 
logistic regression). One reason for failing to demonstrate an improvement in predictions may 
be the fact that the chosen predictive model was limited and inappropriate for the dataset. The 
biomarkers may still be useful predictors, but the researchers may be making incorrect 
assumptions about the data and using a wrong model, without trying to evaluate whether the 
modelling assumptions are correct. (ii) A similar argument may hold for a subset of variables. 
For example, researchers may be able to demonstrate that a common model such as logistic 
regression with covariates defined by biomarkers and clinical variables outperforms logistic 
regression that only uses clinical variables, and may conclude that the biomarkers are 
generally useful for predicting the considered outcome. However, it may happen that the 
logistic assumption is particularly unfavourable to the clinical model (for example, when the 
mapping from the clinical variables to the outcomes is complex, and the classification surface 
cannot be well modelled by a hyperplane in the subspace of clinical variables). In this case, a 
clinical model of some other class (for example, an SVM) that does not use the biomarkers 
could significantly outperform models with biomarkers. In this case, the conclusion that the 
biomarkers are useful for developing a diagnostics, may be misleading - one may be able to 
achieve a superior quality of predictions when considering "richer" clinical models 
(something overlooked by considering model of a single class). We note that the assessment 
of the predictive performance by considering a single model may often be limited, and the 
results may need to be interpreted with some care. This work is an empirical attempt to 
overcome the arbitrariness of a specific model choice. In particular, we considered a larger set 
of models that make different assumptions about the mapping from glycans to outcomes. We 
 32 
  
use (nested) cross-validation to estimate the predictive performance on new previously unseen 
data. We then compare pairs of models of the same class that use clinical variables only and 
clinical variables with glycans, and test how likely it is that using glycans for predictions 
leads to improvements over clinical models independently of the modelling assumptions. 
(Note that the models are generally not nested even when they belong to the same class – so 
we cannot use standard tests). As the evaluation criterion, we use the AUC computed by 
cross-validation over the test folds of data. In some sense, rather than comparing an arbitrary 
model with or without glycans, we are evaluating how easy it may be to use glycomic 
biomarkers to construct a superior diagnostic independently of the modelling details. 
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5. RESULTS 
5.1. IgG glycan measurements in colorectal cancer prognosis 
IgG glycome composition was analysed in 1229 patients with CRC and 538 matching 
controls. Total IgG glycan (combined Fc and Fab glycans) compositions were determined by 
HILIC-UPLC analysis of 2AB labelled glycans as reported recently 
189
.  
 
1. To examine the potential role of individual variation in IgG glyosylation on CRC prognosis 
we initially performed detailed analyses of IgG glycome composition in 1229 patients with 
CRC of all CRC stages. 
2. In addition, we explored the prognostic biomarker potential of IgG glycans after stage 
stratification to account for the different stage prognosis of CRC patients. 
 
Total IgG glycan measurements resulted in 24 chromatogaphic peaks (GP1-GP24) that were 
directly measured glycan structures, and 53 derived traits that represent common features 
shared among several measured glycans (galactosylation, sialylation, core fucosylation and 
the incidence of bisecting GlcNAc. (Table 1) 
20, 185
. A typical chromatogram showing 
seperation of the IgG glycome into individual structures is shown in (Figure 5).  
We restricted our survival analysis to those IgG glycan traits that were found to be robustly 
analysed. Robustness was calculated as follows. On each plate from the CRC cohort we put 3 
standards that were biologically identical. Therefore, differences between measurements of 
standards are consequence of only experimental noise. We then calculated the variance of 
standards only and the variance in the whole CRC population. "Robustness" is defined as the 
ratio of those two variances (Var(Stand)/Var(CRC))*100 (i.e. lower values indicate higher 
robustness) and represents the contribution of experimental variation in total variation.  
 
Thirty nine of the 77 glycan traits whose percentage of experimental variation was below 20% 
were included in the analysis (Table 1). 
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Figure 5. HILIC-UPLC chromatogram of IgG n-glycans. Each IgG contains one conserved N-glycosylation 
site on Asn197 of its heavy chains. Different glycans can be attached to this site and the process seems to be 
highly regulated. UPLC analysis can reveal composition of the glycome attached to a population of IgG 
molecules by separating total IgG N-glycome into 24 chromatographic glycan peaks (GP1–GP24), mostly 
corresponding to individual glycan structures. 
The amount of glycans in each peak is expressed as percentage of total integrated area. 
Glycoforms represented by each peak were analyzed on the basis of their elution positions 
and measured in glucose units then compared to reference values in the  “GlycoBase” 
database for structure assignment 
190
. GU units were assigned according to 2AB labeled 
standard of glucose oligomers of different sizes. Value for each peak is presented as the area 
percentage of the total glycome of the analyzed sample.  
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Table 1. Glycans annotations and experimental variation for each glycan variable 
GROUP Code 
Glycan Peaks and 
derived traits  
Code 
Description Formula Variation 
Total  
glycans 
(neutral + 
charged) 
IGP1 GP1 The percentage of FA1 glycan in total  IgG glycans  GP1 / GP * 100 34.35 
IGP2 GP2 The percentage of A2 glycan in total  IgG glycans  GP2 / GP * 100 34.02 
IGP3 GP4 The percentage of FA2 glycan in total  IgG glycans  GP4 / GP * 100 2.45 
IGP4 GP5 The percentage of M5 glycan in total  IgG glycans  GP5 / GP * 100 32.90 
IGP5 GP6 The percentage of FA2B glycan in total  IgG glycans  GP6 / GP * 100 1.78 
IGP6 GP7 The percentage of A2G1 glycan in total  IgG glycans  GP7 / GP * 100 29.37 
IGP7 GP8 The percentage of FA2[6]G1 glycan in total  IgG glycans  GP8 / GP * 100 10.82 
IGP8 GP9 The percentage of FA2[3]G1 glycan in total  IgG glycans  GP9 / GP * 100 6.71 
IGP9 GP10 The percentage of FA2[6]BG1 glycan in total  IgG glycans  GP10 / GP * 100 2.42 
IGP10 GP11 The percentage of FA2[3]BG1 glycan in total  IgG glycans  GP11 / GP * 100 31.34 
IGP11 GP12 The percentage of A2G2 glycan in total  IgG glycans  GP12 / GP * 100 28.10 
IGP12 GP13 The percentage of A2BG2 glycan in total  IgG glycans  GP13 / GP * 100 95.50 
IGP13 GP14 The percentage of FA2G2 glycan in total  IgG glycans  GP14 / GP * 100 1.05 
IGP14 GP15 The percentage of FA2BG2 glycan in total  IgG glycans  GP15 / GP * 100 12.56 
IGP15 GP16 The percentage of FA2G1S1 glycan in total  IgG glycans  GP16 / GP * 100 33.19 
IGP16 GP17 The percentage of A2G2S1  glycan in total  IgG glycans  GP17/ GP * 100 112.42 
IGP17 GP18 The percentage of FA2G2S1 glycan in total  IgG glycans  GP18 / GP * 100 2.19 
IGP18 GP19 The percentage of FA2BG2S1 glycan in total  IgG glycans  GP19 / GP * 100 15.42 
IGP19 GP20 Structure not determined GP20 / GP * 100 104.69 
IGP20 GP21 The percentage of A2G2S2 glycan in total  IgG glycans  GP21 / GP * 100 49.60 
IGP21 GP22 The percentage of A2BG2S2 glycan in total  IgG glycans  GP22 / GP * 100 96.00 
IGP22 GP23 The percentage of FA2G2S2 glycan in total  IgG glycans  GP23 / GP * 100 25.62 
IGP23 GP24 The percentage of FA2BG2S2 glycan in total  IgG glycans  GP24 / GP * 100 30.39 
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Total IgG 
glycans - 
derived 
parameters 
IGP24 FGS/(FG+FGS) 
The percentage of sialylation of fucosylated galactosylated 
structures without bisecting GlcNAc in total IgG glycans 
SUM(GP16 + GP18 + GP23) / 
SUM(GP16 + GP18 + GP23 + 
GP8 + GP9 + GP14) * 100 18.10 
IGP25 FBGS/(FBG+FBGS) 
The percentage of sialylation of fucosylated galactosylated 
structures with bisecting GlcNAc in total IgG glycans 
SUM(GP19 + GP24) / 
SUM(GP19 + GP24 + GP10 + 
GP11 + GP15) * 100 13.28 
IGP26 FGS/(F+FG+FGS) 
The percentage of sialylation of all fucosylated structures without 
bisecting GlcNAc in total IgG glycans 
SUM(GP16 + GP18 + GP23) / 
SUM(GP16 + GP18 + GP23 + 
GP4 +  GP8 + GP9 + GP14) * 
100 8.10 
IGP27 FBGS/(FB+FBG+FBGS) 
The percentage of sialylation of all fucosylated structures with 
bisecting GlcNAc in total IgG glycans 
SUM(GP19 + GP24) / 
SUM(GP19 + GP24 + GP6 + 
GP10 + GP11 + GP15) * 100 13.02 
IGP28 FG1S1/(FG1+FG1S1) 
The percentage of monosialylation of fucosylated 
monogalactosylated structures without bisecting GlcNAc in total 
IgG glycans 
GP16 / SUM(GP16 + GP8 + 
GP9) * 100 
48.95 
IGP29 
FG2S1/(FG2+FG2S1+FG2
S2) 
The percentage of monosialylation of fucosylated digalactosylated 
structures without bisecting GlcNAc in total IgG glycans 
GP18 / SUM(GP18 + GP14 + 
GP23) * 100 
9.74 
IGP30 
FG2S2/(FG2+FG2S1+FG2
S2) 
The percentage of disialylation of fucosylated digalactosylated 
structures without bisecting GlcNAc in total IgG glycans 
GP23 / SUM(GP23 + GP14 + 
GP18) * 100 
22.02 
IGP31 
FBG2S1/(FBG2+FBG2S1
+FBG2S2) 
The percentage of monosialylation of fucosylated digalactosylated 
structures with bisecting GlcNAc in total IgG glycans 
GP19 / SUM(GP19 + GP15 + 
GP24) * 100 
9.54 
IGP32 
FBG2S2/(FBG2+FBG2S1
+FBG2S2) 
The percentage of disialylation of fucosylated digalactosylated 
structures with bisecting GlcNAc in total IgG glycans 
GP24 / SUM(GP24 + GP15 + 
GP19) * 100 
44.66 
IGP33 FtotalS1/FtotalS2 
Ratio of all fucosylated monosialylated and disialylated structures 
(+/- bisecting GlyNAc) in total IgG glycans 
SUM(GP16 + GP18 + GP19) / 
SUM(GP23 + GP24) 34.85 
IGP34 FS1/FS2 
Ratio of fucosylated monosialylated  and disialylated structures 
(without bisecting GlcNAc) in total IgG glycans 
SUM(GP16 + GP18) / GP23 
29.15 
IGP35 FBS1/FBS2 
Ratio of fucosylated  monosialylated  and disialylated structures 
(with bisecting GlcNAc) in total IgG glycans  
GP19 / GP24 
45.81 
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IGP36 FBStotal/FStotal 
Ratio of all fucosylated sialylated structures with and without 
bisecting GlcNAc in total IgG glycans  
SUM(GP19 + GP24) / 
SUM(GP16 + GP18 + GP23) 6.69 
IGP37 FBS1/FS1 
Ratio of  fucosylated monosialylated structures with and without 
bisecting GlcNAc in total IgG glycans  
GP19 / SUM(GP16 + GP18) 
5.67 
IGP38 FBS1/(FS1+FBS1) 
The incidence of bisecting GlcNAc in all fucosylated 
monosialylated structures in total IgG glycans in total IgG glycans  
GP19 / SUM(GP16 + GP18 + 
GP19) 
5.48 
IGP39 FBS2/FS2 
Ratio of fucosylated disialylated structures with and without 
bisecting GlcNAc in total IgG glycans  
GP24 / GP23 
3.89 
IGP40 FBS2/(FS2+FBS2) 
The incidence of bisecting GlcNAc in all fucosylated disialylated 
structures in total IgG glycans  
GP24 / SUM(GP23 + GP24) 
4.44 
Neutral 
IgG 
glycans 
IGP41 GP1n The percentage of FA1 glycan in total neutral IgG glycans (GPn) GP1 / GPn* 100 
35.92 
IGP42 GP2n The percentage of A2 glycan in total  neutral IgG glycans (GPn) GP2 / GPn* 100 
37.40 
IGP43 GP4n The percentage of FA2 glycan in total  neutral IgG glycans (GPn) GP4 / GPn* 100 
1.27 
IGP44 GP5n The percentage of M5 glycan in total  neutral IgG glycans (GPn) GP5 / GPn* 100 
36.24 
IGP45 GP6n The percentage of FA2B glycan in total  neutral IgG glycans (GPn) GP6 / GPn* 100 
1.02 
IGP46 GP7n The percentage of A2G1 glycan in total  neutral IgG glycans (GPn) GP7 / GPn* 100 
32.32 
IGP47 GP8n 
The percentage of FA2[6]G1 glycan in total neutral IgG glycans 
(GPn) 
GP8 / GPn* 100 
2.69 
IGP48 GP9n 
The percentage of FA2[3]G1 glycan in total  neutral IgG glycans 
(GPn) 
GP9 / GPn* 100 
2.06 
IGP49 GP10n 
The percentage of FA2[6]BG1 glycan in total  neutral IgG glycans 
(GPn) 
GP10 / GPn* 100 
0.91 
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IGP50 GP11n 
The percentage of FA2[3]BG1 glycan in total  neutral IgG glycans 
(GPn) 
GP11 / GPn* 100 
37.96 
IGP51 GP12n The percentage of A2G2 glycan in total  neutral IgG glycans (GPn) GP12 / GPn* 100 
29.22 
IGP52 GP13n 
The percentage of A2BG2 glycan in total  neutral IgG glycans 
(GPn) 
GP13 / GPn* 100 
92.53 
IGP53 GP14n 
The percentage of FA2G2 glycan in total  neutral IgG glycans 
(GPn) 
GP14 / GPn* 100 
0.58 
IGP54 GP15n 
The percentage of FA2BG2 glycan in total  neutral IgG glycans 
(GPn) 
GP15 / GPn* 100 
13.13 
Neutral 
IgG 
glycans - 
derived 
parameters 
IGP55 G0n 
The percentage of agalactosylated structures in total neutral IgG 
glycans  SUM(GP1n: GP4n + GP6n) 1.24 
IGP56 G1n 
The percentage of monogalactosylated structures in total neutral  
IgG glycans  
SUM(GP7n: GP11n) 
1.09 
IGP57 G2n 
The percentage of digalactosylated structures in total neutral IgG 
glycans  
SUM(GP12n: GP15n) 
1.51 
IGP58 Fn total 
The percentage of all fucosylated structures  (+/- bisecting 
GlcNAc) in total neutral IgG glycans  
SUM(GP1n+ GP4n+ GP6n+ 
GP8n+ GP9n+ GP10n+ 
GP11n+ GP14n+ GP15n) 44.04 
IGP59 FG0n total/G0n 
The percentage of fucosylation of agalactosylated structures in 
total neutral IgG glycans  
SUM(GP1n+ GP4n+ GP6n) / 
G0n * 100 40.29 
IGP60 FG1n total/G1n 
The percentage of fucosylation of monogalactosylated structures in 
total neutral IgG glycans  
SUM(GP8n+ GP9n+ GP10n+ 
GP11n) / G1n * 100 20.74 
IGP61 FG2n total /G2n 
The percentage of fucosylation of digalactosylated structures in 
total neutral IgG glycans  
SUM(GP14n+ GP15) / G2n * 
100 81.14 
IGP62 Fn 
The percentage of fucosylated  structures (without bisecting 
GlcNAc) in total neutral IgG glycans  
SUM(GP1n+ GP4n+ GP8n+ 
GP9n+ GP14n) 11.33 
IGP63 FG0n/G0n 
The percentage of fucosylation of agalactosylated structures 
(without bisecting GlcNAc) in total neutral IgG glycans  
SUM(GP1n+ GP4n) / G0n * 100 
4.70 
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IGP64 FG1n/G1n 
The percentage of fucosylation of monogalactosylated structures 
(without bisecting GlcNAc) in total neutral IgG glycans  
SUM(GP8n+ GP9n) / G1n * 100 
5.89 
IGP65 FG2n/G2n 
The percentage of fucosylation of digalactosylated structures 
(without bisecting GlcNAc) in total neutral IgG glycans  
GP14n/ G2n * 100 
57.82 
IGP66 FBn 
The percentage of fucosylated structures (with bisecting GlcNAc) in 
total neutral IgG glycans  
SUM(GP6n + GP10n + GP11n 
+ GP15n) 2.27 
IGP67 FBG0n/G0n 
The percentage of fucosylation of agalactosylated structures (with 
bisecting GlcNAc) in total neutral IgG glycans  
GP6n/ G0n * 100 
1.06 
IGP68 FBG1
n
/G1
n
 
The percentage of fucosylation of monogalactosylated structures 
(with bisecting GlcNAc) in total neutral IgG glycans  
SUM(GP10n + GP11n) / G1n * 
100 2.70 
IGP69 FBG2n/G2n 
The percentage of fucosylation of digalactosylated structures (with 
bisecting GlcNAc) in total neutral IgG glycans  
GP15n / G2n * 100 
21.03 
IGP70 FBn/Fn   
Ratio of fucosylated structures with and without bisecting GlcNAc 
in total neutral IgG glycans  
FBn/ Fn * 100  
3.39 
IGP71 FBn/Fn total  
The incidence of bisecting GlcNAc in all fucosylated structures in 
total neutral IgG glycans 
FBn/ Fn total * 100 
3.43 
IGP72 Fn/(Bn + FBn) 
Ratio of fucosylated non-bisecting GlcNAc structures and all 
structures with bisecting GlcNAc in total neutral IgG glycans  
Fn/(GP13n + FBn ) 
6.00 
IGP73 Bn/(Fn + FBn)  
Ratio of structures with bisecting GlcNAc and all fucosylated 
structures (+/- bisecting GlcNAc) in total neutral IgG glycans  
GP13n/ (Fn+ FBn ) * 1000 
92.61 
IGP74 FBG2n/FG2n  
Ratio of fucosylated digalactosylated structures with and without 
bisecting GlcNAc in total neutral IgG glycans  
GP15n/GP14n  
28.12 
IGP75 FBG2n /(FG2n + FBG2n ) 
The incidence of bisecting GlcNAc in all fucosylated 
digalactosylated structures in total neutral IgG glycans  
GP15n/(GP14n + GP15n) * 100 
28.43 
IGP76 FG2n/(BG2n + FBG2n) 
Ratio of fucosylated digalactosylated non-bisecting GlcNAc 
structures and all digalactosylated structures with bisecting 
GlcNAc in total neutral IgG glycans  
GP14n/(GP13n + GP15n) 
52.69 
IGP77 BG2n/(FG2n + FBG2n)  
Ratio of digalactosylated structures with bisecting GlcNAc and all 
fucosylated digalactosylated structures (+/- bisecting GlcNAc) in 
total neutral IgG glycans  
GP13n/(GP14n + GP15n) * 
1000 
106.54 
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5.2. Survival analysis 
Among the 1229 patients, there were 9563 person-years of follow-up. There were 489 deaths, 
including 385 from CRC.Median follow-up was 9.4 years (IQR: 4.4 to 10.6 years) overall, 
and 10.3 years (IQR: 9.6 to 11.0 years) for live patients.  
 
Summary statistics and univariate Cox regression analysis for the confounding factors that 
were included in the subsequent glycan analysis are presented in (Table 2). Of them stage at 
diagnosis and post-surgery CRP levels were strongly associated with all-cause and CRC-
specific mortality (all-cause mortality: stage 3 vs. stage 1 OR (95% CI): 2.65 (1.96, 3.59), p-
value 3.0x10
-10
; stage 4 vs. stage 1 OR (95% CI): 14.32 (10.37, 19.77), p-value 8.1x10
-19
; 
CRP levels >10 mg/l vs. ≤10mg/l OR(95% CI): 2.13 (1.67, 2.72), p-value 1.1x10-9).  
 
Age at diagnosis, sex and site of cancer (colon or rectum) were not associated with all-cause 
or CRC-specific mortality. 
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Table 2. Summary statistics and univariate Cox regression for factors influencing all-
cause and CRC mortality. 
 
All-cause mortality Deceased 
Cases  
N=489 
Survived/ 
Censored cases 
N=740 
p-value HR (95% CI) p-value 
Mean age (SD) 59.94 (10.15) 58.59 (9.87) 0.02 1.01 (1.00, 1.02) 0.09 
Sex      
Men 287 416  1.00  
Women 202 324 0.39 0.96 (0.80, 1.15) 0.67 
AJCC stage      
1 54 195  1.00  
2 115 306  1.35 (0.98, 1.87) 0.07 
3 186 227  2.65 (1.96, 3.59) 3.0x10-10 
4 134 12 <10-5 14.32 (10.37, 19.77) 8.3x10-19 
Site      
Colon 263 430  1.00  
Rectum 223 304 0.12 1.14 (0.95, 1.36) 0.15 
Mean BMI(SD)1 26.86 (4.77) 26.32 (4.09) 0.05 1.03 (1.01, 1.05) 0.02 
Mean CRP(SD) 5.99 (14.24) 2.54 (8.88) <10-5 1.02 (1.01, 1.02) 1.2x10-11 
CRP      
≤10mg/l 412 687    
>10 mg/l 77 53 <10-5 2.13 (1.67, 2.72) 1.1x10-9 
CRC mortality Deceased 
Cases  
N=385 
Survived/ 
Censored cases  
N=844 
p-value HR (95% CI) p-value 
Mean age (SD)1 58.81 (10.23) 59.27 (9.89) 0.46 1.00 (0.99, 1.01) 0.48 
Sex      
Men 212 491  1.00  
Women 173 353 0.31 1.12 (0.91, 1.36) 0.28 
AJCC stage      
1 22 227  1.00  
2 76 345  2.17 (1.35, 3.49) 0.001 
3 159 254  5.40 (3.46, 8.43) 1.3x10-13 
4 128 18 <10-5 30.63 (19.38, 48.40) 1.2x1048 
Site      
Colon 205 488  1.00  
Rectum 178 349 0.12 1.16 (0.95, 1.42) 0.15 
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Mean BMI (SD)2 27.08 (4.88) 26.29 (4.12) 0.007 1.04 (1.01, 1.06) 0.002 
Mean CRP(SD) 6.57 (15.24) 2.71 (8.98) <10-5 1.02 (1.01, 1.03) 4.5x10-12 
CRP      
≤10mg/l 318 781  1.00  
>10 mg/l 67 63 <10-5 2.37 (1.82, 3.09) 1.4x10-10 
 
BMI available for 1057 CRC cases (415 CRC deaths and 642 survived / censored). 
 
The univariate glycan HRs for the whole sample are presented in (Table 3 and Table 4) for 
all-cause mortality and in (Table 5 and Table 6) for CRC specific mortality. 
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Table 3.  All cause analysis for rank transformed glycans. Q value represents the adjusted p-values using the false discovery rate method 
(Benjamini–Hochberg procedure). 
Glycan Dead 
(N=489) 
Survived 
(N=740) 
Model II (AJCC, age, sex, 
time between sample and surgery, operation type, BMI, CRP, 
n=952) 
 Mean (SD) Mean (SD) HR (95% CI) p-value q-value 
Total IgG glycans (neutral and charged); Measured 
GP4 26.39 (7.33) 23.87 (6.37) 1.28 (1.14, 1.43) 2.6x10-5 0.0008 
GP6 6.34 (1.88) 5.79 (1.57) 1.19 (1.06, 1.34) 0.002 0.05 
GP8 18.26 (2.21) 18.67 (1.81) 0.87 (0.78, 0.97) 0.01 0.18 
GP9 9.38 (1.36) 9.83 (1.35) 0.83 (0.75, 0.92) 0.0003 0.009 
GP10 5.45 (1.23) 5.48 (1.15) 0.93 (0.84, 1.04) 0.2 0.74 
GP11 10.19 (3.13) 11.44 (3.13) 0.77 (0.68, 0.86) 9.6x10-6 0.0004 
GP15 1.38 (0.41) 1.50 (0.43) 0.86 (0.77, 0.96) 0.007 0.133 
GP18 7.78 (2.29) 8.47 (2.34) 0.79 (0.71, 0.89) 4.9x10-5 0.002 
GP19 1.87 (0.38) 1.90 (0.39) 0.98 (0.89, 1.08) 0.7 0.74 
Sialylation; Derived 
FGS/(FG+FGS) 24.78 (3.20) 24.95 (3.10) 0.93 (0.84, 1.03) 0.18 0.74 
FBGS/(FBG+FBGS 32.83 (6.17) 32.58 (6.34) 1.04 (0.94, 1.15) 0.47 0.74 
FGS/(F+FG+FGS) 16.35 (3.63) 17.35 (3.61) 0.81 (0.72, 0.90) 0.0001 0.003 
FBGS/(FB+FBG+FBGS) 21.21 (4.88) 21.82 (4.96) 0.95 (0.86, 1.05) 0.3 0.74 
FG2S1/(FG2+FG2S1+FG2S2) 40.18 (2.99) 39.51 (2.77) 1.06 (0.95, 1.18) 0.28 0.74 
FBG2S1/(FBG2+FBG2S1+FBG2S2) 37.02 (3.87) 36.41 (3.97) 1.12 (1.01, 1.24) 0.03 0.51 
Bisecting GlcNAc; Derived 
FBStotal/FStotal 0.30 (0.08) 0.28 (0.07) 1.19 (1.06, 1.33) 0.002 0.05 
FBS1/FS1 0.17 (0.05) 0.16 (0.05) 1.18 (1.06, 1.32) 0.003 0.07 
FBS1/(FS1+FBS1) 0.14 (0.04) 0.14 (0.03) 1.19 (1.06, 1.32) 0.002 0.05 
FBS2/FS2 1.35 (0.32) 1.27 (0.30) 1.17 (1.05, 1.31) 0.005 0.11 
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FBS2/(FS2+FBS2) 0.56 (0.06) 0.55 (0.06) 1.17 (1.05, 1.30) 0.005 0.11 
Neutral IgG glycans; Measured 
GP4n 32.33 (8.02) 29.56 (7.02) 1.28 (1.14, 1.43) 2.6x10-5 0.0008 
GP6n 7.78 (2.07) 7.18 (1.76) 1.17 (1.05, 1.31) 0.006 0.12 
GP8n 22.59 (3.09) 23.32 (2.52) 0.83 (0.74, 0.92) 0.001 0.028 
GP9n 11.60 (1.81) 12.28 (1.75) 0.79 (0.71, 0.88) 1.5x10-5 0.0005 
GP10n 6.73 (1.54) 6.85 (1.46) 0.90 (0.81, 1.01) 0.06 0.74 
GP14n 12.70 (4.29) 14.39 (4.37) 0.76 (0.68, 0.86) 7.4x10-6 0.0003 
GP15n 1.72 (0.54) 1.89 (0.59) 0.85 (0.76, 0.95) 0.003 0.07 
Galactosylation; Derived 
G0n 41.15 (9.19) 37.69 (8.09) 1.31 (1.16, 1.47) 5.5x10-6 0.0002 
G1n 42.72 (4.71) 44.26 (3.56) 0.78 (0.69, 0.87) 1.3x10-5 0.0005 
G2n 15.65 (5.00) 17.61 (5.15) 0.78 (0.69, 0.87) 2.4x10-5 0.0008 
Core fucosylation and bisecting GlcNAc; Derived 
Fn 79.47 (3.74) 79.77 (3.46) 0.96 (0.86, 1.07) 0.48 0.74 
FG0n/G0n 78.81 (4.29) 78.69 (4.11) 1.04 (0.93, 1.16) 0.46 0.74 
FG1n/G1n 80.03 (3.79) 80.45 (3.56) 0.94 (0.85, 1.05) 0.31 0.74 
FBn 17.29 (3.20) 16.97 (2.90) 1.02 (0.91, 1.14) 0.73 0.74 
FBG0n/G0n 19.15 (3.88) 19.30 (3.65) 0.94 (0.84,  1.05) 0.25 0.74 
FBG1n/G1n 18.20 (3.46) 17.82 (3.25) 1.04 (0.93, 1.16) 0.5 0.74 
FBn/Fn   0.22 (0.05) 0.21 (0.05) 1.02 (0.92, 1.14) 0.68 0.74 
FBn/Fn total  17.88 (3.38) 17.55 (3.07) 1.02 (0.92 , 1.14) 0.68 0.74 
Fn/(Bn + FBn) 4.65 (1.09) 4.71 (1.01) 0.98 (0.88, 1.09) 0.74 0.74 
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Table 4. All cause analysis 
Code Glycan Dead 
(N=489) 
Survived 
(N=740) 
Crude model (n=1229) Model I (AJCC, age, sex, n=1229) Model II (AJCC, age, sex, 
time between sample and 
surgery, operation type, bmi, 
CRP n=952) 
  Mean (SD) Mean (SD) HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Total IgG glycans (neutral and charged); Measured 
IGP3 Continuous 26.39 (7.33) 23.87 (6.37) 1.04 (1.03, 1.06) 4.7x10
-12 
1.04 (1.03, 1.06) 7.5x10
-11
 1.04 (1.02, 1.05) 7.5x10
-6
 
 RT   1.36 (1.24, 1.48) 5.9x10-11 1.35 (1.23, 1.48) 5.0x10-10 1.28 (1.14, 1.43) 2.6x10-5 
IGP5 Continuous 6.34 (1.88) 5.79 (1.57) 1.15 (1.09, 1.21) 1.5x10-8 1.14 (1.08, 1.20) 3.5x10-7 1.11 (1.04,  1.18) 0.001 
 RT   1.28 (1.17, 1.40) 9.7x10-8 1.27 (1.15, 1.39) 1.4x10-6 1.19 (1.06, 1.34) 0.002 
IGP7 Continuous 18.26 (2.21) 18.67 (1.81) 0.91 (0.87, 0.96) 0.0001 0.93 (0.88, 0.97) 0.001 0.92 (0.87, 0.97) 0.003 
 RT   0.85 (0.77, 0.93) 0.001 0.87 (0.79, 0.95) 0.003 0.87 (0.78, 0.97) 0.01 
IGP8 Continuous 9.38 (1.36) 9.83 (1.35) 0.83 (0.78, 0.89) 3.4x10-8 0.86 (0.80, 0.91) 2.6x10-6 0.87 (0.81, 0.94) 0.0002 
 RT   0.78 (0.74, 0.85) 3.4x10-8 0.81 (0.74, 0.89) 4.4x10-6 0.83 (0.75, 0.92) 0.0003 
IGP9 Continuous 5.45 (1.23) 5.48 (1.15) 0.96 (0.89, 1.04) 0.35 0.96 (0.88, 1.03) 0.26 0.95 (0.87, 1.04) 0.29 
 RT   0.95 (0.87, 1.04) 0.25 0.94 (0.85, 1.03) 0.16 0.93 (0.84, 1.04) 0.20 
IGP13 Continuous 10.19 (3.13) 11.44 (3.13) 0.89 (0.87, 0.92) 8.9x10-13 0.90 (0.87, 0.93) 1.4x10-10 0.92 (0.89, 0.96) 4.0x10-5 
 RT   0.70 (0.64, 0.77) 5.2x10-14 0.71 (0.65, 0.79) 1.6x10-11 0.77 (0.68, 0.86) 9.6x10-6 
IGP14 Continuous 1.38 (0.41) 1.50 (0.43) 0.55 (0.44, 0.70) 4.0x10-7 0.59 (0.46, 0.74) 5.9x10-6 0.70 (0.53, 0.92) 0.01 
 RT   0.78 (0.71, 0.85) 9.0x10-8 0.80 (0.73, 0.88) 2.0x10-6 0.86 (0.77, 0.96) 0.007 
IGP17 Continuous 7.78 (2.29) 8.47 (2.34) 0.89 (0.85, 0.93) 9.3x10-8 0.89 (0.85, 0.93) 1.3x10-7 0.91 (0.86, 0.96) 0.0002 
 RT   0.76 (0.70, 0.83) 4.4x10-9 0.76 (0.69, 0.83) 8.4x10-9 0.79 (0.71, 0.89) 4.9x10-5 
IGP18 Continuous 1.87 (0.38) 1.90 (0.39) 0.85 (0.67, 1.08) 0.18 0.81 (0.65, 1.02) 0.08 0.94 (0.73, 1.22) 0.64 
 RT   0.94 (0.86, 1.03) 0.18 0.93 (0.85, 1.01) 0.10 0.98 (0.89, 1.08) 0.70 
Sialylation 
IGP24 Continuous 24.78 (3.20) 24.95 (3.10) 0.99 (0.96, 1.01) 0.33 0.97 (0.95, 1.00) 0.06 0.98 (0.95, 1.01) 0.18 
 RT   0.95 (0.87, 1.04) 0.29 0.92 (0.84, 1.00) 0.06 0.93 (0.84, 1.03) 0.18 
IGP25 Continuous 32.83 (6.17) 32.58 (6.34) 1.01 (0.99, 1.02) 0.38 1.00 (0.99, 1.02) 0.67 1.01 (0.99, 1.02) 0.48 
 RT   1.04 (0.95, 1.14) 0.37 1.02 (0.93, 1.12) 0.65 1.04 (0.94, 1.15) 0.47 
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IGP26 Continuous 16.35 (3.63) 17.35 (3.61) 0.94 (0.91, 0.96) 7.3x10-7 0.93 (0.91, 0.96) 2.7x10-7 0.94 (0.92, 0.97) 0.0003 
 RT   0.79 (0.72, 0.86) 1.6x10
-7 
0.77 (0.71, 0.85) 6.2x10
-8 
0.81 (0.72, 0.90) 0.0001 
IGP27 Continuous 21.21 (4.88) 21.82 (4.96) 0.98 (0.96, 1.00) 0.04 0.98 (0.96, 1.00) 0.03 0.99 (0.97, 1.01) 0.30 
 RT   0.91 (0.83, 0.99) 0.04 0.91 (0.83, 0.99) 0.03 0.95 (0.86, 1.05) 0.30 
IGP29 Continuous 40.18 (2.99) 39.51 (2.77) 1.07 (1.04, 1.10) 1.2x10-5 1.03 (1.00, 1.06) 0.03 1.01 (0.98, 1.05) 0.47 
 RT   1.23 (1.12, 1.35) 9.2x10-6 1.12 (1.03, 1.23) 0.10 1.06 (0.95, 1.18) 0.28 
IGP31 Continuous 37.02 (3.87) 36.41 (3.97) 1.04 (1.01, 1.06) 0.002 1.03 (1.01, 1.05) 0.006 1.03 (1.00, 1.05) 0.04 
 RT   1.15 (1.05, 1.26) 0.002 1.14 (1.04, 1.24) 0.004 1.12 (1.01, 1.24) 0.03 
Bisecting GlcNAc 
IGP36 Continuous 0.30 (0.08) 0.28 (0.07) 8.74 (2.87, 26.66) 0.0001 7.95 (2.43, 26.01) 0.001 9.40 (2.30, 38.49) 0.002 
 RT   1.19 (1.09, 1.30) 0.0001 1.18 (1.07, 1.29) 0.001 1.19 (1.06, 1.33) 0.002 
IGP37 Continuous 0.17 (0.05) 0.16 (0.05) 19.00 (3.31, 109.06) 0.001 19.22 (3.12, 118.60) 0.001 30.56 (3.50, 267.02) 0.002 
 RT   1.16 (1.06, 1.27) 0.001 1.16 (1.06, 1.27) 0.002 1.18 (1.06, 1.32) 0.003 
IGP38 Continuous 0.14 (0.04) 0.14 (0.03) 76.90 (6.38, 927.03) 0.001 73.95 (5.58, 980.16) 0.001 126.7 (5.94, 2701) 0.002 
 RT   1.17 (1.07, 1.28) 0.001 1.16 (1.06, 1.28) 0.001 1.19 (1.06, 1.32) 0.002 
IGP39 Continuous 1.35 (0.32) 1.27 (0.30) 1.82 (1.39, 2.39) 1.5x10-5 1.66 (1.26, 2.19) 0.0003 1.62 (1.16, 2.27) 0.005 
 RT   1.22 (1.11, 1.33) 1.4x10-5 1.19 (1.09, 1.30) 0.0002 1.17 (1.05, 1.31) 0.005 
IGP40 Continuous 0.56 (0.06) 0.55 (0.06) 30.19 (6.24, 146.08) 2.3x10-5 19.39 (3.90, 96.34) 0.0003 13.96 (2.03, 96.03) 0.007 
 RT   1.22 (1.11, 1.33) 1.9x10-5 1.19 (1.08, 1.30) 0.0002 1.17 (1.05, 1.30) 0.005 
Neutral IgG glycans 
IGP43 Continuous 32.33 (8.02) 29.56 (7.02) 1.04 (1.03, 1.05) 3.7x10-12 1.04 (1.03, 1.05) 1.2x10-10 1.03 (1.02, 1.05) 1.0x10-5 
 RT   1.36 (1.24, 1.49) 4.3x10-11 1.35 (1.22, 1.48) 6.9x10-10 1.28 (1.14, 1.43) 2.6x10-5 
IGP45 Continuous 7.78 (2.07) 7.18 (1.76) 1.13 (1.08, 1.18) 4.9x10-8 1.12 (1.07, 1.17) 2.0x10-6 1.09 (1.03, 1.15) 0.002 
 RT   1.27 (1.16, 1.39) 2.9x10-7 1.24 (1.13, 1.37) 9.2x10-6 1.17 (1.05, 1.31) 0.006 
IGP47 Continuous 22.59 (3.09) 23.32 (2.52) 0.92 (0.89, 0.95) 1.1x10-6 0.93 (0.90, 0.96) 5.0x10-6 0.93 (0.90, 0.97) 0.0002 
 RT   0.81 (0.74, 0.88) 4.7x10-6 0.81 (0.74, 0.89) 1.4x10-5 0.83 (0.74, 0.92) 0.001 
IGP48 Continuous 11.60 (1.81) 12.28 (1.75) 0.85 (0.81, 0.89) 1.6x10-10 0.86 (0.82, 0.91) 8.8x10-9 0.88 (0.83, 0.93) 1.3x10-5 
 RT   0.74 (0.68, 0.81) 1.5x10-10 0.76 (0.70, 0.84) 1.0x10-8 0.79 (0.71, 0.88) 1.5x10-5 
IGP49 Continuous 6.73 (1.54) 6.85 (1.46) 0.95 (0.89, 1.01) 0.08 0.94 (0.88, 1.00) 0.04 0.94 (0.87, 1.01) 0.09 
 RT   0.91 (0.83, 1.00) 0.05 0.90 (0.82, 0.98) 0.02 0.90 (0.81, 1.01) 0.06 
IGP53 Continuous 12.70 (4.29) 14.39 (4.37) 0.92 (0.90, 0.94) 3.9x10-12 0.93 (0.91, 0.95) 1.9x10-10 0.94 (0.92, 0.97) 4.7x10-5 
 RT   0.70 (0.64, 0.77) 8.5x10-14 0.71 (0.65, 0.79) 1.0x10-11 0.76 (0.68, 0.86) 7.4x10-6 
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IGP54 Continuous 1.72 (0.54) 1.89 (0.59) 0.64 (0.54, 0.75) 1.7x10-7 0.66 (0.55, 0.78) 1.5x10-6 0.75 (0.61, 0.92) 0.005 
 RT   0.77 (0.71, 0.85) 3.4x10
-8 
0.79 (0.72, 0.87) 4.5x10
-7 
0.85 (0.76, 0.95) 0.003 
Galactosylation 
IGP55 Continuous 41.15 (9.19) 37.69 (8.09) 1.04 (1.03, 1.05) 1.2x10-13 1.04 (1.03, 1.05) 5.9x10-12 1.03 (1.02, 1.04) 2.0x10-6 
 RT   1.39 (1.27, 1.53) 1.0x10-12 1.38 (1.26, 1.52) 2.7x10-11 1.31 (1.16, 1.47) 5.5x10-6 
IGP56 Continuous 42.72 (4.71) 44.26 (3.56) 0.93 (0.91, 0.95) 1.7x10-12 0.93 (0.92, 0.95) 2.2x10-11 0.94 (0.92, 0.96) 2.1x10-7 
 RT   0.75 (0.69, 0.83) 2.2x10-9 0.76 (0.69, 0.83) 8.3x10-9 0.78 (0.69, 0.87) 1.3x10-5 
IGP57 Continuous 15.65 (5.00) 17.61 (5.15) 0.94 (0.92, 0.95) 5.9x10-12 0.94 (0.92, 0.96) 4.2x10-10 0.95 (0.93, 0.98) 0.0001 
 RT   0.71 (0.65, 0.78) 2.5x10-13 0.72 (0.66, 0.80) 3.6x10-11 0.78 (0.69, 0.87) 2.4x10-5 
Core fucosylation and bisecting GlcNAc 
IGP62 Continuous 79.47 (3.74) 79.77 (3.46) 0.99 (0.96, 1.01) 0.27 0.99 (0.96, 1.02) 0.42 0.99 (0.96, 1.02) 0.41 
 RT   0.96 (0.87, 1.05) 0.32 0.97 (0.88, 1.06) 0.52 0.96 (0.86, 1.07) 0.48 
IGP63 Continuous 78.81 (4.29) 78.69 (4.11) 1.01 (0.99, 1.03) 0.34 1.01 (0.99, 1.03) 0.29 1.01 (0.98, 1.04) 0.51 
 RT   1.05 (0.96, 1.15) 0.30 1.06 (0.96, 1.16) 0.24 1.04 (0.93, 1.16) 0.46 
IGP64 Continuous 80.03 (3.79) 80.45 (3.56) 0.98 (0.96, 1.00) 0.10 0.98 (0.96, 1.01) 0.18 0.98 (0.95, 1.01) 0.25 
 RT   0.93 (0.85, 1.02) 0.12 0.95 (0.86, 1.04) 0.24 0.94 (0.85, 1.05) 0.31 
IGP66 Continuous 17.29 (3.20) 16.97 (2.90) 1.02 (0.99, 1.05) 0.14 1.01 (0.98, 1.05) 0.38 1.01 (0.97, 1.05) 0.64 
 RT   1.06 (0.97, 1.16) 0.19 1.03 (0.94, 1.13) 0.50 1.02 (0.91, 1.14) 0.73 
IGP67 Continuous 19.15 (3.88) 19.30 (3.65) 0.99 (0.96, 1.01) 0.26 0.98 (0.96, 1.01) 0.17 0.98 (0.96, 1.01) 0.28 
 RT   0.95 (0.86, 1.03) 0.22 0.93 (0.85, 1.02) 0.13 0.94 (0.84,  1.05) 0.25 
IGP68 Continuous 18.20 (3.46) 17.82 (3.25) 1.02 (0.99, 1.05) 0.12 1.02 (0.99, 1.04) 0.27 1.01 (0.98, 1.05) 0.44 
 RT   1.07 (0.98, 1.17) 0.13 1.05 (0.95, 1.15) 0.34 1.04 (0.93, 1.16) 0.50 
IGP70 Continuous 0.22 (0.05) 0.21 (0.05) 4.33 (0.71, 26.41) 0.11 2.73 (0.41, 18.15) 0.30 2.05 (0.23, 18.63) 0.52 
 RT   1.06 (0.97, 1.16) 0.19 1.03 (0.94, 1.14) 0.49 1.02 (0.92, 1.14) 0.68 
IGP71 Continuous 17.88 (3.38) 17.55 (3.07) 1.02 (0.99, 1.05) 0.16 1.01 (0.98, 1.04) 0.38 1.01 (0.98, 1.04) 0.59 
 RT   1.06 (0.97, 1.16) 0.21 1.03 (0.94, 1.14) 0.49 1.02 (0.92 , 1.14) 0.68 
IGP72 Continuous 4.65 (1.09) 4.71 (1.01) 0.97 (0.89, 1.06) 0.51 1.00 (0.91, 1.09) 0.93 0.99 (0.89, 1.10) 0.85 
 RT   0.96 (0.87, 1.05) 0.32 0.98 (0.89, 1.07) 0.64 0.98 (0.88, 1.09) 0.74 
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Table 5. CRC-specific analysis for rank transformed glycans. Q value represents the adjusted p-values using the false discovery rate 
method (Benjamini– Hochberg procedure). 
Glycan Dead 
(N=385) 
Survived 
(N=844) 
Model II (AJCC, age, sex, 
time between sample and surgery, operation type, CRP, bmi, 
n=971) 
 Mean (SD) Mean (SD) HR (95% CI) p-value q-value 
Total IgG glycans (neutral and charged); Measured 
GP4 26.20 (7.31) 24.27 (6.59) 1.23 (1.09, 1.40) 0.001 0.04 
GP6 6.23 (1.85) 5.91 (1.63) 1.10 (0.97, 1.25) 0.14 0.99 
GP8 18.33 (2.13) 18.59 (1.91) 0.92 (0.81, 1.04) 0.16 0.99 
GP9 9.46 (1.35) 9.74 (1.38) 0.90 (0.80, 1.01) 0.06 0.99 
GP10 5.40 (1.19) 5.50 (1.18) 0.90 (0.80, 1.02) 0.11 0.99 
GP11 10.30 (3.19) 11.24 (3.15) 0.81 (0.71, 0.92) 0.002 0.06 
GP15 1.38 (0.40) 1.49 (0.43) 0.86 (0.76, 0.98) 0.02 0.46 
GP18 7.87 (2.31) 8.35 (2.34) 0.82 (0.72, 0.93) 0.002 0.06 
GP19 1.87 (0.37) 1.90 (0.39) 1.00 (0.90, 1.12) 0.98 0.99 
Sialylation; Derived 
FGS/(FG+FGS) 24.84 (3.24) 24.90 (3.09) 0.90 (0.80, 1.01) 0.08 0.99 
FBGS/(FBG+FBGS 32.93 (6.13) 32.56 (6.34) 1.05 (0.94, 1.19) 0.38 0.99 
FGS/(F+FG+FGS) 16.47 (3.64) 17.17 (3.63) 0.82 (0.72, 0.92) 0.001 0.04 
FBGS/(FB+FBG+FBGS) 21.38 (4.93) 21.66 (4.94) 0.99 (0.88, 1.11) 0.8 0.99 
FG2S1/(FG2+FG2S1+FG2S2) 40.22 (3.05) 39.57 (2.77) 1.00 (0.89., 1.13) 0.99 0.99 
FBG2S1/(FBG2+FBG2S1+FBG2S2) 37.11 (3.80) 36.44 (3.99) 1.17 (1.04, 1.31) 0.009 0.25 
Bisecting GlcNAc; Derived 
FBStotal/FStotal 0.30 (0.07) 0.29 (0.08) 1.17 (1.03, 1.33) 0.02 0.46 
FBS1/FS1 0.17 (0.05) 0.16 (0.05) 1.19 (1.05, 1.35) 0.006 0.17 
FBS1/(FS1+FBS1) 0.14 (0.03) 0.14 (0.03) 1.19 (1.06, 1.35) 0.005 0.15 
FBS2/FS2 1.33 (0.32) 1.29 (0.30) 1.10 (0.98, 1.25) 0.12 0.99 
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FBS2/(FS2+FBS2) 0.56 (0.06) 0.55 (0.06) 1.10 (0.97, 1.25) 0.13 0.99 
Neutral IgG glycans; Measured 
GP4n 32.14 (8.00) 29.98 (7.24) 1.24 (1.09, 1.41) 0.001 0.04 
GP6n 7.65 (2.07) 7.31 (1.83) 1.08 (0.94, 1.22) 0.27 0.99 
GP8n 22.71 (3.01) 23.18 (2.66) 0.87 (0.77, 0.98) 0.02 0.46 
GP9n 11.72 (1.81) 12.14 (1.79) 0.85 (0.76, 0.97) 0.01 0.26 
GP10n 6.68 (1.49) 6.85 (1.50)  0.88 (0.77, 0.99) 0.03 0.66 
GP14n 12.86 (4.38) 14.11 (4.38) 0.80 (0.71, 0.92) 0.001 0.04 
GP15n 1.72 (0.53) 1.87 (0.59) 0.85 (0.75, 0.97) 0.01 0.26 
Galactosylation; Derived 
G0n 40.83 (9.18) 38.26 (8.36) 1.24 (1.09, 1.41) 0.001 0.04 
G1n 42.90 (4.63) 43.99 (3.83) 0.82 (0.72, 0.94) 0.003 0.09 
G2n 15.79 (5.09) 17.30 (5.16) 0.81 (0.71, 0.93) 0.002 0.06 
Core fucosylation and bisecting GlcNAc; Derived 
Fn 79.68 (3.70) 79.63 (3.52) 1.02 (0.90, 1.15) 0.77 0.99 
FG0n/G0n 79.01 (4.23) 78.62 (4.16) 1.10 (0.97, 1.24) 0.13 0.99 
FG1n/G1n 80.24 (3.73) 80.30 (3.62) 1.00 (0.89, 1.14) 0.94 0.99 
FBn 17.10 (3.15) 17.09 (2.97) 0.95 (0.84, 1.08) 0.44 0.99 
FBG0n/G0n 18.98 (3.81) 19.36 (3.70) 0.89 (0.79, 1.01) 0.07 0.99 
FBG1n/G1n 18.01 (3.39) 17.96 (3.32) 0.97 (0.86, 1.10) 0.64 0.99 
FBn/Fn   0.21 (0.05) 0.21 (0.05) 0.95 (0.84, 1.08) 0.47 0.99 
FBn/Fn total  17.68 (3.33) 17.68 (3.14) 0.96 (0.85, 1.09) 0.5 0.99 
Fn/(Bn + FBn) 4.71 (1.06) 4.68 (1.03) 1.05 (0.92, 1.18) 0.47 0.99 
 50 
  
Table 6. CRC-specific analysis 
Code Glycan Dead 
(N=385) 
Survived 
(N=844) 
Crude model (n=1229) Model I (AJCC, age, sex, 
n=1229) 
Model II (AJCC, age, sex, 
time between sample and 
surgery, operation type, CRP, 
bmi, n=971) 
  Mean (SD) Mean (SD) HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Total IgG glycans (neutral and charged); Measured 
IGP3 Continuous 26.20 (7.31) 24.27 (6.59) 1.04 (1.02, 1.05) 5.9x10-8 1.04 (1.03, 1.06) 2.2x10-8 1.03 (1.01, 1.05) 0.001 
 RT   1.31 (1.18, 1.45) 2.8x10-7 1.33 (1.20, 1.48) 5.5x10-8 1.23 (1.09, 1.40) 0.001 
IGP5 Continuous 6.23 (1.85) 5.91 (1.63) 1.10 (1.04, 1.17) 0.0004 1.12 (1.05, 1.18) 0.0002 1.06 (0.99,  1.14) 0.10 
 RT   1.18 (1.07, 1.31) 0.001 1.22 (1.09, 1.35) 0.0003 1.10 (0.97, 1.25) 0.14 
IGP7 Continuous 18.33 (2.13) 18.59 (1.91) 0.94 (0.89, 0.99) 0.01 0.94 (0.89, 0.99) 0.01 0.95 (0.89, 1.01) 0.10 
 RT   0.89 (0.80, 0.99) 0.03 0.89 (0.80, 0.98) 0.02 0.92 (0.81, 1.04) 0.16 
IGP8 Continuous 9.46 (1.35) 9.74 (1.38) 0.87 (0.81, 0.94) 0.003 0.90 (0.84, 0.97) 0.006 0.92 (0.84, 1.00) 0.05 
 RT   0.83 (0.75, 0.92) 0.0003 0.88 (0.79, 0.97) 0.009 0.90 (0.80, 1.01) 0.06 
IGP9 Continuous 5.40 (1.19) 5.50 (1.18) 0.93 (0.85, 1.01) 0.10 0.93 (0.85, 1.02) 0.11 0.92 (0.83, 1.03) 0.15 
 RT   0.91 (0.82, 1.01) 0.08 0.91 (0.82, 1.01) 0.07 0.90 (0.80, 1.02) 0.11 
IGP13 Continuous 10.30 (3.19) 11.24 (3.15) 0.91 (0.88, 0.94) 3.5x10-8 0.91 (0.88, 0.94) 5.3x10-8 0.94 (0.90, 0.98) 0.004 
 RT   0.73 (0.66, 0.81) 5.3x10-9 0.73 (0.66, 0.81) 1.5x10-8 0.81 (0.71, 0.92) 0.002 
IGP14 Continuous 1.38 (0.40) 1.49 (0.43) 0.54 (0.42, 0.70) 2.9x10-6 0.56 (0.43, 0.72) 1.2x10-5 0.70 (0.51, 0.96) 0.03 
 RT   0.77 (0.70, 0.86) 9.7x10-7 0.79 (0.71, 0.87) 5.7x10-6 0.86 (0.76, 0.98) 0.02 
IGP17 Continuous 7.87 (2.31) 8.35 (2.34) 0.91 (0.87, 0.96) 0.0001 0.90 (0.85, 0.94) 5.2x10
-6
 0.92 (0.87, 0.97) 0.003 
 RT   0.80 (0.72, 0.89) 2.4x10-5 0.77 (0.70, 0.86) 1.4x10-6 0.82 (0.72, 0.93) 0.002 
IGP18 Continuous 1.87 (0.37) 1.90 (0.39) 0.85 (0.65, 1.10) 0.22 0.78 (0.60, 1.02) 0.07 0.99 (0.74, 1.33) 0.97 
 RT   0.94 (0.85, 1.04) 0.24 0.92 (0.83, 1.01) 0.08 1.00 (0.90, 1.12) 0.98 
Sialylation; Derived 
IGP24 Continuous 24.84 (3.24) 24.90 (3.09) 0.99 (0.96, 1.02) 0.63 0.97 (0.94, 1.00) 0.06 0.97 (0.93, 1.00) 0.09 
 RT   0.97 (0.88, 1.07) 0.56 0.91 (0.83, 1.01) 0.07 0.90 (0.80, 1.01) 0.08 
IGP25 Continuous 32.93 (6.13) 32.56 (6.34) 1.01 (0.99, 1.03) 0.27 1.00 (0.99, 1.02) 0.67 1.01 (0.99, 1.03) 0.37 
 51 
  
 RT   1.06 (0.96, 1.17) 0.26 1.02 (0.92, 1.13) 0.65 1.05 (0.94, 1.19) 0.38 
IGP26 Continuous 16.47 (3.64) 17.17 (3.63) 0.95 (0.92, 0.98) 0.0003 0.94 (0.91, 0.96) 7.4x10
-6
 0.95 (0.92, 0.98) 0.002 
 RT   0.82 (0.74, 0.91) 0.0001 0.78 (0.71, 0.87) 3.4x10-6 0.82 (0.72, 0.92) 0.001 
IGP27 Continuous 21.38 (4.93) 21.66 (4.94) 0.99 (0.97, 1.01) 0.29 0.98 (0.96, 1.00) 0.08 1.00 (0.97, 1.02) 0.79 
 RT   0.95 (0.86, 1.05) 0.30 0.92 (0.83, 1.01) 0.09 0.99 (0.88, 1.11) 0.80 
IGP29 Continuous 40.22 (3.05) 39.57 (2.77) 1.07 (1.04, 1.11) 4.0x10-5 1.02 (0.99, 1.06) 0.13 0.99 (0.96, 1.03) 0.75 
 RT   1.24 (1.12, 1.38) 3.7x10-5 1.10 (1.00, 1.22) 0.05 1.00 (0.89., 1.13) 0.99 
IGP31 Continuous 37.11 (3.80) 36.44 (3.99) 1.04 (1.01, 1.07) 0.002 1.04 (1.01, 1.06) 0.006 1.04 (1.01, 1.07) 0.01 
 RT   1.18 (1.06, 1.30) 0.001 1.15 (1.05, 1.27) 0.004 1.17 (1.04, 1.31) 0.009 
Bisecting GlcNAc; Derived 
IGP36 Continuous 0.30 (0.07) 0.29 (0.08) 4.42 (1.23, 15.89) 0.02 5.06 (1.30, 19.60) 0.02 7.14 (1.41, 36.18) 0.02 
 RT   1.13 (1.03, 1.25) 0.01 1.14 (1.03, 1.27) 0.01 1.17 (1.03, 1.33) 0.02 
IGP37 Continuous 0.17 (0.05) 0.16 (0.05) 7.92 (1.06, 58.84) 0.04 11.26 (1.42, 89.56) 0.02 30.51 (2.53, 367.34) 0.007 
 RT   1.12 (1.01, 1.23) 0.03 1.13 (1.02, 1.26) 0.02 1.19 (1.05, 1.35) 0.006 
IGP38 Continuous 0.14 (0.03) 0.14 (0.03) 24.79 (1.45, 423.15) 0.03 40.48 (2.19, 748.37) 0.01 138.34 (4.24, 4509) 0.006 
 RT   1.12 (1.02, 1.24) 0.02 1.14 (1.03, 1.27) 0.01 1.19 (1.06, 1.35) 0.005 
IGP39 Continuous 1.33 (0.32) 1.29 (0.30) 1.53 (1.12, 2.08) 0.008 1.42 (1.04, 1.94) 0.03 1.35 (0.92, 1.98) 0.13 
 RT   1.15 (1.04, 1.27) 0.006 1.13 (1.02, 1.25) 0.02 1.10 (0.98, 1.25) 0.12 
IGP40 Continuous 0.56 (0.06) 0.55 (0.06) 10.50 (1.78, 61.78) 0.009 7.90 (1.32, 47.39) 0.02 4.87 (0.55, 43.15) 0.16 
 RT   1.15 (1.04, 1.27) 0.008 1.13 (1.02, 1.25) 0.02 1.10 (0.97, 1.25) 0.13 
Neutral IgG glycans; Derived 
IGP43 Continuous 32.14 (8.00) 29.98 (7.24) 1.04 (1.02, 1.05) 3.5x10-8 1.02 (1.03, 1.05) 2.8x10-8 1.03 (1.01, 1.05) 0.001 
 RT   1.32 (1.19, 1.46) 1.6x10-7 1.33 (1.20, 1.48) 6.4x10-8 1.24 (1.09, 1.41) 0.001 
IGP45 Continuous 7.65 (2.07) 7.31 (1.83) 1.09 (1.04, 1.14) 0.0009 1.10 (1.04, 1.15) 0.001 1.04 (0.98, 1.11) 0.19 
 RT   1.17 (1.06, 1.30) 0.002 1.19 (1.07, 1.33) 0.001 1.08 (0.94, 1.22) 0.27 
IGP47 Continuous 22.71 (3.01) 23.18 (2.66) 0.94 (0.91, 0.98) 0.001 0.93 (0.90, 0.97) 0.0002 0.95 (0.91, 0.99) 0.02 
 RT   0.85 (0.77, 0.95) 0.003 0.83 (0.75, 0.92) 0.0003 0.87 (0.77, 0.98) 0.02 
IGP48 Continuous 11.72 (1.81) 12.14 (1.79) 0.89 (0.84, 0.94) 2.2x10-5 0.90 (0.85, 0.95) 0.0002 0.92 (0.86, 0.98) 0.01 
 RT   0.80 (0.72, 0.89) 2.1x10-5 0.82 (0.74, 0.91) 0.0002 0.85 (0.76, 0.97) 0.01 
IGP49 Continuous 6.68 (1.49) 6.85 (1.50) 0.92 (0.86, 0.99) 0.03 0.91 (0.85, 0.98) 0.01 0.92 (0.84, 1.00) 0.04 
 RT   0.89 (0.80, 0.98) 0.02 0.87 (0.78, 0.97) 0.009 0.88 (0.77, 0.99) 0.03 
IGP53 Continuous 12.86 (4.38) 14.11 (4.38) 0.93 (0.91, 0.96) 1.1x10-7 0.93 (0.91, 0.96) 5.6x10-8 0.95 (0.93, 0.98) 0.003 
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 RT   0.74 (0.67, 0.82) 9.1x10-9 0.73 (0.66, 0.81) 9.7x10-9 0.80 (0.71, 0.92) 0.001 
IGP54 Continuous 1.72 (0.53) 1.87 (0.59) 0.63 (0.52, 0.76) 2.4x10
-6
 0.63 (0.52, 0.77) 3.9x10
-6
 0.76 (0.60, 0.95) 0.02 
 RT   0.77 (0.70, 0.86) 8.5x10-11 0.78 (0.70, 0.86) 2.0x10-6 0.85 (0.75, 0.97) 0.01 
Galactosylation; Derived 
IGP55 Continuous 40.83 (9.18) 38.26 (8.36) 1.03 (1.02, 1.04) 1.7x10-8 1.03 (1.02, 1.05) 1.0x10-8 1.02 (1.01, 1.04) 0.001 
 RT   1.33 (1.20, 1.47) 7.0x10-8 1.35 (1.22, 1.50) 2.3x10-8 1.24 (1.09, 1.41) 0.001 
IGP56 Continuous 42.90 (4.63) 43.99 (3.83) 0.94 (0.92, 0.96) 2.5x10-7 0.94 (0.92, 0.96) 1.1x10-7 0.95 (0.92, 0.98) 0.0004 
 RT   0.80 (0.72, 0.88) 1.5x10-5 0.78 (0.70, 0.86) 2.4x10-6 0.82 (0.72, 0.94) 0.003 
IGP57 Continuous 15.79 (5.09) 17.30 (5.16) 0.94 (0.92, 0.96) 6.5x10-8 0.94 (0.92, 0.96) 6.1x10-8 0.96 (0.94, 0.99) 0.005 
 RT   0.74 (0.66, 0.82) 7.0x10-9 0.73 (0.66, 0.82) 1.2x10-8 0.81 (0.71, 0.93) 0.002 
Core fucosylation and bisecting GlcNAc; Derived 
IGP62 Continuous 79.68 (3.70) 79.63 (3.52) 1.00 (0.98, 1.03) 0.79 1.00 (0.97, 1.03) 0.94 1.00 (0.97, 1.04) 0.88 
 RT   1.02 (0.92, 1.13) 0.71 1.01 (0.91, 1.13) 0.80 1.02 (0.90, 1.15) 0.77 
IGP63 Continuous 79.01 (4.23) 78.62 (4.16) 1.02 (1.00, 1.05) 0.07 1.02 (1.00, 1.05) 0.10 1.02 (0.99, 1.05) 0.17 
 RT   1.10 (1.00, 1.22) 0.06 1.10 (0.99, 1.22) 0.07 1.10 (0.97, 1.24) 0.13 
IGP64 Continuous 80.24 (3.73) 80.30 (3.62) 1.00 (0.97, 1.02) 0.84 1.00 (0.97, 1.02) 0.75 1.00 (0.96, 1.03) 0.94 
 RT   0.99 (0.90, 1.10) 0.92 0.99 (0.89, 1.11) 0.90 1.00 (0.89, 1.14) 0.94 
IGP66 Continuous 17.10 (3.15) 17.09 (2.97) 1.00 (0.97, 1.03) 0.99 1.00 (0.96, 1.03) 0.95 0.99 (0.95, 1.03) 0.51 
 RT   0.99 (0.90, 1.10) 0.89 0.99 (0.89, 1.10) 0.80 0.95 (0.84, 1.08) 0.44 
IGP67 Continuous 18.98 (3.81) 19.36 (3.70) 0.97 (0.95, 1.00) 0.06 0.97 (0.95, 1.00) 0.06 0.97 (0.94, 1.00) 0.08 
 RT   0.90 (0.82, 1.00) 0.05 0.90 (0.81, 1.00) 0.04 0.89 (0.79, 1.01) 0.07 
IGP68 Continuous 18.01 (3.39) 17.96 (3.32) 1.00 (0.97, 1.03) 0.87 1.00 (0.97, 1.03) 0.93 0.99 (0.96, 1.03) 0.73 
 RT   1.00 (0.91, 1.11) 0.94 1.00 (0.90, 1.11) 0.93 0.97 (0.86, 1.10) 0.64 
IGP70 Continuous 0.21 (0.05) 0.21 (0.05) 1.08 (0.13, 8.62) 0.94 1.06 (0.12, 9.53) 0.30 0.50 (0.04, 6.76) 0.60 
 RT   0.99 (0.90, 1.10) 0.87 0.99 (0.89, 1.10) 0.79 0.95 (0.84, 1.08) 0.47 
IGP71 Continuous 17.68 (3.33) 17.68 (3.14) 1.00 (0.97, 1.03) 0.96 1.00 (0.97, 1.03) 0.96 0.99 (0.95, 1.03) 0.58 
 RT   0.99 (0.89, 1.10) 0.85 0.99 (0.89, 1.10) 0.80 0.96 (0.85, 1.09) 0.50 
IGP72 Continuous 4.71 (1.06) 4.68 (1.03) 1.03 (0.93, 1.13) 0.61 1.03 (0.93, 1.14) 0.54 1.05 (0.93, 1.18) 0.42 
 RT   1.02 (0.92, 1.13) 0.68 1.02 (0.92, 1.14) 0.67 1.05 (0.92, 1.18) 0.47 
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These results show that IgG glycans linked to mainly galactosylation are strongly associated 
with all-cause mortality and CRC mortality.  
In particular an increase in the percentage of agalactosylated structures (G0
n
) and a decrease 
in mono- and di-galactosylated structures (G1
n
, G2
n
) was associated with poorer all-cause 
and CRC-specific mortality. Statistically significant associations were also observed for 
decreased sialylation and increase in the incidence of bisecting GlcNAc (Tables 3 and 5).  
 
Results were similar when AJCC stage 4 patients were excluded from the analysis (Tables 7 
and 8) . The minus logarithm of the q-values (FDR corrected p-values) of all 39 glycan traits 
for all-cause mortality and CRC-specific model III are presented in a Manhattan-like plot 
(Figure  6).  
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Table 7. All-cause mortality analysis for stages 1-3. 
 
Code Glycan Dead 
(N=355) 
Survived 
(N=728) 
Crude model (n=1083) Model I (AJCC, age, sex, 
n=1083) 
Model II (AJCC, age, sex, 
time between sample and surgery, 
operation type, bmi, CRP n=850) 
  Mean (SD) Mean (SD) HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Total IgG glycans (neutral and charged); Measured 
IGP3 Continuous 26.11 (7.30) 23.90 (6.34) 1.04 (1.03, 1.06) 9.5x10-8 1.04 (1.02, 1.05) 1.6x10-6 1.04 (1.02, 1.06) 9.6x10-5 
 RT   1.32 (1.18, 1.47) 4.4x10-7 1.29 (1.16, 1.45) 8.13x10-6 1.28 (1.11, 1.46) 0.0004 
IGP5 Continuous 6.43 (1.86) 5.80 (1.86) 1.18 (1.12, 1.25) 3.3x10-9 1.16 (1.10, 1.24) 7.6x10-7 1.16 (1.08, 1.25) 3.8x10-5 
 RT   1.35 (1.22, 1.51) 3.0x10-8 1.30 (1.16, 1.47) 7.2x10-6 1.30 (1.13, 1.49) 0.0002 
IGP7 Continuous 18.25 (2.18) 18.66 (1.80) 0.91 (0.86, 0.96) 0.001 0.92 (0.87, 0.98) 0.006 0.91 (0.85, 0.97) 0.002 
 RT   0.84 (0.75, 0.93) 0.001 0.87 (0.78, 0.97) 0.01 0.84 (0.74, 0.96) 0.008 
IGP8 Continuous 9.35 (1.39) 9.84 (1.34) 0.81 (0.75, 0.87) 5.9x10-8 0.81 (0.75, 0.88) 2.1x10-7 0.80 (0.73, 0.87) 7.9x10-7 
 RT   0.75 (0.67, 0.83) 6.9x10-8 0.75 (0.68, 0.84) 2.8x10-7 0.73 (0.65, 0.83) 1.0x10-6 
IGP9 Continuous 5.57 (1.27) 5.48 (1.16) 1.05 (0.96, 1.14) 0.32 1.02 (0.93, 1.12) 0.65 1.00 (0.91, 1.11) 0.94 
 RT   1.04 (0.94, 1.16) 0.44 1.01 (0.91, 1.13) 0.81 1.00 (0.88, 1.13) 0.95 
IGP13 Continuous 10.29 (3.07) 11.42 (3.11) 0.90 (0.87, 0.93) 8.1x10-9 0.91 (0.87, 0.94) 7.9x10-7 0.92 (0.88, 0.96) 0.0003 
 RT   0.71 (0.64, 0.80) 1.6x10-9 0.73 (0.65, 0.82) 1.6x10-7 0.75 (0.65, 0.87) 7.5x10-5 
IGP14 Continuous 1.41 (0.41) 1.50 (0.43) 0.64 (0.49, 0.83) 0.001 0.67 (0.51, 0.87) 0.003 0.73 (0.53, 1.00) 0.05 
 RT   0.83 (0.74, 0.92) 0.0004 0.84 (0.75, 0.94) 0.002 0.87 (0.76, 0.99) 0.03 
IGP17 Continuous 7.83 (2.30) 8.45 (2.28) 0.90 (0.86, 0.94) 2.6x10-5 0.91 (0.86, 0.96) 0.0005 0.92 (0.87, 0.99) 0.02 
 RT   0.77 (0.70, 0.86) 3.2x10-6 0.79 (0.70, 0.89) 5.7x10-5 0.81 (0.71, 0.93) 0.003 
IGP18 Continuous 1.88 (0.39) 1.90 (0.39) 0.89 (0.67, 1.16) 0.38 0.87 (0.67, 1.13) 0.31 0.89 (0.66, 1.20) 0.43 
 RT   0.95 (0.86, 1.05) 0.33 0.95 (0.86, 1.05) 0.33 0.95 (0.85, 1.07) 0.40 
Sialylation 
IGP24 Continuous 24.78 (3.18) 24.93 (3.04) 0.99 (0.95, 1.02) 0.49 0.99 (0.96, 1.03) 0.58 1.00 (0.96, 1.04) 0.88 
 RT   0.96 (0.86, 1.06) 0.40 0.96 (0.86, 1.07) 0.48 1.00 (0.88, 1.13) 0.99 
IGP25 Continuous 32.49 (6.30) 32.58 (6.38) 1.00 (0.98, 1.02) 0.91 1.00 (0.98, 1.02) 0.94 1.00 (0.98, 1.02 0.90 
 RT   0.99 (0.90, 1.10) 0.91 1.00 (0.90, 1.10) 0.96 1.01 (0.90, 1.13) 0.89 
IGP26 Continuous 16.43 (3.64) 17.32 (3.55) 0.94 (0.91, 0.97) 0.0001 0.95 (0.92, 0.98) 0.001 0.95 (0.92, 0.99) 0.02 
 RT   0.80 (0.72, 0.89) 4.0x10-5 0.81 (0.73, 0.91) 0.0002 0.83 (0.73, 0.95) 0.007 
IGP27 Continuous 21.01 (5.01) 21.81 (4.97) 0.97 (0.95, 1.00) 0.02 0.98 (0.96, 1.00) 0.05 0.98 (0.96, 1.01) 0.14 
 RT   0.87 (0.79, 0.97) 0.01 0.90 (0.81, 1.00) 0.05 0.91 (0.81, 1.02) 0.12 
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IGP29 Continuous 40.09 (2.90) 39.49 (2.70) 1.07 (1.03, 1.11) 0.0001 1.06 (1.02, 1.10) 0.001 1.06 (1.01, 1.10) 0.009 
 RT   1.23 (1.10, 1.37) 0.0002 1.20 (1.07, 1.34) 0.001 1.19 (1.05, 1.35) 0.007 
IGP31 Continuous 36.78 (3.86) 36.40 (3.97) 1.02 (1.00, 1.05) 0.10 1.02 (0.99, 1.05) 0.12 1.01 (0.98, 1.04) 0.58 
 RT   1.10 (0.99, 1.21) 0.08 1.09 (0.98, 1.21) 0.10 1.04 (0.92, 1.17) 0.53 
Bisecting GlcNAc 
IGP36 Continuous 0.30 (0.08) 0.28 (0.07) 10.21 (2.80, 37.30) 0.0004 7.18 (1.82, 28.32) 0.005 7.26 (1.42, 37.22) 0.02 
 RT   1.20 (1.09, 1.34) 0.0004 1.17 (1.05, 1.30) 0.006 1.16 (1.02, 1.32) 0.02 
IGP37 Continuous 0.17 (0.05) 0.16 (0.05) 20.26 (2.63, 155.9) 0.004 13.32 (1.57, 112.9) 0.02 11.89 (0.94, 150.5) 0.06 
 RT   1.16 (1.05, 1.29) 0.005 1.13 (1.02, 1.26) 0.02 1.12 (0.99, 1.28) 0.08 
IGP38 Continuous 0.14 (0.04) 0.14 (0.03) 84.20 (4.58, 1549) 0.003 43.03 (2.04, 909.9) 0.02 33.95 (0.92, 12.46) 0.06 
 RT   1.17 (1.05, 1.30) 0.003 1.14 (1.02, 1.27) 0.02 1.13 (0.99, 1.28) 0.07 
IGP39 Continuous 1.36 (0.33) 1.27 (0.30) 2.04 (1.49, 2.81) 1.0x10-5 1.86 (1.34, 2.58) 0.0002 1.84 (1.24, 2.73) 0.002 
 RT   1.26 (1.13, 1.40) 2.0x10-5 1.22 (1.10, 1.36) 0.0003 1.21 (1.06, 1.37) 0.005 
IGP40 Continuous 0.56 (0.06) 0.55 (0.06) 55.05 (8.57, 353.6) 2.4x10-5 32.58 (4.82, 220.4) 0.0004 24.66 (2.52, 241.26) 0.006 
 RT   1.26 (1.13, 1.40) 2.2x10-5 1.22 (1.09, 1.36) 0.0003 1.20 (1.06, 1.37) 0.005 
Neutral IgG glycans 
IGP43 Continuous 31.97 (7.93) 29.59 (6.98) 1.04 (1.02, 1.05) 1.3x10-7 1.04 (1.02, 1.05) 2.4x10-6 1.03 (1.02, 1.05) 0.0001 
 RT   1.32 (1.18, 1.47) 5.3x10-7 1.29 (1.15, 1.45) 1.0x10-5 1.28 (1.12, 1.47) 0.0004 
IGP45 Continuous 7.88 (2.08) 7.18 (1.75) 1.16 (1.10, 1.22) 5.4x10-9 1.14 (1.08, 1.21) 1.6x10-6 1.14 (1.07, 1.22) 5.8x10-5 
 RT   1.35 (1.21, 1.50) 4.8x10-8 1.29 (1.15, 1.45) 1.5x10-5 1.29 (1.12, 1.48) 0.0003 
IGP47 Continuous 22.58 (3.07) 23.30 (2.50) 0.92 (0.88, 0.95) 1.3x10-5 0.93 (0.89, 0.97) 0.0004 0.92 (0.88, 0.97) 0.0004 
 RT   0.79 (0.71, 0.89) 3.8x10-5 0.82 (0.73, 0.92) 0.001 0.81 (0.71, 0.92) 0.002 
IGP48 Continuous 11.56 (1.84) 12.29 (1.74) 0.83 (0.78, 0.88) 8.8x10-10 0.84 (0.79, 0.89) 6.5x10-9 0.83 (0.77, 0.89) 1.1x10-7 
 RT   0.72 (0.64, 0.80) 8.0x10-10 0.72 (0.65, 0.81) 7.0x10-9 0.71 (0.63, 0.81) 1.2x10-7 
IGP49 Continuous 6.88 (1.60) 6.84 (1.47) 1.01 (0.94, 1.08) 0.80 0.99 (0.93, 1.07) 0.88 0.99 (0.91, 1.07) 0.73 
 RT   1.00 (0.90, 1.12) 0.95 0.98 (0.88, 1.09) 0.72 0.97 (0.86, 1.10) 0.63 
IGP53 Continuous 12.82 (4.23) 14.36 (4.34) 0.93 (0.90, 0.95) 2.0x10-8 0.93 (0.91, 0.96) 1.5x10-6 0.94 (0.91, 0.97) 0.001 
 RT   0.72 (0.64, 0.80) 1.8x10-9 0.73 (0.65, 0.82) 1.5x10-7 0.75 (0.65, 0.87) 7.8x10-5 
IGP54 Continuous 1.76 (0.55) 1.88 (0.59) 0.70 (0.58, 0.85) 0.0004 0.73 (0.60, 0.89) 0.002 0.78 (0.62, 0.99) 0.04 
 RT   0.82 (0.73, 0.91) 0.0002 0.83 (0.75, 0.93) 0.001 0.86 (0.76, 0.98) 0.02 
Galactosylation 
IGP55 Continuous 40.89 (9.04) 37.72 (8.04) 1.04 (1.03, 1.05) 1.7x10-9 1.04 (1.02, 1.05) 7.1x10-8 1.04 (1.02, 1.05) 8.4x10-6 
 RT   1.38 (1.24, 1.54) 6.7x10-9 1.35 (1.21, 1.52) 2.9x10-7 1.34 (1.17, 1.54) 2.9x10-5 
IGP56 Continuous 42.83 (4.68) 42.25 (3.54) 0.93 (0.91, 0.96) 6.5x10-9 0.94 (0.91, 0.96) 6.9x10-8 0.93 (0.90, 0.96) 3.3x10-7 
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 RT   0.76 (0.68, 0.85) 9.3x10-7 0.77 (0.69, 0.87) 1.0x10-5 0.75 (0.65, 0.86) 2.6x10-5 
IGP57 Continuous 15.81 (4.93) 17.58 (5.12) 0.94 (0.92, 0.96) 4.1x10
-8 
0.94 (0.92, 0.97) 2.5x10
-6 
0.95 (0.93, 0.98) 0.001 
 RT   0.72 (0.65, 0.81) 5.4x10-9 0.74 (0.66, 0.83) 3.6x10-7 0.76 (0.66, 0.88) 0.0002 
Core fucosylation and bisecting GlcNAc 
IGP62 Continuous 79.17 (3.89) 79.77 (3.47) 0.97 (0.94, 0.99) 0.02 0.98 (0.95, 1.01) 0.11 0.97 (0.94, 1.01) 0.12 
 RT   0.89 (0.80, 0.99) 0.03 0.92 (0.83, 1.03) 0.15 0.91 (0.81, 1.03) 0.15 
IGP63 Continuous 78.42 (4.42) 78.69 (4.14) 0.99 (0.97, 1.01) 0.41 1.00 (0.97, 1.02) 0.74 0.99 (0.96, 1.02) 0.54 
 RT   0.96 (0.86, 1.07) 0.46 0.99 (0.89, 1.10) 0.81 0.96 (0.85, 1.09) 0.57 
IGP64 Continuous 79.71 (3.94) 80.45 (3.57) 0.96 (0.93, 0.99) 0.003 0.97 (0.94, 1.00) 0.03 0.97 (0.94, 1.00) 0.04 
 RT   0.86 (0.77, 0.96) 0.005 0.89 (0.80, 0.99) 0.04 0.88 (0.78, 1.00) 0.05 
IGP66 Continuous 17.58 (3.31) 16.97 (2.91) 1.05 (1.02, 1.09) 0.002 1.04 (1.00, 1.07) 0.04 1.04 (1.00, 1.08) 0.08 
 RT   1.16 (1.05, 1.29) 0.005 1.11 (1.00, 1.24) 0.06 1.11 (0.98, 1.26) 0.10 
IGP67 Continuous 19.52 (3.98) 19.29 (3.67) 1.01 (0.98, 1.04) 0.44 1.00 (0.98, 1.03) 0.83 1.01 (0.97, 1.04) 0.67 
 RT   1.04 (0.93, 1.15) 0.51 1.00 (0.90, 1.12) 0.93 1.02 (0.90, 1.16) 0.71 
IGP68 Continuous 18.52 (3.59) 17.82 (3.27) 1.05 (1.02, 1.08) 0.002 1.04 (1.01, 1.07) 0.02 1.04 (1.00, 1.08) 0.04 
 RT   1.17 (1.05, 1.30) 0.003 1.13 (1.01, 1.25) 0.03 1.13 (1.00, 1.28) 0.05 
IGP70 Continuous 0.22 (0.05) 0.21 (0.05) 27.42 (3.53, 213.1) 0.002 10.93 (1.32, 90.70) 0.03 10.14 (0.88, 116.8) 0.06 
 RT   1.16 (1.05, 1.29) 0.005 1.11 (0.99, 1.24) 0.06 1.11 (0.98, 1.26) 0.10 
IGP71 Continuous 18.18 (3.50) 17.55 (3.08) 1.05 (1.02, 1.08) 0.003 1.03 (1.00, 1.07) 0.04 1.03 (1.00, 1.07) 0.08 
 RT   1.16 (1.04, 1.29) 0.006 1.10 (0.99, 1.23) 0.07 1.11 (0.98, 1.26) 0.11 
IGP72 Continuous 4.57 (1.10) 4.72 (1.01) 0.90 (0.81, 1.00) 0.04 0.94 (0.84, 1.05) 0.25 0.92 (0.81, 1.04) 0.19 
 RT   0.88 (0.79, 0.97) 0.01 0.92 (0.82, 1.02) 0.12 0.91 (0.80, 1.03) 0.15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 57 
  
Table 8. CRC-specific mortality analysis for stages 1-3. 
 
Code Glycan Dead 
(N=257) 
Survived 
(N=826) 
Crude model (n=1083) Model I (AJCC, age, sex, 
n=1083) 
Model II (AJCC, age, sex, 
time between sample and 
surgery, operation type, bmi, 
CRP n=850) 
  Mean (SD) Mean (SD) HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Total IgG glycans (neutral and charged); Measured 
IGP3 Continuous 25.76 (7.28) 24.27 (6.53) 1.03 (1.01, 1.05) 0.0004 1.04 (1.02, 1.05) 0.0001 1.03 (1.01, 1.06) 0.004 
 RT   1.24 (1.10, 1.40) 0.001 1.28 (1.12, 1.46) 0.002 1.24 (1.05, 1.45) 0.01 
IGP5 Continuous 6.29 (1.85) 5.91 (1.63) 1.13 (1.05, 1.21) 0.005 1.13 (1.05, 1.22) 0.001 1.10 (1.01, 1.20) 0.04 
 RT   1.23 (1.09, 1.40) 0.001 1.23 (1.08, 1.42) 0.002 1.17 (0.99, 1.37) 0.06 
IGP7 Continuous 18.33 (2.09) 18.59 (1.90) 0.93 (0.88, 1.00) 0.04 0.94 (0.88, 1.00) 0.05 0.93 (0.86, 1.00) 0.07 
 RT   0.89 (0.78, 1.01) 0.07 0.89 (0.78, 1.02) 0.09 0.88 (0.76, 1.03) 0.11 
IGP8 Continuous 9.46 (1.38) 9.75 (1.37) 0.86 (0.79, 0.94) 0.001 0.86 (0.79, 0.95) 0.002 0.84 (0.75, 0.93) 0.001 
 RT   0.82 (0.72, 0.92) 0.001 0.82 (0.73, 0.93) 0.002 0.79 (0.68, 0.91) 0.001 
IGP9 Continuous 5.54 (1.25) 5.50 (1.18) 1.02 (0.92, 1.13) 0.67 0.99 (0.89, 1.10) 0.83 0.97 (0.85, 1.10) 0.59 
 RT   1.02 (0.90, 1.15) 0.77 0.98 (0.86, 1.11) 0.73 0.95 (0.82, 1.10) 0.52 
IGP13 Continuous 10.48 (3.14) 11.23 (3.13) 0.92 (0.89, 0.96) 0.0001 0.91 (0.87, 0.96) 8.3x10-5 0.93 (0.88, 0.99) 0.02 
 RT   0.77 (0.68, 0.87) 6.0x10-5 0.74 (0.65, 0.85) 3.1x10-5 0.79 (0.67, 0.93) 0.006 
IGP14 Continuous 1.41 (0.41) 1.49 (0.43) 0.66 (0.48, 0.89) 0.007 0.64 (0.47, 0.87) 0.004 0.73 (0.50, 1.06) 0.10 
 RT   0.84 (0.74, 0.95) 0.005 0.83 (0.73, 0.94) 0.003 0.87 (0.75, 1.01) 0.07 
IGP17 Continuous 7.99 (2.33) 8.33 (2.29) 0.93 (0.88, 0.99) 0.02 0.92 (0.87, 0.98) 0.007 0.95 (0.88, 1.02) 0.16 
 RT   0.84 (0.74, 0.95) 0.007 0.81 (0.71, 0.93) 0.003 0.86 (0.73, 1.01) 0.07 
IGP18 Continuous 1.88 (0.38) 1.89 (0.39) 0.89 (0.65, 1.23) 0.49 0.86 (0.63, 1.17) 0.34 0.94 (0.66, 1.33) 0.71 
 RT   0.96 (0.85, 1.08) 0.47 0.95 (0.85, 1.07) 0.40 0.97 (0.85, 1.11) 0.69 
Sialylation 
IGP24 Continuous 24.87 (3.25) 24.88 (3.03) 1.00 (0.96, 1.04) 0.93 0.99 (0.95, 1.03) 0.66 1.00 (0.96, 1.05) 0.85 
 RT   0.98 (0.87, 1.12) 0.81 0.96 (0.85, 1.09) 0.56 1.00 (0.86, 1.16) 0.99 
IGP25 Continuous 32.52 (6.35) 32.56 (6.35) 1.00 (0.98, 1.02) 0.98 1.00 (0.98, 1.02) 0.91 1.01 (0.98, 1.03) 0.62 
 RT   1.00 (0.89, 1.13) 0.99 1.01 (0.90, 1.13) 0.90 1.04 (0.90, 1.19) 0.62 
IGP26 Continuous 16.64 (3.67) 17.15 (3.58) 0.96 (0.93, 0.99) 0.02 0.95 (0.92, 0.99) 0.007 0.96 (0.92, 1.01) 0.11 
 RT   0.85 (0.75, 0.97) 0.01 0.83 (0.73, 0.94) 0.004 0.86 (0.74, 1.01) 0.06 
IGP27 Continuous 21.19 (5.12) 21.66 (4.95) 0.98 (0.96, 1.01) 0.17 0.98 (0.96, 1.01) 0.20 0.99 (0.96, 1.02) 0.63 
 RT   0.91 (0.81, 1.03) 0.14 0.92 (0.82, 1.04) 0.20 0.96 (0.84, 1.11) 0.59 
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IGP29 Continuous 40.13 (2.97) 39.55 (2.71) 1.08 (1.03, 1.12) 0.001 1.06 (1.02, 1.10) 0.008 1.05 (1.00, 1.10) 0.05 
 RT   1.24 (1.09, 1.41) 0.001 1.19 (1.05, 1.36) 0.007 1.17 (1.01, 1.36) 0.04 
IGP31 Continuous 36.84 (3.79) 36.43 (3.97) 1.03 (1.00, 1.06) 0.10 1.03 (1.00, 1.06) 0.06 1.02 (0.98, 1.05) 0.32 
 RT   1.11 (0.98, 1.26) 0.09 1.13 (1.00, 1.27) 0.05 1.08 (0.94, 1.24) 0.28 
Bisecting GlcNAc 
IGP36 Continuous 0.29 (0.07) 0.29 (0.08) 4.00 (0.84, 19.03) 0.08 3.86 (0.75, 19.74) 0.11 4.17 (0.58, 29.87) 0.16 
 RT   1.12 (0.99, 1.27) 0.06 1.12 (0.99, 1.27) 0.08 1.12 (0.96, 1.31) 0.14 
IGP37 Continuous 0.17 (0.05) 0.16 (0.05) 6.17 (0.53, 72.39) 0.15 6.98 (0.55, 89.35) 0.14 7.93 (0.37, 168.5) 0.18 
 RT   1.10 (0.97, 1.24) 0.13 1.11 (0.98, 1.26) 0.11 1.11 (0.95, 1.29) 0.19 
IGP38 Continuous 0.14 (0.03) 0.14 (0.03) 17.82 (0.55, 577.2) 0.11 20.69 (0.56, 761.0) 0.10 21.73 (0.29, 1602) 0.16 
 RT   1.11 (0.98, 1.26) 0.10 1.12 (0.98, 1.27) 0.09 1.12 (0.96, 1.30) 0.16 
IGP39 Continuous 1.34 (0.33) 1.29 (0.30) 1.61 (1.10, 2.35) 0.02 1.52 (1.03, 2.25) 0.04 1.45 (0.90, 2.35) 0.13 
 RT   1.16 (1.03, 1.32) 0.02 1.15 (1.01, 1.30) 0.03 1.11 (0.95, 1.30) 0.17 
IGP40 Continuous 0.56 (0.06) 0.55 (0.06) 13.15 (1.49, 116.1) 0.02 10.21 (1.10, 95.12) 0.04 5.86 (0.39, 88.93) 0.20 
 RT   1.16 (1.03, 1.31) 0.02 1.14 (1.01, 1.30) 0.04 1.11 (0.95, 1.30) 0.18 
Neutral IgG glycans 
IGP43 Continuous 31.61 (7.90) 29.98 (7.18) 1.03 (1.01, 1.05) 0.0004 1.03 (1.02, 1.05) 0.0001 1.03 (1.01, 1.05) 0.004 
 RT   1.24 (1.10, 1.41) 0.001 1.28 (1.12, 1.46) 0.0002 1.24 (1.06, 1.46) 0.008 
IGP45 Continuous 7.73 (2.07) 7.31 (1.83) 1.11 (1.05, 1.18) 0.001 1.11 (1.04, 1.19) 0.001 1.08 (1.00, 1.17) 0.05 
 RT   1.23 (1.08, 1.39) 0.001 1.22 (1.07, 1.40) 0.004 1.16 (0.98, 1.36) 0.08 
IGP47 Continuous 22.73 (2.97) 23.17 (2.63) 0.94 (0.90, 0.99) 0.01 0.94 (0.90, 0.98) 0.009 0.94 (0.89, 1.00) 0.04 
 RT   0.86 (0.75, 0.97) 0.02 0.85 (0.74, 0.97) 0.02 0.86 (0.74, 1.00) 0.06 
IGP48 Continuous 11.72 (1.84) 12.15 (1.78) 0.88 (0.82, 0.94) 0.0002 0.88 (0.82, 0.94) 0.0003 0.86 (0.79, 0.94) 0.0004 
 RT   0.79 (0.70, 0.90) 0.0002 0.79 (0.70, 0.90) 0.0003 0.76 (0.66, 0.89) 0.0004 
IGP49 Continuous 6.86 (1.56) 6.85 (1.50) 1.00 (0.92, 1.08) 0.96 0.97 (0.89, 1.05) 0.47 0.96 (0.87, 1.06) 0.42 
 RT   0.99 (0.87, 1.12) 0.88 0.95 (0.84, 1.07) 0.41 0.93 (0.81, 1.08) 0.36 
IGP53 Continuous 13.10 (4.34) 14.10 (4.35) 0.94 (0.92, 0.97) 0.0002 0.94 (0.91, 0.97) 0.0001 0.95 (0.92, 0.99) 0.02 
 RT   0.77 (0.68, 0.88) 7.4x10-5 0.75 (0.65, 0.86) 3.2x10-5 0.79 (0.67, 0.94) 0.007 
IGP54 Continuous 1.76 (0.54) 1.87 (0.59) 0.72 (0.58, 0.91) 0.005 0.70 (0.56, 0.88) 0.003 0.78 (0.59, 1.04) 0.09 
 RT   0.83 (0.73, 0.94) 0.004 0.82 (0.73, 0.93) 0.002 0.87 (0.74, 1.01) 0.07 
Galactosylation 
IGP55 Continuous 40.35 (9.00) 38.27 (8.29) 1.03 (1.01, 1.04) 8.3x10-5 1.03 (1.02, 1.05) 2.4x10-5 1.03 (1.01, 1.05) 0.002 
 RT   1.28 (1.12, 1.45) 0.0002 1.32 (1.15, 1.51) 5.3x10-5 1.27 (1.08, 1.50) 0.005 
IGP56 Continuous 43.11 (4.56) 43.99 (3.79) 0.95 (0.92, 0.98) 0.0003 0.94 (0.92, 0.97) 6.8x10-5 0.94 (0.91, 0.97) 0.0005 
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 RT   0.82 (0.72, 0.93) 0.003 0.80 (0.70, 0.91) 0.001 0.79 (0.67, 0.93) 0.004 
IGP57 Continuous 16.08 (5.03) 17.29 (5.12) 0.95 (0.93, 0.98) 0.0002 0.95 (0.92, 0.97) 0.0001 0.96 (0.93, 0.99) 0.02 
 RT   0.77 (0.68, 0.88) 6.2x10-5 0.75 (0.65, 0.86) 2.9x10-5 0.80 (0.67, 0.94) 0.008 
Core fucosylation and bisecting GlcNAc 
IGP62 Continuous 79.40 (3.90) 79.63 (3.54) 0.98 (0.95, 1.02) 0.34 0.99 (0.96, 1.03) 0.68 0.99 (0.95, 1.04) 0.77 
 RT   0.95 (0.84, 1.08) 0.43 0.98 (0.87, 1.12) 0.80 0.99 (0.85, 1.15) 0.87 
IGP63 Continuous 78.59 (4.39) 78.61 (4.18) 1.00 (0.97, 1.03) 0.99 1.01 (0.98, 1.04) 0.57 1.01 (0.97, 1.04) 0.67 
 RT   1.01 (0.89, 1.14) 0.93 1.04 (0.92, 1.18) 0.51 1.04 (0.90, 1.21) 0.61 
IGP64 Continuous 79.92 (3.92) 80.30 (3.65) 0.98 (0.94, 1.01) 0.14 0.98 (0.95, 1.02) 0.33 0.98 (0.95, 1.01) 0.43 
 RT   0.92 (0.81, 1.04) 0.18 0.95 (0.84, 1.08) 0.41 0.95 (0.82, 1.10) 0.50 
IGP66 Continuous 17.41 (3.29) 17.09 (2.98) 1.03 (0.99, 1.07) 0.12 1.02 (0.98, 1.06) 0.37 1.01 (0.96, 1.06) 0.68 
 RT   1.09 (0.96, 1.23) 0.17 1.05 (0.92, 1.19) 0.49 1.02 (0.88, 1.19) 0.77 
IGP67 Continuous 19.40 (3.95) 19.36 (3.72) 1.00 (0.97, 1.03) 0.94 0.99 (0.96, 1.02) 0.57 0.99 (0.95, 1.03) 0.62 
 RT   1.00 (0.88, 1.13) 0.99 0.96 (0.85, 1.09) 0.51 0.96 (0.83, 1.11) 0.58 
IGP68 Continuous 18.35 (3.54) 17.95 (3.34) 1.03 (1.00, 1.07) 0.08 1.02 (0.98, 1.06) 0.26 1.02 (0.97, 1.06) 0.44 
 RT   1.10 (0.98, 1.25) 0.12 1.06 (0.94, 1.20) 0.34 1.05 (0.91, 1.22) 0.52 
IGP70 Continuous 0.22 (0.05) 0.21 (0.05) 7.65 (0.66, 88.88) 0.10 3.42 (0.27, 42.66) 0.34 2.01 (0.10, 39.38) 0.65 
 RT   1.09 (0.96, 1.23) 0.19 1.04 (0.92, 1.18) 0.53 1.02 (0.88, 1.19) 0.79 
IGP71 Continuous 18.00 (3.49) 17.68 (3.15) 1.03 (0.99, 1.07) 0.14 1.02 (0.98, 1.06) 0.42 1.01 (0.96, 1.06) 0.68 
 RT   1.08 (0.96, 1.23) 0.21 1.04 (0.92, 1.18) 0.55 1.03 (0.88, 1.19) 0.78 
IGP72 Continuous 4.62 (1.06) 4.68 (1.04) 0.95 (0.84, 1.07) 0.40 0.99 (0.87, 1.12) 0.82 1.00 (0.86, 1.15) 0.95 
 RT   0.94 (0.83, 1.06) 0.30 0.97 (0.86, 1.11) 0.69 0.99 (0.85, 1.15) 0.88 
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Figure 6. Minus logarithm of the FDR corrected p-values (q values) of all 39 glycan variables for all 
causes and CRC-specific mortality (Model III). Q- value threshold of significance <0.05. 
 
Stratified analysis by stage for all-cause and CRC-specific mortality is presented in (Tables 9 
and 10). 
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Table 9. All-cause mortality analysis by stage [Model II; rank transformed variables] 
 
Code AJCC stage 1 (n=210) AJCC stage 2 (n=327) AJCC stage 3 (n=313) AJCC stage 4 (n=102) 
 HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Total IgG glycans (neutral and charged); Measured 
IGP3 1.32 (0.96, 1.81) 0.09 1.93 (0.99, 3.78) 0.05 1.27 (1.05, 1.55) 0.02 1.15 (0.93, 1.42) 0.21 
IGP5 1.29 (0.92, 1.82) 0.14 1.46 (1.16, 1.84) 0.001 1.20 (0.99, 1.47) 0.07 1.01 (0.83, 1.24) 0.90 
IGP7 0.65 (0.47, 0.90) 0.009 0.76 (0.61, 0.96) 0.02 0.95 (0.79, 1.13) 0.55 1.00 (0.81, 1.22) 0.97 
IGP8 0.77 (0.56, 1.06) 0.11 0.57 (0.46, 0.72) 9.3x10-7 0.84 (0.71, 0.99) 0.04 1.25 (1.00, 1.57) 0.05 
IGP9 0.95 (0.70, 1.29) 0.73 1.03 (0.83, 1.28) 0.77 0.98 (0.82, 1.18) 0.85 0.89 (0.70, 1.12) 0.32 
IGP13 0.76 (0.55, 1.05) 0.09 0.72 (0.57, 0.93) 0.01 0.77 (0.62, 0.95) 0.02 0.91 (0.74, 1.12) 0.38 
IGP14 0.89 (0.64, 1.23) 0.47 0.90 (0.72, 1.13) 0.38 0.85 (0.71, 1.03) 0.09 0.93 (0.73, 1.18) 0.55 
IGP17 0.87 (0.63, 1.19) 0.38 0.79 (0.62, 1.01) 0.06 0.81 (0.67, 0.99) 0.04 0.79 (0.65, 0.97) 0.02 
IGP18 0.91 (0.67, 1.23) 0.54 0.86 (0.70, 1.07) 0.17 1.02 (0.88, 1.19) 0.77 1.09 (0.85, 1.40) 0.49 
Sialylation 
IGP24 1.19 (0.87, 1.64) 0.28 1.08 (0.86, 1.35) 0.51 0.92 (0.77, 1.09) 0.32 0.75 (0.63, 0.91) 0.003 
IGP25 1.04 (0.76, 1.42) 0.80 0.97 (0.78, 1.20) 0.76 1.03 (0.88, 1.21) 0.70 1.00 (0.78, 1.28) 0.98 
IGP26 0.90 (0.66, 1.22) 0.49 0.86 (0.68, 1.08) 0.20 0.80 (0.67, 0.97) 0.02 0.78 (0.63, 0.95) 0.01 
IGP27 0.91 (0.66, 1.25) 0.57 0.84 (0.68, 1.03) 0.10 0.96 (0.82, 1.13) 0.66 0.98 (0.78, 1.23) 0.88 
IGP29 1.43 (1.05, 1.96) 0.03 1.19 (0.95, 1.50) 0.13 1.11 (0.93, 1.33) 0.24 0.73 (0.60, 0.89) 0.002 
IGP31 0.97 (0.71, 1.33) 0.84 0.87 (0.70, 1.07) 0.19 1.17 (0.99, 1.38) 0.06 1.39 (1.09, 1.76) 0.008 
Bisecting GlcNAc 
IGP36 1.12 (0.81, 1.55) 0.48 1.18 (0.93, 1.49) 0.18 1.18 (0.98, 1.41) 0.08 1.24 (0.98, 1.57) 0.07 
IGP37 1.04 (0.76, 1.42) 0.81 1.05 (0.85, 1.33) 0.70 1.19 (1.00, 1.43) 0.05 1.36 (1.09, 1.71) 0.008 
IGP38 1.06 (0.77, 1.46) 0.72 1.06 (0.83, 1.35) 0.64 1.19 (1.00, 1.43) 0.05 1.36 (1.08, 1.71) 0.008 
IGP39 1.17 (0.86, 1.59) 0.33 1.26 (1.00, 1.59) 0.05 1.23 (1.02, 1.47) 0.03 1.05 (0.86, 1.30) 0.63 
IGP40 1.16 (0.85, 1.59) 0.34 1.25 (0.99, 1.58) 0.06 1.22 (1.02, 1.47) 0.03 1.05 (0.85, 1.29) 0.65 
Neutral IgG glycans 
IGP43 1.35 (0.98, 1.85) 0.07 1.25 (0.98, 1.60) 0.07 1.27 (1.04, 1.54) 0.02 1.12 (0.91, 1.39) 0.29 
IGP45 1.29 (0.92, 1.82) 0.14 1.49 (1.18, 1.88) 0.001 1.17 (0.96, 1.43) 0.11 0.96 (0.78, 1.19) 0.74 
IGP47 0.67 (0.48, 0.92) 0.02 0.75 (0.60, 0.95) 0.02 0.89 (0.74, 1.07) 0.20 0.90 (0.74, 1.09) 0.29 
IGP48 0.78 (0.57, 1.06) 0.12 0.57 (0.46, 0.72) 8.1x10-7 0.79 (0.66, 0.95) 0.01 1.16 (0.92, 1.47) 0.20 
IGP49 0.94 (0.68, 1.28) 0.68 1.01 (0.82, 1.25) 0.92 0.95 (0.80, 1.14) 0.58 0.83 (0.66, 1.05) 0.12 
IGP53 0.77 (0.56, 1.06) 0.11 0.73 (0.57, 0.93) 0.01 0.77 (0.62, 0.94) 0.01 0.89 (0.72, 1.09) 0.25 
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IGP54 0.88 (0.64, 1.23) 0.46 0.90 (0.71, 1.12) 0.34 0.85 (0.70, 1.01) 0.07 0.90 (0.71, 1.12) 0.34 
Galactosylation 
IGP55 1.39 (1.00, 1.92) 0.05 1.38 (1.08, 1.76) 0.009 1.31 (1.07, 1.60) 0.01 1.10 (0.89, 1.35) 0.38 
IGP56 0.71 (0.51, 0.98) 0.04 0.69 (0.54, 0.87) 0.002 0.80 (0.66, 0.98) 0.03 0.95 (0.77, 1.17) 0.64 
IGP57 0.78 (0.56, 1.07) 0.12 0.78 (0.61, 0.99) 0.05 0.76 (0.66, 0.93) 0.008 0.91 (0.73, 1.12) 0.35 
Core fucosylation and bisecting GlcNAc 
IGP62 0.94 (0.68, 1.31) 0.73 0.75 (0.60, 0.94) 0.01 1.00 (0.84, 1.19) 0.99 1.03 (0.80, 1.32) 0.82 
IGP63 1.03 (0.76, 1.41) 0.85 0.84 (0.64, 1.01) 0.06 1.03 (0.87, 1.23) 0.74 1.14 (0.91, 1.44) 0.25 
IGP64 0.83 (0.60, 1.15) 0.26 0.77 (0.62, 0.96) 0.02 0.97 (0.81, 1.15) 0.69 1.09 (0.85, 1.41) 0.50 
IGP66 1.13 (0.82, 1.55) 0.47 1.25 (1.00, 1.55) 0.05 1.03 (0.86, 1.23) 0.73 0.87 (0.70, 1.10) 0.24 
IGP67 0.99 (0.73, 1.35) 0.97 1.15 (0.95, 1.49) 0.13 0.96 (0.80, 1.14) 0.64 0.84 (0.68, 1.05) 0.12 
IGP68 1.20 (0.87, 1.66) 0.26 1.24 (1.00, 1.53) 0.05 1.05 (0.88, 1.25) 0.58 0.86 (0.68, 1.10) 0.23 
IGP70 1.13 (0.81, 1.57) 0.47 1.28 (1.02, 1.59) 0.03 1.02 (0.86, 1.22) 0.79 0.88 (0.69, 1.11) 0.28 
IGP71 1.11 (0.81, 1.53) 0.52 1.27 (1.02, 1.58) 0.03 1.02 (0.86, 1.22) 0.79 0.89 (0.71, 1.12) 0.32 
IGP72 0.91 (0.66, 1.26) 0.59 0.79 (0.63, 0.98) 0.03 0.99 (0.83, 1.18) 0.92 1.11 (0.88, 1.40) 0.38 
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Table 10. CRC-specific mortality analysis by stage [Model II; rank transformed variables] 
Code AJCC stage 1 (n=210) AJCC stage 2 (n=327) AJCC stage 3 (n=313) AJCC stage 4 (n=102) 
 HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Total IgG glycans (neutral and charged); Measured 
IGP3 1.14 (0.67, 1.95) 0.63 1.21 (0.90, 1.62) 0.21 1.26 (1.02, 1.55) 0.04 1.15 (0.92, 1.43) 0.21 
IGP5 0.94 (0.55, 1.61) 0.82 1.35 (1.01, 1.80) 0.04 1.10 (0.88, 1.36) 0.40 1.01 (0.82, 1.24) 0.94 
IGP7 0.81 (0.48, 1.35) 0.42 0.74 (0.56, 0.98) 0.04 0.96 (0.79, 1.17) 0.71 1.00 (0.81, 1.24) 0.97 
IGP8 0.72 (0.42, 1.24) 0.24 0.67 (0.51, 0.88) 0.004 0.85 (0.71, 1.02) 0.09 1.25 (0.99, 1.57) 0.06 
IGP9 0.86 (0.52, 1.42) 0.56 1.00 (0.77, 1.31) 0.98 0.92 (0.76, 1.12) 0.42 0.88 (0.69, 1.12) 0.30 
IGP13 0.98 (0.57, 1.69) 0.95 0.76 (0.56, 1.03) 0.08 0.78 (0.62, 0.98) 0.04 0.91 (0.71, 1.13) 0.39 
IGP14 0.85 (0.50, 1.46) 0.56 0.91 (0.69, 1.20) 0.51 0.86 (0.70, 1.05) 0.13 0.92 (0.72, 1.18) 0.53 
IGP17 1.12 (0.65, 1.94) 0.68 0.82 (0.61, 1.11) 0.20 0.85 (0.68, 1.05) 0.13 0.79 (0.64, 0.97) 0.02 
IGP18 1.03 (0.62, 1.70) 0.92 0.84 (0.64, 1.08) 0.18 1.04 (0.88, 1.23) 0.64 1.07 (0.83, 1.38) 0.61 
Sialylation 
IGP24 1.29 (0.77, 2.18) 0.34 1.05 (0.79, 1.39) 0.74 0.96 (0.79, 1.16) 0.64 0.75 (0.62, 0.90) 0.003 
IGP25 1.23 (0.72, 2.11) 0.44 0.93 (0.71, 1.22) 0.61 1.08 (0.91, 1.29) 0.39 1.00 (0.78, 1.28) 0.99 
IGP26 1.08 (0.64, 1.82) 0.77 0.87 (0.66, 1.16) 0.35 0.84 (0.68, 1.03) 0.09 0.77 (0.62, 0.95) 0.01 
IGP27 1.19 (0.69, 2.05) 0.53 0.84 (0.64, 1.08) 0.18 1.02 (0.86, 1.22) 0.79 0.98 (0.77, 1.23) 0.85 
IGP29 1.40 (0.85, 2.31) 0.19 1.17 (0.88, 1.55) 0.28 1.14 (0.94, 1.38) 0.20 0.73 (0.60, 0.90) 0.002 
IGP31 1.05 (0.63, 1.73) 0.86 0.89 (0.69, 1.16) 0.41 1.18 (0.98, 1.42) 0.07 1.38 (1.08, 1.76) 0.01 
Bisecting GlcNAc 
IGP36 1.02 (0.61, 1.72) 0.94 1.10 (0.82, 1.46) 0.53 1.15 (0.95, 1.40) 0.15 1.23 (0.97, 1.57) 0.09 
IGP37 0.98 (0.59, 1.63) 0.94 0.99 (0.74, 1.33) 0.96 1.18 (0.97, 1.44) 0.10 1.36 (1.07, 1.71) 0.01 
IGP38 0.99 (0.59, 1.65) 0.96 1.01 (0.75, 1.36) 0.93 1.18 (0.98, 1.44) 0.09 1.35 (1.07, 1.71) 0.01 
IGP39 0.91 (0.55, 1.49) 0.71 1.22 (0.91, 1.63) 0.18 1.11 (0.91, 1.36) 0.29 1.05 (0.85, 1.30) 0.64 
IGP40 0.91 (0.55, 1.50) 0.71 1.21 (0.90, 1.61) 0.21 1.11 (0.91, 1.36) 0.29 1.05 (0.85, 1.30) 0.66 
Neutral IgG glycans 
IGP43 1.20 (0.70, 2.05) 0.51 1.21 (0.90, 1.63) 0.21 1.22 (1.02, 1.56) 0.03 1.12 (0.90, 1.40) 0.30 
IGP45 0.95 (0.55, 1.63) 0.85 1.37 (1.02, 1.83) 0.03 1.08 (0.87, 1.33) 0.51 0.96 (0.77, 1.19) 0.69 
IGP47 0.87 (0.51, 1.47) 0.60 0.74 (0.56, 0.99) 0.04 0.92 (0.75, 1.12) 0.41 0.90 (0.74, 1.10) 0.32 
IGP48 0.78 (0.46, 1.31) 0.34 0.67 (0.51, 0.88) 0.003 0.82 (0.67, 0.99) 0.04 1.16 (0.91, 1.47) 0.23 
 64 
  
IGP49 0.87 (0.53, 1.45) 0.60 0.99 (0.76, 1.29) 0.93 0.90 (0.74, 1.10) 0.30 0.82 (0.65, 1.04) 0.11 
IGP53 1.00 (0.58, 1.72) 0.99 0.77 (0.57, 1.04) 0.09 0.79 (0.63, 0.98) 0.04 0.88 (0.72, 1.09) 0.26 
IGP54 0.88 (0.51, 1.50) 0.63 0.91 (0.69, 1.20) 0.49 0.85 (0.70, 1.04) 0.12 0.89 (0.70, 1.12) 0.32 
Galactosylation 
IGP55 1.14 (0.66, 1.97) 0.64 1.30 (0.96, 1.75) 0.09 1.27 (1.02, 1.59) 0.03 1.10 (0.89, 1.36) 0.40 
IGP56 0.76 (0.45, 1.29) 0.32 0.73 (0.55, 0.98) 0.04 0.82 (0.66, 1.02) 0.07 0.95 (0.77, 1.18) 0.65 
IGP57 0.96 (0.56, 1.65) 0.88 0.82 (0.61, 1.10) 0.18 0.78 (0.62, 0.97) 0.03 0.90 (0.73, 1.12) 0.36 
Core fucosylation and bisecting GlcNAc 
IGP62 1.19 (0.69, 2.05) 0.53 0.80 (0.61, 1.05) 0.11 1.06 (0.88, 1.29) 0.52 1.04 (0.81, 1.33) 0.78 
IGP63 1.23 (0.73, 2.06) 0.44 0.87 (0.65, 1.15) 0.33 1.10 (0.91, 1.33) 0.32 1.15 (0.91, 1.45) 0.25 
IGP64 0.99 (0.58, 1.68) 0.96 0.80 (0.61, 1.06) 0.12 1.03 (0.85, 1.24) 0.77 1.11 (0.85, 1.43) 0.45 
IGP66 0.88 (0.52, 1.47) 0.61 1.18 (0.90, 1.55) 0.22 0.96 (0.79, 1.17) 0.68 0.86 (0.69, 1.09) 0.21 
IGP67 0.84 (0.50, 1.38) 0.49 1.14 (0.86, 1.50) 0.36 0.90 (0.74, 1.09) 0.29 0.84 (0.67, 1.04) 0.12 
IGP68 0.98 (0.58, 1.64) 0.93 1.19 (0.91, 1.55) 0.19 0.98 (0.81, 1.19) 0.84 0.85 (0.67, 1.09) 0.20 
IGP70 0.87 (0.51, 1.47) 0.61 1.22 (0.92, 1.60) 0.16 0.95 (0.78, 1.15) 0.61 0.87 (0.68, 1.10) 0.25 
IGP71 0.87 (0.52, 1.46) 0.59 1.20 (0.92, 1.58) 0.18 0.95 (0.79, 1.16) 0.64 0.88 (0.70, 1.11) 0.29 
IGP72 1.17 (0.70, 1.98) 0.55 0.83 (0.63, 1.09) 0.17 1.06 (0.88, 1.29) 0.54 1.12 (0.89, 1.42) 0.33 
 65 
  
An increase in the percentage of agalactosylated structures (G0
n
) and a decrease in mono- and 
di-galactosylated structures (G1
n
, G2
n
) was associated with poorer all-cause and CRC-
specific mortality in stages 1, 2 and 3 (p-values from all-cause mortality models for G0
n
: 
stage 1: 0.05, stage 2: 0.009 and stage 3: 0.01) but not in stage 4 (p-value for G0
n
: 0.38). 
In contrast, decrease in sialylation and increase in incidence of bisecting GlcNAc were 
statistically significantly associated with all-cause and CRC-specific mortality only in stage 4 
(p-values from all-cause mortality models for stage 4 for FGS/(FG+FGS): 0.03;  
FGS/(F+FG+FGS): 0.01; FG2S1/(FG2+FG2S1+FG2S2): FBG2S1/(FBG2+FBG2S1+FBG2S 
2): 0.008; FBS1/FS1: 0.008). 
Finally, only in stage 2 disease IgG glycans linked to core fucosylation were associated with 
all-cause and CRC-specific mortality (Tables 9 and 10).  
Multivariate Cox regression clinical algorithms (including all the covariates of model III) 
showed good prediction of subsequent all cause (Harrell’s C=0.73, AUC= 0.75, IDI=0.02 [as 
compared to model II that included AJCC stage, age and sex]) and CRC-mortality (Harrell’s 
C=0.77, AUC= 0.79, IDI=0.04 [as compared to model II that included AJCC stage, age and 
sex]).  Using glycans in addition to the clinical factors (that were selected by generalised 
boosted regression) did not lead to any statistically significant improvements for the whole 
sample analysis (Table 11) or after stage stratification (Tables 12 and 13). This was 
reconfirmed by using Cox regression with L1 (LASSO) penalties on model parameters 
191
, as 
there were no significant differences in the validation deviances of models with and without 
glycans both for the whole sample and stage-stratified designs. 
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Table 11. Multivariate Cox regression of the a) clinical parameters and b) clinical and glycan parameters. 
 
Clinical 
algorithm 
All-cause mortality Clinical 
algorithm 
CRC mortality 
HR (95% CI) p-value HR (95% CI) p-value 
Age 1.03 (1.01-1.04) 9.2x10-6 Age 1.02 (1.00-1.03) 0.02 
Sex 0.91 (0.74-1.12) 0.36 Sex 1.03 (0.82-1.29) 0.82 
AJCC stage 2 vs 1 1.30 (0.92-1.83) 0.14 AJCC stage 2 vs 1 2.22 (1.33-3.72) 0.002 
AJCC stage 3 vs 1  2.44 (1.77-3.38) 7.3x10-8 AJCC stage 3 vs 1  5.02 (3.09-8.15) 6.7x10-11 
AJCC stage 4 vs 1 15.92 (11.16-22.70)  <2.0x10-16 AJCC stage 4 vs 1 34.05 (20.60-56.29) <2.0x10-16 
CRP  1.96 (1.47-2.62) 4.9 x10-6 CRP  2.08 (1.52-2.86) 4.8 x10-6 
BMI    1.04 (1.01-1.06) 0.002 BMI   1.05 (1.02-1.08) 0.0001 
Harrell's C 0.73  Harrell's C 0.77  
IDI* 0.02  IDI* 0.04  
AUC 0.74  AUC 0.79  
Clinical/glycans algorithm All-cause mortality Clinical/glycans 
algorithm 
CRC mortality 
HR (95% CI) p-value HR (95% CI) p-value 
Age  1.02 (1.01-1.03) 0.003 Age  1.01 (0.99-1.02) 0.28 
Sex  0.91 (0.74-1.12) 0.36 Sex 1.04 (0.82-1.30) 0.77 
AJCC stage 2 vs 1 1.33 (0.94-1.88) 0.11 AJCC stage 2 vs 1  2.24 (1.34-3.74) 0.002 
AJCC stage 3 vs 1  2.49 (1.80-3.45) 4.1x10-8 AJCC stage 3 vs 1  5.01 (3.09-8.14) 7.1x10-11 
AJCC stage 4 vs 1  15.72 (10.99-22.49) <2.0x10-16 AJCC stage 4 vs 1  33.63 (20.18-56.04) <2.0x10-16 
CRP 1.66 (1.23-2.25) 0.001 CRP  1.84 (1.31-2.59) 0.0004 
BMI  1.03 (1.01-1.06) 0.006 BMI   1.05 (1.02-1.07) 0.0007 
IGP48  1.69 (0.64-4.47) 0.29 IGP29 0.92 (0.81-1.05) 0.21 
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IGP26  0.72 (0.55-0.95) 0.02 IGP13  0.85 (0.74-0.97) 0.01 
IGP8 0.53 (0.21-1.30) 0.16 
IGP8  0.91 (0.81-1.03) 0.14 
Harrell's C 0.73  Harrell's C 0.77  
IDI** 0.05  IDI** 0.03  
AUC 0.75  AUC 0.79  
* The IDI was calculated based on the comparison of model II (adjusted for stage, sex and age) and the full clinical model III (adjusted for stage, age, sex, bmi and CRP – 
presented here). 
** The IDI was calculated based on the comparison of the full clinical model III (adjusted for stage, age, sex, bmi and CRP) and the full clinical model III with the three 
top selected glycans. 
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Table 12. Multivariate Cox regression and estimate of the Harrell’s concordance coefficient of the a) clinical parameters and b) clinical 
and glycan parameters by AJCC stage for all-cause mortality. 
 
  Stage 1 Stage 2 Stage 3  Stage 4  
Clinical algorithm 
All-cause mortality All-cause mortality All-cause mortality All-cause mortality 
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Age 1.07 (1.03, 1.11) 0.0006 1.04 (1.02, 1.07) 0.0009  1.02 (1.00, 1.04) 0.03  1.01 (0.99, 1.03) 0.44 
Sex 0.73 (0.40, 1.34) 0.31  0.96 (0.63, 1.46) 0.85  0.95 (0.68, 1.33) 0.77 0.94 (0.63, 1.40) 0.76 
CRP  2.84 (1.20, 6.78) 0.02  1.96 (1.06, 3.63) 0.18  1.70 (1.02, 2.83) 0.04  1.95 (1.18, 3.22) 0.01 
BMI  1.02 (0.95, 1.10) 0.61 1.09 (1.04, 1.14)  0.0005  1.01 (0.97, 1.05) 0.49 1.04 (0.99, 1.08) 0.10 
Harrell's C 0.68   0.65   0.55   0.61   
IDI   n/a*   0.09§    0.08§    0.13§   
AUC  n/a*   0.66   0.58   0.63   
Clinical & glycans 
algorithm 
All-cause mortality* All-cause mortality All-cause mortality All-cause mortality 
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Age   1.04 (1.01, 1.06) 0.006  1.01 (0.99, 1.03) 0.23 1.00 (0.98, 1.02) 0.45 
Sex    0.98 (0.64, 1.50) 0.93  0.94 (0.67, 1.32) 0.73 1.00 (0.66, 1.52) 0.67 
CRP   2.33 (1.24, 4.39) 0.01 1.47 (0.88, 2.47) 0.14 1.53 (0.86, 2.73) 0.03 
BMI     1.07 (1.02, 1.12)  0.003  1.01 (0.97, 1.05) 0.65 1.03 (0.98, 1.08) 0.05 
Top Glycan 1**   0.59 (0.46, 0.76) 2.6x10
-5 1.06 (0.85,1.32) 0.61  1.11 (0.81, 1.51) 0.53 
Top Glycan 2**   0.95 (0.77, 1.17) 0.63 1.39 (1.03, 1.89) 0.03  0.98 (0.72, 1.33) 0.90 
Top Glycan 3**    1.06 (0.83, 1.35) 0.62 0.75 (0.55, 1.01) 0.06  0.77 (0.58, 1.02) 0.07 
Harrell's C   0.67   0.53   0.61   
IDI    0.15§§     0.12§§     0.41§§    
AUC    0.72   0.60   0.69   
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* Due to the low number of observations, cross-validation was not possible and therefore we could not calculate the IDI and AUC values. Harrell's C coefficient were 
calculated based on the fitting all dataset 
§ The IDI was calculated based on the comparison of the model II (adjusted for AJCC, age and sex) and the full clinical model III (adjusted for stage, age, sex, BMI and CRP 
– presented here). 
** Top Glycans for: Stage 2 IGP48, IGP18, IGP43; Stage 3 IGP43, IGP29, IGP24; Stage 4 IGP27, IGP49, IGP17 
§§ The IDI was calculated based on the comparison of full clinical model III (adjusted for stage, age, sex, bmi and CRP) and the model with these clinical factors plus the 
three top selected glycans. 
 
 
Table 13. Multivariate Cox regression and estimate of the Harrell’s concordance coefficient of the a) clinical parameters and b) clinical 
and glycan parameters by AJCC stage for CRC mortality. 
 
  Stage 1 Stage 2 Stage 3  Stage 4  
Clinical algorithm 
CRC mortality CRC mortality CRC mortality CRC mortality 
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Age 1.06 (1.00, 1.12) 0.05 1.03 (1.00, 1.06) 0.05 1.01 (0.99-1.03) 0.23 1.01 (0.99, 1.03) 0.48 
Sex  0.59 (0.21, 1.64) 0.31 1.35 (0.82, 2.22) 0.24  1.02 (0.71-1.46) 0.92  0.97 (0.65, 1.44) 0.86 
CRP 1.04 (0.93, 1.16) 0.49 2.09 (1.02, 4.3) 0.04 1.92 (1.13-3.25) 0.02 1.04 (0.99, 1.08) 0.09 
BMI  2.52 (0.57, 11.19) 0.22 1.13 (1.07, 1.19) 7.9x10
-6 1.02 (0.98-1.06) 0.34 1.04 (0.99, 1.08) 0.07 
Harrell's C 0.68   0.63   0.55   0.56   
IDI   n/a*   0.11§    0.06§    0.12§   
AUC  n/a*   0.68   0.56   0.63   
Clinical & glycans 
algorithm 
CRC mortality* CRC mortality CRC mortality CRC mortality 
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Age    1.02 (0.99,1.05) 0.17 1.01 (0.99, 1.03) 0.22   1.01 (0.99, 1.03) 0.42 
Sex   1.38 (0.83,2.27) 0.21 1.03 (0.71, 1.49) 0.87    1.09 (0.71, 1.66) 0.70 
CRP   2.32 (1.10,4.87) 0.03  1.80 (1.06, 3.07) 0.03  2.22 (1.21, 4.06) 0.01 
BMI    1.11 (1.05,1.17) 8.34E-05
  1.02 (0.98, 1.06) 0.39    1.04 (0.99, 1.09) 0.12 
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Top Glycan 1**   0.81 (0.24,2.68) 0.73  0.91 (0.62, 1.34) 0.64   1.17 (0.87, 1.59) 0.29 
Top Glycan 2**   0.87 (0.59,1.29) 0.50  1.15 (0.95, 1.40) 0.16 
 0.70 (0.55,0.90) 0.005 
Top Glycan 3**   0.88 (0.29,2.63) 0.82  0.97 (0.66, 1.41) 0.87  0.87 (0.67, 1.13) 0.30 
Harrell's C   0.61   0.51   0.61   
IDI    0.14§§    0.08§§    0.43§§   
AUC    0.71   0.59   0.71   
 
* Due to the low number of observations, cross-validation was not possible and therefore we could not calculate the IDI and AUC values. Harrell's C coefficient were 
calculated based on the fitting all dataset 
§ The IDI was calculated based on the comparison of the model II (adjusted for AJCC, age and sex) and the full clinical model III (adjusted for stage, age, sex, BMI and CRP 
– presented here). 
** Top Glycans for: Stage 2 IGP48, IGP56, IGP8; Stage 3 IGP67, IGP29, IGP49. IGP49, IGP63 and IGP9 were prioritised equally by generalised boosted 
approach, but results for IGP49 is only presented; Stage 4 IGP27, IGP24, IGP49 
§§ The IDI was calculated based on the comparison of full clinical model III (adjusted for stage, age, sex, bmi and CRP) and the model with these clinical factors plus the 
three top selected glycans  
 
 
Similarly, predictions of the 5-year risk of death using the clinical factors stage, age, sex, BMI and CRP (e.g. AUC=0.80, Positive Predictive 
Value [PPV or precision] =0.80, using the Naïve Bayes classifier with a kernel density estimator for the marginal distributions) were not 
significantly improved by the addition of glycans data to the clinical factors Tables 14 and 15. 
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Table 14. Predictions of 5 year risk of CRC death for models with clinical factors and 
clinical and glycan factors using k-nearest neighbours, LASSO, Naïve Bayes, PAM, 
Support Vector Machines, Decision Trees, and Boosted Stump classifiers. The results 
are summarized over 10 cross-validation folds. 
Clinical model with age, sex and stage (n=950) 
 AUC Accuracy PPV Sensitivity Specificity 
Maximum Prior 0.5 0.7379 - 0 1 
k Nearest Neighbours 0.6619 0.7284 0.4833 0.5221 0.8017 
LASSO 0.7786 0.8189 0.8738 0.3614 0.9815 
Naive Bayes normal 0.7627 0.8179 0.8654 0.3614 0.9800 
Naive Bayes kernel 0.7587 0.8179 0.8654 0.3614 0.9800 
PAM 0.7626 0.7379 - 0 1 
SVM linear 0.6831 0.7253 0.4805 0.5944 0.7718 
SVM quadratic 0.6854 0.7000 0.4503 0.6546 0.7161 
SVM cubic 0.7047 0.6884 0.4434 0.7390 0.6705 
SVM RBF 0.7014 0.7389 0.5016 0.6125 0.7803 
Decision Trees 0.6430 0.8189 0.8738 0.3614 0.9815 
Boosted stumps 0.7691 0.8200 0.8750 0.3655 0.9815 
Clinical model with age, sex, stage, BMI, CRP (n=950) 
 AUC Accuracy PPV Sensitivity Specificity 
Maximum Prior 0.5 0.7379 - 0 1 
k Nearest Neighbours 0.6310 0.7211 0.4661 0.4418 0.8203 
LASSO 0.8052 0.8105 0.7315 0.4378 0.9429 
Naive Bayes normal 0.8076 0.8116 0.7108 0.4739 0.9315 
Naive Bayes kernel 0.7962 0.8095 0.7931 0.3695 0.9658 
PAM 0.8039 0.7379 - 0 1 
SVM linear 0.7237 0.7337 0.4944 0.7028 0.7447 
SVM quadratic 0.7096 0.7568 0.5315 0.6104 0.8088 
SVM cubic 0.6884 0.7274 0.4840 0.6064 0.7703 
SVM RBF 0.6965 0.7221 0.4776 0.6426 0.7504 
Decision Trees 0.6476 0.8189 0.8738 0.3614 0.9815 
Boosted stumps 0.7978 0.8189 0.7770 0.4337 0.9558 
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Table 15. Predictions of 5 year risk of CRC death for models with the extended set of 
clinical factors with and without glycans using k-nearest neighbours, LASSO, PAM, 
Support Vector Machines, Decision Trees, and Boosted Stump classifiers. The results 
are summarized over 10 cross-validation folds. 
Clinical model with age, sex, BMI, CRP, type of operation, time between operation and blood 
collection, and stage of cancer (n=949) 
 AUC Accuracy PPV Sensitivity Specificity 
Maximum Prior 0.5 0.7379 - 0 1 
k Nearest Neighbours 0.6174 0.7081 0.4398 0.4274 0.8074 
LASSO 0.8042 0.8061 0.7192 0.4234 0.9415 
PAM 0.8036 0.7492 0.9167 0.0444 0.9986 
SVM linear 0.7229 0.7292 0.4875 0.7097 0.7361 
SVM cubic 0.7047 0.7408 0.5032 0.6290 0.7803 
SVM RBF 0.6764 0.7144 0.4639 0.5968 0.7561 
Decision Trees 0.6331 0.8188 0.8725 0.3589 0.9815 
Boosted stumps 0.8086 0.8124 0.7431 0.4315 0.9472 
Clinical model with age, sex, BMI, CRP, type of operation, time between operation and blood 
collection, stage of cancer, and log-transformed glycans (n=949) 
 AUC Accuracy PPV Sensitivity Specificity 
Maximum Prior 0.5 0.7387 - 0 1 
k Nearest Neighbours 0.5713 0.6881 0.3857 0.3266 0.8160 
LASSO 0.7980 0.8093 0.7557 0.3992 0.9544 
PAM 0.6918 0.7576 0.6667 0.1452 0.9743 
SVM linear 0.7068 0.7208 0.4759 0.6774 0.7361 
SVM cubic 0.6449 0.7218 0.4688 0.4839 0.8060 
SVM RBF 0.5 0.7387 - 0 1 
Decision Trees 0.6447 0.8188 0.8725 0.3589 0.9815 
Boosted stumps 0.7849 0.8072 0.7305 0.4153 0.9458 
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When patients were stratified by stage, adding glycans to the clinical variables improved the 
prediction results, did not change them, or made them worse, depending on the stage of 
cancer and on the chosen models. We tested whether independently of the choice of a model 
class, adding glycans to clinical covariates would improve predictions of a model of the same 
class estimated on independent test data using cross-validation. We performed two instances 
of the paired Wilcoxon sign-rank test comparing models with and without glycans, including 
all the considered models (W), or including only the models of disparate classes (Wd) as 
discussed in Methods. We showed that there was no significant improvement in the prediction 
of the rapid progressors using glycans (in addition to the clinical factors) for stage 2 
(pW ~ 0.99, pWd ~ 0.98) as measured by cumulative (merged) AUC on the validation data 
(Table 16). Similarly, for stage 3 the impact of the glycans was not consistent across the 
models, varied depending on the modelling assumptions, and was not significant overall 
(pW ~ 0.75, pWd ~ 0.58; (Table 17).   
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Table 16. Predictions of rapid progressors in stage 2 for models with extending set of 
clinical factors with and without glycan using k-nearest neighbours, LASSO, PAM, 
Support Vector Machines, Decision Trees, and Boosted Stump classifiers. The results 
are summarized over 10 cross-validation folds. 
Clinical model for stage 2 with age, sex, BMI, CRP, type of operation, time between operation and 
blood collection, and stage of cancer (n=326) 
 AUC Accuracy PPV Sensitivity Specificity 
Maximum Prior 0.5 0.9356 - 0 1 
k Nearest Neighbours 0.5863 0.8896 0.2000 0.2381 0.9344 
LASSO 0.7820 0.9356 0.5000 0.0476 0.9967 
PAM 0.7066 0.9356 - 0 1 
SVM linear 0.7440 0.7699 0.1786 0.7143 0.7738 
SVM quadratic 0.6939 0.8006 0.1765 0.5714 0.8164 
SVM cubic 0.6200 0.8282 0.1569 0.3810 0.8590 
SVM RBF 0.6331 0.8528 0.1860 0.3810 0.8852 
Decision Trees 0.4746 0.9356 - 0 1 
Boosted stumps 0.6911 0.9325 0.4286 0.1429 0.9869 
Clinical model for stage 2 with age, sex, BMI, CRP, type of operation, time between operation and 
blood collection, stage of cancer, and log-transformed glycans (n=326) 
 AUC Accuracy PPV Sensitivity Specificity 
Maximum Prior 0.5 0.9356 - 0 1 
k Nearest Neighbours 0.5912 0.8988 0.2273 0.2381 0.9443 
LASSO 0.7369 0.9356 0.5000 0.0476 0.9967 
PAM 0.6623 0.9356 - 0 1 
SVM linear 0.6537 0.7669 0.1429 0.5238 0.7836 
SVM quadratic 0.5674 0.8957 0.1905 0.1905 0.9443 
SVM cubic 0.4976 0.8896 0.0588 0.0476 0.9475 
SVM RBF 0.5 0.9356 - 0 1 
Decision Trees 0.4746 0.9356 - 0 1 
Boosted stumps 0.5864 0.9294 0.2500 0.0476 0.9902 
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Table 17. Predictions of rapid progressors in stage 3 for models with the extended set of 
clinical factors with and without glycans using k-nearest neighbour, LASSO, PAM, 
Support Vector Machines, Decision Trees, and Boosted Stump classifiers. The results 
are summarized over 10 cross-validation folds. 
 
Clinical model for stage 3 with age, sex, BMI, CRP, type of operation, time between operation and 
blood collection, and stage of cancer (n=312) 
 AUC Accuracy PPV Sensitivity Specificity 
Maximum Prior 0.5 0.8782 - 0 1 
k Nearest Neighbours 0.4438 0.7596 0.0256 0.0263 0.8613 
LASSO 0.6259 0.8782 - 0 1 
PAM 0.4802 0.8782 - 0 1 
SVM linear 0.5864 0.7115 0.1905 0.4211 0.7518 
SVM quadratic 0.5412 0.6122 0.1453 0.4474 0.6350 
SVM cubic 0.5133 0.6827 0.1325 0.2895 0.7372 
SVM RBF 0.5360 0.6827 0.1494 0.3421 0.7299 
Decision Trees 0.4901 0.8782 - 0 1 
Boosted stumps 0.5965 0.8782 - 0 1 
Clinical model for stage 3 with age, sex, BMI, CRP, type of operation, time between operation and 
blood collection, stage of cancer, and log-transformed glycans (n=312) 
 AUC Accuracy PPV Sensitivity Specificity 
Maximum Prior 0.5 0.8782 - 0 1 
k Nearest Neighbours 0.4972 0.7949 0.1176 0.1053 0.8905 
LASSO 0.5953 0.8782 - 0 1 
PAM 0.5645 0.8814 1 0.0263 1 
SVM linear 0.5941 0.7051 0.1932 0.4474 0.7409 
SVM quadratic 0.5169 0.7885 0.1500 0.1579 0.8759 
SVM cubic 0.5107 0.8173 0.1481 0.1053 0.9161 
SVM RBF 0.5000 0.8782 - 0 1 
Decision Trees 0.4745 0.8782 - 0 1 
Boosted stumps 0.4483 0.8494 0.2353 0.1053 0.9526 
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On the other hand, there was a significant improvement in the prediction of the rapid 
progressors using glycans for stage 4 (Table 18), with pW ~ 0.01, pWd ~ 0.04, leading to the 
median gain in the test AUC of 0.08. Importantly, the inclusion of glycans in the models 
consistently resulted in the improved quality of predictions across the range of the considered 
models, and independently of whether the restricted or extended sets of clinical variables were 
used in the adjustments. The results were qualitatively similar for multiple repetitions of 10-
fold cross-validation with random partitions into non-overlapping test folds, and 
independently of whether 10-fold or two-fold cross-validation was used to estimate the AUC 
on test data for the considered models. The best extended clinical model had the test AUC of 
0.58, with the PPV of 0.35. The best model augmented with unfiltered log-transformed 
glycans had the test AUC of 0.66, with the PPV of 0.62.  
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Table 18. Predictions of rapid progressors in stage 4 for models with the extended set of 
clinical factors with and without glycans using k-nearest neighbour, LASSO, PAM, 
Support Vector Machines, Decision Trees, and Boosted Stump classifiers. The results 
are summarized over 10 cross-validation folds. 
Clinical model for stage 4 with age, sex, BMI, CRP, type of operation, time between operation and 
blood collection, and stage of cancer (n=102) 
 AUC Accuracy PPV Sensitivity Specificity 
Maximum Prior 0.5 0.7059 - 0 1 
k Nearest Neighbours 0.5 0.5686 0.2941 0.3333 0.6667 
LASSO 0.4331 0.6961 0.3333 0.0333 0.9722 
PAM 0.4535 0.7059 - 0 1 
SVM linear 0.5514 0.5588 0.3404 0.5333 0.5694 
SVM quadratic 0.5819 0.6569 0.4138 0.4000 0.7639 
SVM cubic 0.5472 0.6078 0.3529 0.4000 0.6944 
SVM RBF 0.5278 0.6078 0.3333 0.3333 0.7222 
Decision Trees 0.4899 0.7059 - 0 1 
Boosted stumps 0.5505 0.6471 0.3125 0.1667 0.8472 
Clinical model for stage 4 with age, sex, BMI, CRP, type of operation, time between operation and 
blood collection, stage of cancer, and log-transformed glycans (n=102) 
 AUC Accuracy PPV Sensitivity Specificity 
Maximum Prior 0.5 0.7059 - 0 1 
k Nearest Neighbours 0.5819 0.6569 0.4138 0.4000 0.7639 
LASSO 0.5815 0.6863 0 0 0.9722 
PAM 0.5257 0.6765 0 0 0.9583 
SVM linear 0.5972 0.6373 0.4054 0.5000 0.6944 
SVM quadratic 0.5778 0.6373 0.3939 0.4333 0.7222 
SVM cubic 0.6486 0.7647 0.6875 0.3667 0.9306 
SVM RBF 0.5000 0.7059 - 0 1 
Decision Trees 0.6569 0.7353 0.6154 0.2667 0.9306 
Boosted stumps 0.5565 0.6863 0.4500 0.3000 0.8472 
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5.3. IgG glycome composition in CRC patients and matching controls. 
To test whether alteration on IgG glycome composition between CRC patients and controls 
could potentially have relevance as a clinically useful biomarker of CRC risk, analyses of 
clinical characteristics among 760 patients and 538 matching controls were done. 
 
Descriptive information on CRC patients and healthy controls are presented in (Table 19). 
In addition to 24 directly measured glycan structures, 12 derived traits were calculated from 
the directly measured glycans. These derived traits average particular glycosylation features 
(galactosylation, fucosylation, sialylation) across different individual glycan structures and 
consequently they are more related to individual enzymatic activities and underlying genetic 
polymorphisms (Table 20).  
 
Table 19. Descriptive information on CRC patient and healthy controls 
 
 
 
 
 
  Cases (n = 760) Control (n = 538) p-value 
Age                      (median[IQR]) 52 (48-56) 53 (48-56) 0,274 
Sex                     (Men/Women) 
415 (54.6%) / 345 
(45.4%) 
289 (53.7%) / 248 (46.2%) 0,821 
Smoking status (Current/Ex/ 
Non/unknown) 
133/172/271/184 94/139/211/103 0,836 
BMI             (median[IQR]) 26,3 (23,4-26,8) 27,8 (25,8-28,6) 2,69E-10 
Family History (Low/Medium or 
High/unknown) 
524/197/39 517/6/15 6,50E-44 
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Table 20. Derived glycan traits 
Derived glycan 
traits 
Description 
 
Formula 
G0 total Proportion of agalactosylated structures in total       in total IgG glycans (GP1+GP2+GP4+GP6)/GPt 
G1 total Proportion  of monogalactosylated structures in total IgG glycans (GP7+GP8+GP9+GP10+GP11)/GPt 
G2 total Proportion of digalactosylated structures in total IgG glycans (GP12+GP13+GP14+GP15)/GPt 
F total Proportion of fucosylated structures in total IgG glycans (GP1+GP4+GP6+GP8+GP9+GP10+GP11+ 
GP14+GP15+GP16+GP18+GP19+GP23+GP24)/GPt 
F neutral Proportion of fucosylated structures in total neutral glycans (GP1+GP4+GP6+GP8+GP9+GP10+GP11+GP14+GP15)/GPn 
F sialo Proportion of fucosylated structures in total sialylated glycans (GP16+GP18+GP19+GP23+GP24)/GPs 
B total Proportion of structures with bisecting GlcNAc in total IgG glycans (GP3+GP6+GP10+GP11+GP13+GP15+GP19+GP22+GP24)/GPt 
B neutral Proportion of structures with bisecting GlcNAc in total neutral IgG glycans (GP3+GP6+GP10+GP11+GP13+GP15)/GPn 
B sialo Proportion of structures with bisecting GlcNAc in total sialylated IgG glycans (GP19+GP22+GP24)/GPs 
S total Proportion of sialylated structures in total IgG glycans (GP16+GP17+GP18+GP19+GP20+GP21+GP22+GP23+GP24)/GPt 
S1 total Proportion of monosialylated structures in total IgG glycans (GP16+GP17+GP18+GP19)/GPt 
S2 total Proportion of disialylated structures in total IgG glycans (GP21+GP22+GP23+GP24)/GPt 
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Significant differences were observed in several features of the glycome (Table 21, Figure 7), primarily reflecting decreased galactosylation 
(OR=2.35, p=2.39E-22 for G0 and OR=0.36, p=6.59E-29 for G2) and sialylation (OR=0.72, p=2.73E-05 for S total), as well as increased 
fucosylation of neutral IgG glycans (OR=1.24, p=3.57E-03 for F total) and decreased fucosylation of sialylated glycans (OR=0.72, p=5.85E-05 
for F sialo). 
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Table 21. IgG glycome composition in CRC patients and controls. Only the main derived traits describing glycome composition are 
shown. 
 
 
 
 
Glycan Control (median[IQR]) Patient (median[IQR]) OddsRatio 95%ConfInt p.value p.adjusted 
G0 total 25,35 (20,67-29,24) 29,24 (24,62-34,74) 2,35 (1,95 - 2,82) 2,65E-23 2,39E-22 
G1 total 36,62 (34,87-38,09) 35,94 (34,49-37,39) 0,64 (0,55 - 0,74) 8,09E-10 3,64E-09 
G2 total 16,65 (14,41-19,62) 14,12 (11,71-16,78) 0,36 (0,30 - 0,44) 1,83E-30 6,59E-29 
F total 95,27 (94,42-95,97) 95,39 (94,40-96,11) 1,11 (0,97 - 1,28) 1,27E-01 1,53E-01 
F neutral 97,07 (96,38-97,66) 97,32 (96,50-97,97) 1,24 (1,08 - 1,43) 1,98E-03 3,57E-03 
F sialo 88,47 (86,69-89,79) 87,58 (85,39-89,29) 0,72 (0,62 - 0,84) 2,44E-05 5,85E-05 
B total 18,25 (16,81-20,22) 18,11 (16,49-20,02) 0,88 (0,76 - 1,01) 7,68E-02 9,87E-02 
B neutral 17,97 (16,35-20,54) 17,89 (16,07-19,93) 0,84 (0,73 - 0,97) 1,86E-02 2,91E-02 
B sialo 18,64 (16,48-21,33) 19,19 (16,99-21,71) 1,17 (1,01 - 1,35) 3,85E-02 5,13E-02 
S total 20,71 (18,64-23,62) 19,85 (17,39-21,96) 0,72 (0,62 - 0,83) 1,06E-05 2,73E-05 
S1 total 15,9 (14,07-18,07) 14,97 (12,94-16,74) 0,64 (0,54 - 0,75) 9,16E-09 3,66E-08 
S2 total 4,41 (3,66-5,32) 4,34 (3,65-5,08) 0,96 (0,84 - 1,11) 6,03E-01 6,03E-01 
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Figure 7. IgG glycome composition in CRC patients and matching controls.  
 
 
IgG glycome was analysed in 760 patients with CRC and 538 matching controls. Main 
features of the IgG glycome are presented as box plots showing median values and 25% (box) 
and 75% (line) percentiles for patients and controls. 
Additional information is available in (Table 21 and 22). 
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Table  22. IgG glycome composition in CRC patients and controls 
Glycan 
peak Control (median[IQR]) Patient (median[IQR]) OddsRatio 95%ConfInt p.value p.adjusted 
GP1 
0,12 (0,08-0,22) 0,15 (0,10-0,26) 1,28 (1,11 - 1,48) 5,20E-04 1,17E-03 
GP2 0,49 (0,34-0,71) 0,54 (0,36-0,79) 1,18 (1,03 - 1,37) 2,10E-02 3,15E-02 
GP3 0,37 (0,29-0,52) 0,46 (0,34-0,65) 1,5 (1,29 - 1,74) 4,79E-08 1,72E-07 
GP4 18,68 (15,42-21,98) 22,34 (18,34-26,87) 2,33 (1,94 - 2,79) 1,83E-23 2,20E-22 
GP5 0,29 (0,24-0,37) 0,32 (0,26-0,41) 1,26 (1,09 - 1,46) 1,30E-03 2,47E-03 
GP6 4,97 (4,02-6,01) 5,39 (4,53-6,45) 1,44 (1,23 - 1,69) 4,13E-06 1,24E-05 
GP7 0,57 (0,43-0,75) 0,54 (0,39-0,76) 0,88 (0,77 - 1,02) 8,42E-02 1,05E-01 
GP8 18,9 (17,73-20,18) 18,82 (17,59-19,97) 0,85 (0,74 - 0,98) 2,43E-02 3,51E-02 
GP9 9,87 (8,89-11,04) 9,66 (8,80-10,54) 0,78 (0,68 - 0,90) 5,52E-04 1,17E-03 
GP10 5,62 (4,95-6,43) 5,37 (4,66-6,27) 0,72 (0,62 - 0,83) 4,65E-06 1,29E-05 
GP11 0,82 (0,72-0,95) 0,8 (0,70-0,91) 0,78 (0,68 - 0,91) 8,05E-04 1,61E-03 
GP12 0,68 (0,50-0,93) 0,55 (0,37-0,77) 0,6 (0,51 - 0,70) 9,93E-12 5,11E-11 
GP13 0,45 (0,36-0,57) 0,4 (0,31-0,53) 0,68 (0,58 - 0,78) 1,09E-07 3,55E-07 
GP14 13,59 (11,57-15,90) 11,45 (9,40-13,80) 0,37 (0,30 - 0,45) 4,21E-29 7,57E-28 
GP15 1,73 (1,47-2,06) 1,47 (1,20-1,82) 0,49 (0,41 - 0,57) 6,94E-20 5,00E-19 
GP16 3,27 (2,95-3,65) 3,37 (2,99-3,76) 1,17 (1,02 - 1,34) 2,65E-02 3,67E-02 
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GP17 0,94 (0,82-1,08) 0,92 (0,80-1,07) 0,92 (0,79 - 1,06) 2,39E-01 2,60E-01 
GP18 9,52 (8,09-11,43) 8,47 (6,98-9,99) 0,56 (0,47 - 0,66) 8,05E-13 4,83E-12 
GP19 1,88 (1,65-2,15) 1,81 (1,61-2,07) 0,82 (0,72 - 0,95) 5,63E-03 9,64E-03 
GP20 0,36 (0,25-0,51) 0,38 (0,27-0,52) 1,12 (0,96 - 1,30) 1,41E-01 1,64E-01 
GP21 0,89 (0,74-1,06) 0,92 (0,77-1,10) 1,11 (0,96 - 1,28) 1,71E-01 1,93E-01 
GP22 0,16 (0,11-0,24) 0,15 (0,10-0,21) 0,84 (0,73 - 0,97) 1,62E-02 2,66E-02 
GP23 1,45 (1,14-1,85) 1,4 (1,11-1,72) 0,96 (0,84 - 1,11) 5,96E-01 6,03E-01 
GP24 1,78 (1,48-2,13) 1,74 (1,43-2,08) 0,95 (0,82 - 1,09) 4,44E-01 4,71E-01 
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As many glycan structures showed strong association with CRC, we attempted to build a 
predictive model using regularized logistic regression. Only the 24 directly measured glycan 
traits were used as predictors in the model. Evaluation of model performance was conducted 
using a 10-cross validation procedure. While a model based on age and sex did not show 
significant discriminative power (AUC = 0.499), the addition of glycan variables into the 
model considerably increased the discriminative power of the model (AUC = 0.755, P < 
1x10E-16) (Figure 8). 
 
Figure 8. ROC curve illustrating the performance of regularized logistic regression 
model in predicting disease status for CRC patients and healthy controls. While models 
based only on age and gender did not show predictive power (red line), addition of 
glycan traits increased predictive power of model (black line). 
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Glycome composition is known to change in acute inflammation 
215 
and to evaluate potential 
effects of surgery on the IgG glycome in CRC patients we analysed IgG glycome composition 
in 28 patients (i) before surgery, (ii) 24 after surgery), (iii) 48 h after surgery and (iv) 7 days 
after surgery. We did not observe any consistent and statistically significant changes in the 
IgG glycome that were caused by the surgery. 
To determine whether the observed changes were present before the disease onset, we 
identified 39 individuals from the FINNRISK cohort that were sampled before the initial 
diagnosis. However, when compared to matching controls, no statistically significant changes 
were found. 
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6. DISCUSSION 
This study represents the first comprehensive analysis of IgG glycosylation in CRC. By 
applying the recently developed method for high-throughput glyco-profiling of IgG 
20
 on a 
well-characterized large cohort of 1229 CRC patients and 538 matching controls an important 
gap in knowledge which may have relevance for understanding the immunosurveilance of 
CRC was filled 
178
.  
The research presented here provides results regarding the relationship between the IgG 
glycome composition in plasma of CRC patients with survival outcomes and also it provides 
results about  differences in IgG glycome composition between patients and controls. 
Univariate and multivariate statistical models were applied to examine the associations 
between specific glycan changes and CRC-specific or all-cause mortality. IgG glycans linked 
to galactosylation, sialylation and bisecting GlcNAc were strongly associated with all-cause 
mortality and CRC mortality. Multivariate Cox regression clinical algorithms showed good 
prediction of outcome for all cause and CRC-mortality, but using glycans in addition to the 
clinical factors did not lead to any statistically significant improvements. However, when we 
investigated the prediction of rapid progressors within each AJCC stage, there was an 
improvement in the prediction of the rapid progressors using glycans for stages 3 and 4. 
 
By analysing 760 CRC patients and 538 matching controls it is found that CRC is associated 
with three major alterations in the IgG glycome composition: (i) decrease in IgG 
galactosylation, (ii) decrease in IgG sialylation and (iii) increase in core-fucosylation of 
neutral glycans with concurrent decrease of core fucosylation of sialylated glycans. 
6.1. Stage differences 
It is well established that glycosylation changes are involved in the aetiology of cancer, and 
specifically mark tumor proliferation and metastasis 
26
. IgG is produced and secreted by CRC 
cells and the expression levels of CRC-tumor derived IgG correlated with many clinical and 
pathological characteristics of the tumor (including stage) 
192
. In particular it has been shown 
that expression of IgG was stronger in CRC tissues with TNM stage III–IV, than in those with 
TNM I–II. Similarly, in this study we observed different changes in IgG glycosylation status 
(levels of sialylation and incidence of bisecting GlcNAC) in late-stage disease and we saw an 
improvement in the prediction algorithms using glycans in addition to clinical factors in 
AJCC stage 3 and 4. 
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6.2. Galactosylation, sialylation, GlcNAc and core fucosylation residues present on IgG 
glycans in cancer 
The immune system can identify and destroy new tumor cells through cancer 
immunosurveillance, which functions as an important defence against cancer. A recent review 
on the natural innate and adaptive immunity to cancer has presented evidence from mouse 
models that B cells (which create and release IgG) are important in the surveillance of the 
CRC
 178
. Currently, it is known that inflammation is one of the features of cancer 
193
, but it is 
not known whether the inflammatory process mainly plays an important role in the 
development of cancer, or whether the cancer induces an inflammatory response, or both. IgG 
can demonstrate both pro and anti-inflammatory activity depending on its different glycan 
composition 
81
. Alteration in IgG galactosylation, sialylation, bisecting GlcNAc and 
fucosylation have been previously reported in cancer studies (Table 23).. In particular, a 
decline in plasma IgG glycosylation has predominantly been observed with tumor progression 
and metastasis in gastric, lung, prostate and ovarian cancers 
194, 164, 167, 162, 148, 161, 160, 195 
as well 
as in chronic inflammatory diseases such as rheumatoid arthritis 
143
 and osteoarthritis 
143
, 
inflammatory bowel disease 
196, 197
, systemic lupus erithematosis 
198
, vasculitis 
142
 and some 
other disease 
77
. All previous studies in cancer research had small sample sizes (<100 cancer 
cases) and this is the first time that similar changes in IgG galactosylation were observed in 
CRC prognosis in a study with more than 1000 CRC patients (Table 23).  
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Table 23. Studies on IgG glycosylation changes in cancer  
Author Year Cancer Method Samples Cases Controls Results 
Galactosylation 
Kanoh Y1 2004 Prostate cancer 
Fluorophore-assocd. 
carbohydrate electrophoresis 
(FACE) serum 12 10 
Fr 1 (monogalactosyl oligosaccharide) and 
Fr 2 (digalactosyl oligosaccharide) 
decreased significantly (p<0.05), while Fr 4 
(agalactosyl IgG oligosaccharide) increased 
with PCa tumor progression. The Fr 4 / Fr 1 
+ 2 ratio in metastatic PCa patients was 
significantly higher than in healthy controls 
(p<0.05) 
Aurer I2 2007 Multiple myeloma 
Lectin blotting and 
densitometry blood 16 16 
IgG galactosylation was reduced in multiple 
myeloma 
Kodar K3 2011 Gastric cancer LC-ESI-MS serum 80 51 
Significant increase of agalactosylated 
(GnGnF, GnGn(bi)F), and decrease of 
galactosylated (AGn(bi), AGn(bi)F, AA(bi), 
AAF) 
Bones J4 2011 Gastric cancer 
Hydrophilic interaction liquid 
chromatography with 
fluorescence detection serum 80 30 
The data indicates that in the cancerous state 
there is a switch in IgG production toward 
the more pro-inflammatory IgG G0 
glycoform (agalactosyl). 
Gercel-Taylor C5 2001 Ovarian cancer 
Concanavalin A affinity 
columns and sodium dodecyl 
sulfate-polyacrylamide gel 
electrophoresis serum 62 50 
This report demonstrated the presence of an 
aberrantly glycosylated IgG population in 
cancer patients. 
Saldova R6 2007 Ovarian cancer 
Quantitative NPHPLC and 
exoglycosidase digestion serum 27 34 
 IgG containing agalactosylated structures 
(G0) (mostly represented by FA2) were 
doubled; monogalactosylated (G1) 
decreased; digalactosylated (G2) structures 
decreased  
Alley WR7 2012 Ovarian cancer 
MALDI-TOF Mass-
spectrometric Analysis serum 19 20 
Increased levels of a-galactosylation 
structures were obsd. on N-linked glycans 
derived from IgG, which were independent 
of the presence of fucose residues. 
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Qian Y8 2013 Ovarian cancer 
MALDI-TOF Mass-
spectrometric Analysis serum 32 26 
G0/(G1 + G2·2) was found significantly 
higher in the malignant group than in the 
benign group (0.74 vs 0.34; p < 0.0001) 
Sialylation 
Flemming SC9  1998 Multiple myeloma 
High pressure anion exchange 
chromatography with pulsed 
electrochemical detection 
(HPAE-PED) serum 47 14 
Patients with myeloma showed an increase 
in the proportion of sialylated 
oligosaccharides in comparison with patients 
with MGUS 
Saldova R6 2007 Ovarian cancer 
Quantitative NPHPLC and 
exoglycosidase digestion serum 27 34 The overall sialylation decreased 
Kodar K3 2011 Gastric cancer LC-ESI-MS serum 80 51 
Decrease of monosialylated IgG glycoforms 
(NaAF, NaA(bi)) in cancer patients. 
Bisecting GlcNAC        
Kodar K3 2011 Gastric cancer LC-ESI-MS serum 80 51 
A statistically significant decrease  of 
bisecting GlcNAc was observed in tumor 
stage II and III  
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 It has been reported that the environmental factors could modulate glycosylation of IgG Fc 
199
. Since the composition of IgG Fc glycans is dependent on the regulation of 
glycosyltransferases and glycosidases, it is speculated that the expression and activity of these 
enzymes are differentially regulated in response to stimulation of environmental factors 
Furthermore, it has been hypothesised that decreased IgG galactosylation leads to a more pro-
inflammatory antibody response 
77, 119
, which might influence cancer survival after diagnosis. 
Decreased of IgG galactosylation is caused by decreased Gal T-activity in plasma cells 
200
 or 
due to increased production of specific clones of plasma cells with low expression levels of 
galactosyltransferases 
201
. It was shown that the decrease of Gal-T in B- lymphocyte caused 
the increase of IgG G0 glycoforms in rheumatoid arthritis and other rheumatic diseases
 202, 203
. 
Thus, it was hypothesized that Gal-T activity in plasma cells is down-regulated during tumor 
progression and that this causes the significant increase of agalactosylated IgG, indicating that 
in cancerous state there could be a switch in IgG production toward the more pro-
inflammatory IgG G0 glycoforms. Interestingly, in rheumatoid arthritis patients an increase in 
galactosylation of IgG during combined treatment of infliximab (anti-TNF-α neutralizing 
antibody) and methotrexate was shown, indicating that TNF-α may be involved in regulating 
IgG glycosylation patterns 
204, 205
. Furthermore, experimental and clinical studies on the role 
of TNF- α have demonstrated that the TNF- α is a key player in progression of human CRC 
206, 207
. Increased levels of TNF- α in patients with CRC were associated with poor prognosis 
208
.  Similar to galactosylation, decreased sialylation of IgG results in a proinflammatory IgG 
phenotype 
119
. The key enzyme for the addition of α2,6-sialic acid to glycan termini is β-
galactoside α2,6-sialyltransferase 1 (ST6Gal-1) Removal of the enzyme ST6Gal-1 in a mouse 
model, has been reported to results in more severe pulmonary inflammation 
209
 consistent 
with the importance of sialic acid in anti-inflammation 
81
. Likewise, the same pattern of 
decreased IgG galactosylation and sialylation also occurs with aging in the general population 
210
, generating the hypothesis that decrease in IgG galactosylation and sialylation in CRC may 
be indicative of an inflammatory state. 
 
Currently, there is a gap in knowledge whether the disease affects the glycosylation of all or 
just antigen-specific IgG, which then are responsible for the overall change observed in total 
IgG. There have been reports that agalactosylated and asialylated antigen-specific IgG are 
involved in the pathogenesis of some diseases, such as anti-citrullinated protein antibodies in 
RA and anti-proteinase 3 antibodies in Wegener’s granulomatosis 211, 212. A study further 
showed that there is a variability between glycosylation pattern of antigen-specific IgG and 
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total IgG. In our study we found that in the same manner as decreased galactosylation is 
associated with poorer prognosis, decreased sialylation was also linked to poorer prognosis, 
which replicated findings of two small studies on ovarian 
195
 and gastric cancer 
162
, but the 
opposite was found, in a study of multiple myeloma 
213
 where increased sialylation of IgG 
was linked to higher risk of multiple myeloma. Therefore, through both decreased 
galactosylation and decreased sialylation, IgG in CRC patients with poorer prognosis had 
significantly greater pro-inflammatory properties (decreased galactosylation and sialylation) 
than CRC patients with better prognosis. Furthermore elevated occurrence of bisecting 
GlcNAc and lack of core fucose results in increased ADCC activity. In our study we found 
higher occurrence of bisecting GlcNAc in CRC patients of poorer prognosis, but IgG core 
fucosylation changes were associated with all-cause or CRC-specific mortality only in stage 2 
CRC patients. 
Likewise, when comparing CRC patients with matching controls, we have observed 
consistent decreases in all structures with two terminal galactoses (A2BG2 (GP13), FA2G2 
(GP14) and FA2BG2 (GP15)) and an increase in structures without galactoses (A2 (GP2), 
A2B (GP3), FA2 (GP4) and FA2B (GP6)) (Table 22). The decrease in galactosylation was 
also evident in the derived traits G0 and G2 that average galactosylation of several individual 
glycans (G0: OR=2,35; p =2,39E-22; G2: OR=0,36; p=6,59E-29). Several directly measured 
IgG glycans containing sialic acid, as well as the derived trait “S1 total” (measuring all 
monosialylated IgG glycans) were also decreased in CRC patients (Table 21). 
Since decreases in galactosylation and sialylation have also been observed in a number of 
other diseases 
77
, this pattern of glycan changes (which are consistent with a decrease in the 
immunosuppressive potential of IgG) is not specific for CRC. 
Taking into consideration that little is known about the mechanisms of regulation of IgG 
glycosylation 
214
, and since IgG N-glycosylation is controlled through a complex interplay 
between loci affecting an overlapping spectrum of glycome measurements, and through 
interection of genes directly involved in glycosylation and those that presumably have 
‘higher-level’’regulatory function 189, it is very difficult to speculate about potential 
mechanisms and causes of differences in IgG glycosylation in CRC patients. Another feature 
of human IgG glycome is its possibility to change particularly in the stituation of disturbed 
homeostasis 
215
, despite the fact that the heritability of IgG glycosylation is relatively high (up 
to 80%) 
20
. The heritability of galactosylation is estimated to be between 40% and 70% and of 
sialylation between 30% and 60% 
20, 210
. Besides this, galactosylation of IgG can change quite 
rapidly in acute inflammation 
215
. Recently, it was reported that in rheumatic arthritis, 
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decreased galactosylation has been demonstrated to predate the onset of disease 
197
, indicating 
that they may be a part of the disease pathophysiology. In an analogous attempt to address 
causality in this study we were able to identify 39 individuals that were sampled before the 
initial diagnosis of CRC. However, when compared to matching controls (individuals of the 
same age that did not develop CRC in the same period after recruitment) we did not identify 
any statistically significant differences. Since the sample size was very small it was hard to 
derive any conclusions from this exploratory part of the study, beside the fact that we were 
not able to show any differences in IgG glycome composition before the onset of CRC. 
It is unquestionable that N-linked IgG Fc glycans are essential in determining distinct effector 
functions. Recently, Barb, A.W.A et al. 
216
 in their study using Nuclear Magnetic Rezonance 
(NMR) revealed that glycans attached to Fc part of IgG are more exposed structurally than 
previously shown, providing detailed description of the interaction between glycans on IgG 
Fc and the respective receptor, and give further insight into the immunomodulatory role of 
IgG Fc glycans. Furthermore,as ADCC is one of the crucial mechanisms in killing tumor 
cells, activation of ADCC is believed to be an important mechanism of therapeutic 
monoclonal antibodies, as indicated by the fact that a common single-nucleotide 
polymorphism in FcγRIIIa (V158F) is correlated with clinical responses to cetuximab 217 and 
rituximab
 218
. Core-fucose is added to glycans by the fucosyltransferase 8 enzyme (encoded 
by FUT8 gene), which has recently been reported to be functionally relevant in some cancers 
219, 220
. The levels of IgG molecules without core-fucose vary between 1.3% and 19% and we 
postulated that this may have a significant impact on antibody-dependent cellular cytotoxicity 
(ADCC) and thus capacity to eliminate cancer cells 
20
. The recently developed therapeutic 
IgG antibodies for cancer therapy are glyco-engineered to remove core-fucose on the Fc 
glycans in order to increase clinical efficacy of monoclonal antibodies due to enhancement of 
their therapeutic effect through ADCC mediated killing
 221, 222
. Recently it has been shown 
that properly glyco-engineered antibodies 
221
 can efficiently elicit ADCC even in 
immunocompromised CRC patients 
223
. This observation indicates that efficient 
immunosurveilance of tumor cells depends on antibody/Fc receptor affinity. Thus, increased 
levels of core-fucose on neutral IgG glycans in CRC patients may influence disease risk and 
course by decreasing the ability of IgG to activate ADCC.  
Interestingly, core-fucose was decreased in sialylated glycans. The increase in core fucose on 
neutral glycans, with concurrent decrease of core-fucose on sialylated glycans has not been 
previously reported. This is the first report of different direction of changes in fucosylation in 
sialylated and neutral glycans. Recent studies clearly demonstrated that some antigen-specific 
 94 
  
antibodies can have significantly different levels of fucose 
224
 but it is hard to evaluate the 
importance in the different fucosylation of sialylated and neutral IgGs, since the relevance of 
sialylation on the impact of fucose on IgG function is currently not known 
225
. This is further 
supported by the observation that polymorphisms in the FUT8 gene seem to be associated 
with increased risk for CRC 
226
. Additional evidence supporting a possible functional 
importance of  FUT8 in colorectal cancer is the recent observation that micro RNA MiR-198 
represses tumor growth and metastasis in colorectal cancer by targeting FUT8 
227
. The finding 
that similar pattern of changes in FUT8 expression can be observed or inferred in both the 
tumor tissue and the antibody-producing B lymphocytes 
226
 points to the importance of 
general mechanisms controlling fucosylation in CRC and implies that the same features of 
genetic makeup influence  glyco-gene expression (and thereby glycosylation profile) in both 
the tumor tissue and in B cells. This view is further strengthened by the observation of 
differential expression of the B-cell-specific transcription factor Ikaros IKZF1- which has 
been reported to be associated with the risk of various cancers 
228
 in tumor tissue of CRC 
patients. 
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7. CONCLUSION  
Alteration in IgG glycosylation has a significant impact in the pathogenesis of numerous 
diseases providing insights into disease state and progression. Consequently, there is an 
indispensable need to search for new IgG glycan biomarkers that could serve as more 
sensitive diagnostic and prognostic tools which could be used to distinguish between different 
forms/stages of disease and to monitor the efficacy of various new treatment options. Inter-
individual differences in IgG glycome are very important in this aspect, by virtue of their role 
in understanding the host defence reaction responses to the presence of the disease. 
 
1. The plasma IgG glycan differences which we observed at the time of CRC diagnosis are 
consistent with significantly increased IgG pro-inflammatory activity being associated with 
poorer CRC prognosis, especially in late stage (stages 3 and 4) CRC. In the absence of 
validated biomarkers to improve upon prognostic information from existing 
clinicopathological factors the potential of these novel IgG glycan biomarkers merits further 
investigation. 
In particular, the improved predictive power in models including glycan factors in stage 4 
patients is interesting. Currently, there are various strategies that are employed when using 
chemotherapy 
229
 in stage 4 disease. Therefore having a novel biomarker or prediction model 
that could help selected patients that may have a better prognosis and a more indolent disease 
course would be useful as these patients could perhaps be offered sequential single agent 
chemotherapy with lower toxicity when compared to a more aggressive combination strategy. 
Furtheremore, there is a great interest in novel immunotherapies in cancer and therefore it 
would be useful to identify a more ‘immunogenic’ tumor based on identified IgG glyco-
markers with a particular response to immunotherapy. Certainly to date the most encouraging 
results for immunotherapies (incl. PD-1 inhibitors) have been in tumors such as melanoma 
that are thought to be highly immunogenic and there is interest in investigating mismatch 
repair deficient colon cancer which are often associated histologically with a heavy immune 
infiltrate. Recent studies 
215
 demonstrated that IgG glycosylation changes are very dynamic 
and variable between individuals, thus longitudinal studies are needed to fully investigate the 
prognostic potential of IgG glycosylation changes in CRC. 
 
2. Significant plasma IgG glycome composition differences are demonstrated between CRC 
patients and controls. We were not able to detect these differences in historical samples (taken 
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before CRC had developed in these patients). This could indicate that the changes are due to 
reverse causality (due to the disease process or treatment effects). However, it may also be 
due to inadequate study power in this small sub-study and so additional studies are required to 
investigate this further.  
Considering the functional relevance of IgG glycosylation for both tumor immunosurveilance 
and clinical efficacy of therapy with monoclonal antibodies, individual variation in IgG 
glycosylation may turn out to be important for prediction of disease course or the choice of 
therapy, thus warranting further, more detailed studies of IgG glycosylation in CRC. 
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8. SAŽETAK / ABSTRACT IN CROATIAN 
UVOD: Rak debelog crijeva je zloćudna novotvorina debelog crijeva i rektuma, te je još 
uvijek povezan s lošom prognozom, niskom stopom preživljavanja i vrlo često relativno 
kasnom dijagnozom. 
 
MATERIJALI I METODE: Analizirali smo glikozilaciju imunoglobulina G (IgG) u 
populaciji od 1229 ljudi oboljenih od raka debelog crijeva te 538 odgovarajućih kontrolnih 
uzoraka. Utjecaj operacije na glikozilaciju procjenjen je kod 28 bolesnika uzorkovanih prije i 
tri puta nakon operacije. Nadalje, glikozilacija IgG-a analizirana je i u 39 uzoraka krvne 
plazme izuzete prije prve dijagnoze. 
 
REZULTATI: Klinički algoritmi pokazali su dobro predviđanje ukupne smrtnosti kao i 
smrtnosti uzrokovane rakom debelog crijeva. Uključivanje podataka o IgG glikanima u 
regresijske modele nije dovelo do statistički značajnog poboljšanja u ukupnoj prognozi 
preživljavanja (Harrellov C indeks: 0.73, 0.77; AUC: 0.75, 0.79; IDI: 0.02, 0.04). Međutim, u 
odnosu na modele temeljene isključivo na kliničkim podacima uključivanjem podataka o IgG 
glikanima značajno je poboljšano predviđanje “rapidnih progresora” kod bolesnika u AJCC 
četvrtoj fazi (AUC 0.53 vs 0.75, IDI 0.21). Analizom kliničkih podataka 760 pacijenata i 538 
odgovarajućih kontrola utvrđena je povezanost raka debelog crijeva s padom stupnja 
galaktozilacije i sijalinizacije IgG glikana, s porastom fukozilacije neutralnih IgG glikana te 
padom fukozilacije sijaliniziranih IgG glikana.  
 
ZAKLJUČAK: Karakteristike glikozilacije IgG-a kod pacijenata oboljelih od raka debelog 
crijeva u skladu su sa značajno povećanom proupalnom aktivnošću IgG-a povezanom s 
lošijom prognozom, pogotovo u kasnijem stadiju. S obzirom na funkcionalnu važnost 
glikozilacije IgG-a u imunološkom nadzoru i učinkovitosti terapije monoklonskim 
antitijelima, individualne varijacije u glikozilaciji IgG-a mogle bi imati važnu ulogu u 
predviđanju tijeka bolesti ili izboru terapije.   
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9. ABSTRACT IN ENGLISH 
IMMUNOGLOBULIN G GLYCOSYLATION IN PATIENTS WITH COLORECTAL 
CANCER 
 
PhD candidate: Kujtim Thaçi 
Year: 2017 
 
INTRODUCTION: Colorectal cancer (CRC) is a malignant neoplasm of the colon and the 
rectum. CRC is still associated with poor prognosis, low survival rate and usually relatively 
late diagnosis. 
 
MATERIALS AND METHODS: We analysed IgG glycome composition in 1229 patients 
with CRC and 538 matching controls. Effects of surgery were evaluated in 28 patients 
sampled before and three times after surgery. Furthermore, IgG glycome composition was 
analysed in 39 plasma samples collected before initial diagnosis of CRC.  
 
RESULTS: Clinical algorithms showed good prediction of all cause and CRC mortality. The 
inclusion of IgG glycan data in regression models did not lead to any statistically significant 
improvements in overall prediction of survival (Harrell’s C: 0.73, 0.77; AUC: 0.75, 0.79, IDI: 
0.02, 0.04 respectively). However, the inclusion of IgG glycan data substantially improved 
the prediction of rapid progressors over clinical models in AJCC stage 4 patients (AUC 0.53 
vs. 0.75, IDI 0.21). When analysing clinical characteristics among 760 patients and 538 
matching controls it was found that CRC associates with decrease in IgG galactosylation, IgG 
sialylation and increase in core-fucosylation of neutral glycans with concurrent decrease of 
core fucosylation of sialylated glycans.  
 
COCLUSION: The glycan differences among CRC patients are consistent with significantly 
increased IgG pro-inflammatory activity being associated with poorer CRC prognosis, 
especially in late stage CRC. Considering the functional relevance of IgG glycosylation for 
both tumor immunosurveilance and clinical  efficacy of therapy with monoclonal antibodies, 
individual variation in IgG glycosylation may turn out to be important for prediction of 
disease course or the choice of therapy. 
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11. LIST OF FIGURES AND TABLES 
Figures 
 
Figure 1. The structure of an IgG1 molecule. (A) Fab and Fc portion (B).Complex 
biantennary glycan structure attached to Asn 297 in Fc portion of IgG 
molecule. Structural schemes are given in terms of blue square (N-
acetylglucosamine), red triangle (fucose), green circle (mannose), yellow 
circle (galactose), and purple diamond ( N-acetylneuraminic acid) 
Figure 2. Structural variations in IgG glycans. Initial GlcNAc2Man3GlcNAc2 
structure (red square) can be modified by the addition of bisecting GlcNAc 
(GnTIII), fucose (FUT8) or galactose (GalT). These resulting structures 
can further be modified by the activity of the same enzymes or by the 
addition of the sialic acid (SiaT) 
 
Figure 3. Modulation of IgG function by alternative glycosylation.Structure of the 
glycan on IgG Fc part can significantly affect effector function of IgG 
 
Figure 4. The scematic representation of the human IgG structure and functional 
implication of alternative glycosylation 
 
Figure 5. UPLC analysis of immunoglobulin G (IgG) glycosylation. Each IgG 
contains one conserved N-glycosylation site on Asn197 of its heavy chain. 
Different glycans can be attached to this site and the process seems to be 
highly regulated. UPLC analysis can reveal composition of the glycome 
attached to a population of IgG molecules by separating total IgG N-
glycome into 24 chromatographic glycan peaks (GP1–GP24), mostly 
corresponding to individual glycan structures 
 
Figure 6. Minus logarithm of the FDR corrected p-values (q values) of all 39 glycan 
variables for all causes and CRC-specific mortality (Model III). Q- value 
threshold of significance <0.05 
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Figure 7. IgG glycome composition in CRC patients and matching controls 
 
Figure 8. ROC curve illustrating the performance of regularized logistic regression 
model in predicting disease status for CRC patients and healthy controls. 
While models based only on age and gender did not show predictive power 
(red line), addition of glycan traits increased predictive power of model 
(black line). 
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Table 1. Glycans annotation and experimental variation for each glycan variable 
 
Table 2. Summary statistics and univariate Cox regression for factors influencing 
all-cause and CRC mortality 
 
Table 3. All cause analysis for rank transformed glycans. Q value represents the 
adjusted p-values using the false discovery rate method (Benjamini–
Hochberg procedure). 
 
Table 4. All cause analysis 
 
Table 5. CRC-specific analysis for rank transformed glycans. Q value represents the 
adjusted p-values using the false discovery rate method (Benjamini– 
Hochberg procedure). 
 
Table 6. CRC-specific analysis 
 
Table 7. All-cause mortality analysis for stages 1-3 
 
Table 8. CRC-specific mortality analysis for stages 1-3 
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Table 9. All-cause mortality analysis by stage [Model II; rank transformed variables 
 
Table 10. CRC-specific mortality analysis by stage [Model II; rank transformed 
variables 
 
Table 11. Multivariate Cox regression of the a) clinical parameters and b) clinical 
and glycan parameters 
 
Table 12. Multivariate Cox regression and estimate of the Harrell’s concordance 
coefficient of the a) clinical parameters and b) clinical and glycan 
parameters by AJCC stage for all-cause mortality. 
 
Table 13. Multivariate Cox regression and estimate of the Harrell’s concordance 
coefficient of the a) clinical parameters and b) clinical and glycan 
parameters by AJCC stage for CRC mortality 
 
Table 14. Predictions of 5 year risk of CRC death for models with clinical factors and 
clinical and glycan factors using k-nearest neighbours, LASSO, Naïve 
Bayes, PAM, Support Vector Machines, Decision Trees, and Boosted 
Stump classifiers. The results are summarized over 10 cross-validation 
folds. 
 
Table 15. Predictions of 5 year risk of CRC death for models with the extended set of 
clinical factors with and without glycans using k-nearest neighbours, 
LASSO, PAM, Support Vector Machines, Decision Trees, and Boosted 
Stump classifiers. The results are summarized over 10 cross-validation 
folds. 
 
Table 16. Predictions of rapid progressors in stage 2 for models with extending set of 
clinical factors with and without glycan using k-nearest neighbours, 
LASSO, PAM, Support Vector Machines, Decision Trees, and Boosted 
Stump classifiers. The results are summarized over 10 cross-validation 
folds. 
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Table 17. Predictions of rapid progressors in stage 3 for models with the extended set 
of clinical factors with and without glycans using k-nearest neighbour, 
LASSO, PAM, Support Vector Machines, Decision Trees, and Boosted 
Stump classifiers. The results are summarized over 10 cross-validation 
folds. 
 
Table 18. Predictions of rapid progressors in stage 4 for models with the extended set 
of clinical factors with and without glycans using k-nearest neighbour, 
LASSO, PAM, Support Vector Machines, Decision Trees, and Boosted 
Stump classifiers. The results are summarized over 10 cross-validation 
folds. 
 
Table 19. Descriptive information on CRC patient and healthy controls 
 
Table 20. Derived glycan traits 
 
Table 21. IgG glycome composition in CRC patients and controls. Only the main 
derived traits describing glycome composition are shown. 
 
Table 22. IgG glycome composition in CRC patients and controls 
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